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 “Before you heal someone, ask him if he's willing 
to give up the things that make him sick” 



























Abstract in English 
Background 
A substance use disorder (SUD) is a potentially severe clinical condition with high co-occurrence of 
somatic and mental disorders. The burden of disease attributable to substance use contributes to 11.8 
million deaths worldwide each year or 1.5% of the global disease burden. Prevalence of chronic hepatitis 
C (HCV) have reached endemic proportions among people with severe SUD, more than half will 
experience a mental health disorder at some point during their lives and it may cause poor health-related 
quality of life (HRQoL). Few studies have assessed HCV treatment uptake, impact of substance use 
patterns and mental health, or measured HRQoL as health outcome among long-term patients in opioid 
agonist therapy (OAT). 
 
Methods 
In paper I, HCV treatment uptake among OAT patients was estimated by medication dispensation from 
2014 to 2017 in Sweden and Norway using data from nationwide registries; The Swedish Prescribed 
Drug Register and The Norwegian Prescription Database. HCV prevalence was estimated from a mix 
of primary and secondary data. Paper II and three are nested prospective cohort studies, which recruited 
707 and 609 participants, respectively, across nine OAT outpatient clinics and low-threshold 
municipality clinics in Norway, during 2017-2020. 
 
The ten-item Hopkins Symptom Checklist (SCL-10) and EQ-5D-5L were used to assess symptoms of 
mental health disorders and HRQoL. The SCL-10 involves ten items, which are each scored on four 
dimensions from not bothered at all (item score = 1) to extremely bothered (item score = 4). A linear 
mixed model analysis examined the impact of substance use patterns and sociodemographic factors on 
SCL-10 sum score with beta coefficients with 95% confidence intervals (CI). EQ-5D-5L measures five 
health dimensions on a five-point Likert scale (from no problems (item score = 1) to extreme problems 
(item score = 5)). A UK value set was applied to calculate index values (from 0 to 1). Self-perceived 
health was measured with EQ-VAS (from 0 to 100). Descriptive statistics were derived at baseline and 
central tendency and dispersion reported by means and standard deviation (SD). 
 
Results 
For the HCV treatment uptake study, altogether 3,529 individuals were identified with dispensed OAT 
in the Swedish cohort and 7,739 individuals in the Norwegian cohort. HCV prevalence was estimated 
to be over 50%. Calculations showed that annual HCV and DAA treatment uptake increased in both 
countries. The estimated cumulative HCV treatment uptake among people in need of HCV treatment at 
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the end of 2017 was 28% in Sweden and 31% in Norway. In Sweden, DAA treatment was associated 
with increased age (adjusted odds ratio (aOR) 1.8; 95% CI 1.0-3.2) and dispensation of drugs used for 
diabetes (aOR 3.2; 95% CI 1.8-5.7), whereas in Norway, dispensation of cholesterol modifying agents 
and antibacterials were associated with decreased odds (aOR 0.4; 95%CI 0.2-0.9, aOR 0.8; 95%CI 0.6-
1.0). 
 
Overall, many individuals reported considerable mental distress and impaired HRQoL. The mean (SD) 
SCL-10 score for all items was 2.2 (0.8) at baseline, which showed that 65% of the cohort had a mean 
score >1.85, the standard threshold for likely mental health disorders. Among people with frequent use 
of substances, more symptoms of mental health disorders were observed amid those using 
benzodiazepines (3.6, 95% CI:2.4;4.8), cannabis (1.3, 0.2;2.5), opioids (2.7, 1.1;4.2) compared to those 
with no or less frequent use of these substances. On the contrary, less mental health symptoms were 
observed among people using frequently stimulants (-2.7, -4.1;-1.4). The study also showed that females 
(1.8, 0.7;3.0), having debt worries (2.2, 1.1;3.3) and unstable living conditions (1.7, 0.0;3.3) were 
associated with higher burden of mental health symptoms. There were large individual variations in 
SCL-10 score from baseline to follow-up, but no consistent time trends indicating change over time for 
the whole cohort.  
 
The mean (SD) EQ-5D-5L index value at baseline was 0.7 (0.3) and EQ-VAS 57 (22) compared to 0.9 
(0.2) and 80 (19) for the Norwegian reference population. The study found large individual variations 
in index values, where 43% had >0.8 and 5% had <0.2 at baseline. The lowest EQ-5D-5L index values 
were observed for female patients, age groups older than 40 years and for methadone users. At follow-
up, improvements in HRQoL were observed across almost all health dimensions. Mean (SD) overall 
index value and EQ-VAS at follow up were 0.7 (0.2) and 59 (22) respectively. 
 
Conclusion 
This thesis has revealed numerous challenges related to people with severe SUD, in addition to being a 
very heterogeneous population. Despite increased HCV treatment uptake in both Sweden and Norway 
it was estimated that more than two thirds of the OAT populations in need of treatment were left 
untreated at the beginning of 2018. While the vast majority is experiencing a high burden of mental 
health symptoms and considerable impaired HRQoL, around one third had few mental health symptoms 
and very good HRQoL. These findings emphasize the urgent need for more research, and perhaps more 
gender-and age-adopted treatment. The wide variations seen in SCL-10 and HRQoL support more focus 
on individualized treatment and personalized patient care, and the need for regular assessment of these 
health outcomes in SUD and OAT treatment programs. 
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Sammendrag på norsk (abstract in Norwegian) 
Bakgrunn 
Ruslidelse er en potensiell svært alvorlig klinisk tilstand med høy grad av samtidig forekomst av 
somatisk og mental sykdom. Sykdomsbyrden som tilskrives rusmidler bidrar til 11.8 millioner dødsfall 
hvert år eller 1.5% av den totale globale sykdomsbyrden. Forekomst av kronisk hepatitt C (HCV) har 
nådd endemiske proposisjoner blant mennesker med alvorlig rusavhengighet, mer enn halvparten av 
dem vil oppleve en psykisk lidelse i løpet av livet, og det kan lede til dårlig helse-relatert livskvalitet. 
Det er få studier som har undersøkt behandlingsopptak av HCV, hvordan rusmidler kan påvirke psykisk 




I den første studien som inngår i denne avhandlingen benyttet vi data fra befolkningsbaserte registre; 
läkemedelsregistret i Sverige og reseptregisteret i Norge fra 2014 til 2017.HCV forekomst av kronisk 
HCV ble modellert på bakgrunn av både primære og sekundære datakilder. De to andre studiene som 
inngår i denne avhandlingen er prospektive kohort studier med henholdsvis 707 og 609 deltagere fra ni 
LAR poliklinkker og kommunale mottaks- og omsorgssentre i Norge fra 2017 til 2020. 
 
Vi benyttet Hopkins symptom sjekkliste (SCL-10) og EQ-5D-5L for å evaluere psykisk helse og helse-
relatert livskvalitet. Førstnevnte bruker en ti punkts liste over psykiske tilstander hvor hver enkelt 
dimensjon skåres fra ikke brydd i det hele tatt (skår 1) til ekstremt brydd (skår 4). En lineær mixed model 
analyse undersøkte sammenhengen mellom rusmiddelbruk og sosiodemografiske faktorer på SCL-10 
sum skår, med beta koeffisienter med 95% konfidensintervall. EQ-5D-5L måler fem helse dimensjoner 
på en fem punkts skala (fra ingen problemer (skår 1) til ekstreme problemer (skår 5). For å kunne regne 
ut indeksverdi (fra 0 til 1) ble ett verdi sett fra Storbritannia benyttet. Selvoppfattet helse ble målt med 
EQ-VAS (fra 0 til 100). Deskriptiv statistikk ble rapportert fra inklusjons tidspunkt og sentral tendens 
rapportert med gjennomsnitt og standardavvik (SA). 
 
Resultat 
Til sammen ble henholdsvis 3,529 og 7,739 individer identifisert med forskrevet LAR medisiner i de 
svenske og norske kohortene. HCV forekomsten ble estimert til å være like over 50% i studieperioden. 
Det årlig behandlingsopptaket økte i begge land. Det estimerte kumulative HCV behandlingsopptaket 
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blant de som trengte behandling var 28% i Sverige og 31% i Norge ved utgangen av 2017. De direkte-
virkende antivirale legemidlene var assosiert med økt alder (justert odds ratio (aOR) 1.8; 95% KI 1.0-
3.2) og forskrivning av diabetes medisiner (aOR 3.2; 95% KI 1.8-5.7) i Sverige, mens forskriving av 
kolesterolsenkende legemidler og antibiotika var assosiert med nedsatt odds (aOR 0.4; 95% KI 0.2-0.9; 
aOR 0.8; 95% KI 0.6-1.0) i Norge. 
 
Samlet sett ble det rapportert betydelige symptomer på psykiske lidelser og nedsatt helse-relatert 
livskvalitet blant deltagerne. Gjennomsnitt (SA) SCL-10 skår for de ti psykiske tilstandene var 2.2 (0.8), 
som viste at 65% hadde gjennomsnitt skår over 1.85, som er foreslått terskel for psykiske lidelser. Blant 
de som oppga regelmessig rusinntak ble det observert flere symptomer for psykisk lidelser blant de som 
brukte benzodiazepiner (3.6, 95% KI: 2.4;4.8), cannabis (1.3, 0.2;2.5), og opioider (2.7, 1.1;4.2) 
sammenlignet med de som hadde intet eller uregelmessig bruk av disse rusmidlene. På den andre siden 
ble det funnet færre symptomer blant de som oppga regelmessig bruk av simulanter (-2.7, -4.1;-1.4). 
Resultatet viste også at kvinner (1.8, 0.7;3.0), gjeldsbekymringer (2.2, 1.1;3.3) og ustabil livssituasjon 
(1.7, 0.0;3.3) var assosiert med høyere mental sykdomsbyrde. Det var også store individuelle variasjoner 
i SCL-10, men ingen signifikante tidsendringer på gruppenivå. 
Gjennomsnitt (SA) EQ-5D-5L indeksverdi ved inklusjon var 0.7 (0.3) og for EQ-VAS 57 (22), 
sammenlignet med 0.9 (0.2) og 80 (19) for den generelle norske befolkningen. Igjen var det store 
individuell variasjoner, hvor 43% hadde >0.8 og 5% <0.2 i indeksverdi ved inklusjon. Den laveste 
indeksverdien ble observert blant kvinner, de eldre enn 40 år og for metadon brukere. Ved oppfølging 
ble det observert forbedring i nær sagt alle helse dimensjoner. Gjennomsnitt (SA) indeksverdi og EQ-
VAS ved oppfølging var henholdsvis 0.7 (0.2) og 59 (22). 
 
Konklusjon 
Denne avhandlingen har vist en rekke utfordringer blant personer med alvorlig ruslidelser, men også at 
det er en heterogen populasjon. Til tross for økning i HCV behandlingsopptak både i Sverige og Norge 
blant LAR pasienter, er det estimert at vel to tredjedeler av de som trengte behandling var ubehandlet i 
begynnelsen av 2018. Selv om de fleste samlet sett opplevde en stor psykisk sykdomsbyrde og betydelig 
nedsatt helse-relatert livskvalitet, oppgir vel en tredjedel få symptomer og har en god livskvalitet. Disse 
funnene understreker betydningen av mer forskning. Kanskje vil det være gevinster av mer kjønns- og 
aldersspesifikk behandlingstilnærming i tverrfaglig spesialisert rusbehandling. Evaluering av psykisk 
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Important terminology and definitions 
A substance use disorder (SUD) is a potentially severe clinical condition; it may cause social 
marginalization, long-term impairments in most aspects of an individual’s life, and premature 
death compared to the general population [1]. According to World Health Organization (WHO), 
mental and behavioral disorders due to psychoactive substance use are divided into ten classes; 
alcohol, opioids, cannabinoids, sedative hypnotics, cocaine, other stimulants, hallucinogens, 
tobacco, volatile solvents, and multiple drug use and use of other psychoactive substances [2]. 
For the purpose of this thesis, a SUD is defined as harmful use of, or dependency on a substance 
or class of substances, such as alcohol and or opioids. Harmful use of substances, sometimes 
termed substance abuse, involves the use of substances that have caused either physical or 
psychological harm to an individual’s health over a certain period of time [3]. Substance 
dependency, is a more severe chronic relapsing disorder consisting of a cluster of physiological, 
behavioral, and cognitive phenomena – where the use of the substance or substances have the 
predominant place compared to other behaviors that had greater value before [4]. Thus, a 
dependency of a substance is termed severe SUD in this thesis when known. Harmful use and 
dependency are central in WHO’s international classification of diseases (ICD-10) diagnostic 
system [4]. 
 
Among several possible definitions of comorbidity, a general medical definition is opted for 
this thesis meaning simply that there is a presence or coexistence of additional diseases, either 
somatic or psychiatric, with reference to the initial diagnosis of SUD (or to the index condition 














Anti-HCV  Antibodies to hepatitis C virus 
ATC  Anatomical Therapeutic Chemical Classification System 
CI   Confidence interval 
DAA  Direct-acting antiviral agents 
DALY  Disability-adjusted life years 
DDD  Defined Daily Dose 
HCV  Hepatitis C virus infection 
HCV RNA  Ribonucleic acid (either quantitative or qualitative) 
HRQoL  Health-related quality of life 
NorPD  Norwegian Prescription Database 
OAT  Opioid agonist therapy 
PWID  People who inject drugs 
QoL  Quality of life 
SPDR  The Swedish Prescribed Drug Register 
SUD  Substance use disorder 
SVR  Sustained virologic response 
UL   Uncertainty interval 










1.1 Substance use disorder 
Psychoactive substances have been around for almost as long as humanity, however, it was 
not until early 19th century scientific classification begun [6]. 
 
1.1.1 Burden of disease attributable to substance use disorders 
Globally it was projected that almost 100 million disability-adjusted life years (DALY), or 
some 4% of all DALYs, were attributed to substance use as a risk factor in 2016 [7]. 
Altogether, substance use contributes to 11.8 million deaths worldwide each year, which is 
only secondary to cardiovascular diseases, and represent some 1.5% of the global disease 
burden [7-9]. Premature death, caused by long-term substance use, accounts for most of 
these deaths, 11.4 million; with smoking (7.1) and alcohol (2.8) representing the most 
prevalent risk factors [8]. However, a considerable number of individuals also die directly 
from overdoses each year, where deaths from SUD are differentiated between alcohol and 
illicit drugs including opioids, cocaine, amphetamines/methamphetamines and cannabis [8]. 
Of the around 350,000 directly deaths in 2017 worldwide, 185,000 were from alcohol and 
167,000 from illicit drugs [8, 9]. Unlike the premature deaths, where most deaths are seen 
in people aged 70 years and older, direct deaths mainly affect younger people: over 50% of 
the overdoses are seen in people younger than 50 years old [8]. It was estimated that just 
over two percent of the world population had a severe SUD in 2016 with vast intercountry 
differences in terms of prevalence and distribution of substances used [7]. For instance, in 
the USA and several countries in Eastern Europe, which both saw a prevalence of SUD of 
over five percent, opioids and other illicit drugs dominate in the former while Russia and 
eastern European countries reported chronic use of alcohol as the most commonly abused 
substance [8, 10].  
 
The prevalence of people with severe SUD in Norway was estimated to just over three 
percent at the start of the millennium; after a slight decline towards 2010, the last couple of 
years after have seen a flatten curve at just below three percent up until 2016 [8]. There 
were 621 direct deaths from SUD in Norway in 2018, where alcohol and illicit drugs 
accounted for 335 and 286 deaths, respectively [11]. When adjusted for population growth 
in the same time period, alcohol have seen a marked decline on mortality whereas illicit 
drugs have seen no significant decrease in direct deaths [3]. As seen globally, also in 
Norway severe SUD represent one of the most important risk factors for premature death 




1.1.2 Etiology of substance use disorders 
Despite the long history of substance abuse, it was only from the 1980s, disorders related 
to substance use were recognized as a primary mental health disorder [6]. SUD and mental 
health disorder co-occur; more than half of the people with a SUD will experience a mental 
health disorder at some point during their lives [12, 13]. However, it is less clear whether 
mental health disorders develop mostly as a consequence of substance use or vice versa 
[14]. There seems to be a set of multifactorial risk factors associated with development of 
SUD, such a genetic vulnerability, childhood trauma, low level of educational and 
occupational participation, access to substances, emotional- sexual- and physical abuse [3, 
15, 16]. There is a considerable genetic influence, studies on alcohol use disorders shows 
that genetic vulnerability alone contributes for around 50% of the overall risk factors [17, 
18]. The co-occurrence of SUD and mental health disorders may thus be attributed to shared 
genetic vulnerability and pathophysiological processes possibly related to specific 
neurotransmitter systems, in particular within the dopaminergic system [19, 20]. In addition, 
genetic influence has also shown to be involved in the processing of illicit drugs, drug-
specific changes in gene expression and metabolism [21]. 
 
1.1.3 Opioid dependence – a severe substance use disorder 
Humans have used derivatives from the opium poppy since the sixth millennium before 
Christ and opioids are therefore among the oldest known psychoactive drugs. The active 
ingredient of opium, morphine, was first chemically isolated by Wilhelm Sertürner, before 
Sir Robert Robinson won the 1947 Nobel Prize in chemistry following his derivation of 
morphine’s structural formula [22]. Opioids are used medically for acute and chronic pain 
relief, palliative care and for treatment of opioid dependence with opioid agonist therapy 
(OAT). However, opioids are also consumed for extramedical, or recreational use. 
Traditionally heroine has been the leading opioid used for these purposes worldwide, with 
the exceptions of opium producing countries, such as Afghanistan and neighboring nations, 
and the increased prescriptions of opioids for non-cancer pain in high-income countries such 
as USA and Canada [23, 24]. The latter have produced an iatrogenic epidemic of opioid 
misuse, dependence, and overdoses [25]. For instance, almost 50% of the people enrolled 
in an OAT program in Canada reported their first contact with opioids was through a 
dispensation for medical use of opioids [26]. Many people initiate using extramedical 
opioids for their mind-altering affects and pain relief; however, not everyone will develop 
an opioid dependence [24, 27]. Studies on heroine have shown that around one-third to two-




Opioid dependence is a severe chronic relapsing disorder consisting of a cluster of 
physiological, behavioral, and cognitive phenomena [4]. Worldwide, opioid use disorders 
affect over 16 million people and is responsible for over 120,000 deaths per year [30]. In 
Norway, of the 286 direct deaths recorded from illicit drug use, opioids accounted for 82% 
of those deaths in 2018 [3]. Of all illegal drugs, opioids denote the highest disease burden, 
has the highest demand for treatment, it contributes to substantial increased healthcare costs, 
and has shown a marked increase in opioid related mortality in the last decade [10, 24, 31]. 
People with opioid use disorders suffer not only an early death, but also severe social 
marginalization and long-term impairments in most aspects of their lives [1]. 
 
1.1.4 Opioid agonist therapy 
Opioid treatment programs with methadone dates back to the 1960s in Scandinavia when it 
was first initiated in Sweden [32]. However, it was not until 1998 it was implemented as a 
medical treatment for opioid dependence in Norway [33]. Increased focus on, and 
availability of harm reduction programs, such as OAT have lowered the demand for illegal 
opioids [31]. OAT is an evidence-based medical intervention and considered the gold 
standard of treatment for opioid dependence that augments treatment retention, reduces 
illicit opioid use, improves patients’ health and reduces crude mortality rates significantly 
[24, 34-37]. For instance, results of 22 pooled longitudinal cohort studies showed a crude 
mortality rate for patients on OAT of 0.90 per 100 person years, compared to 1.63 when 
OAT was ceased, and 4.91 for any untreated periods [38]. Most patients in Norwegian OAT 
programs are treated with either buprenorphine, buprenorphine-naloxone, methadone or 
levomethadone, as other opioids are very rarely used and considered outside national 
guidelines [39]. There are currently more than 7,500 people enrolled in OAT programs in 
Norway, which gives an OAT coverage considerably higher compared to the other 
Scandinavian countries of Sweden and Denmark, and the USA [40-43]. It is estimated that 
around 60% of people with opioid dependence are currently enrolled in OAT programs in 
Norway [44]. 
 
With an integrated treatment approach, OAT has been put forward to play a significant role 
in the management of both somatic and psychiatric comorbidities among people with opioid 
dependence; such as its role in the treatment of chronic hepatitis C (HCV) and to reduce the 
risk of HCV acquisition [45, 46], increase uptake of HIV testing and treatment [47], and 






1.2 Somatic comorbidity among people with substance use disorders 
A SUD is a multifactorial disorder often leading to adverse social and health complications, 
hence often termed a biopsychosocial syndrome. The most common somatic complications, 
especially among people who inject drugs (PWID), are overdoses, injuries, and infections, 
however, a range of other less common health complications have also much higher 
prevalence among people with SUD compared to the general population [50-52]. People 
with severe SUD also have a higher risk of diseases that are more common in the general 
population, including various cancers and cardiovascular diseases [51, 52] 
 
1.2.1 People who inject drugs 
Worldwide, around 11 million people injected drugs in 2017 [53]. PWID are associated 
with increased risk for both morbidity and mortality compared to the general population, 
and the risk of premature death is up 15 times higher among people who use illicit opioids 
[35, 37]. Opioids are the most common drug used by PWID, however, stimulants, which 
include methamphetamine, amphetamine, and cocaine, represent a significant proportion of 
injected drugs and contributes to the second highest proportion of disease attributed to SUD 
globally [53]. In Western Europe around 20% of the PWID report stimulants as their main 
injected drug, while 40 to 50% of PWID in North America inject stimulants as their main 
drug [53]. Mortality rates and cause of death of PWID varies according to drug culture, low- 
to high-income countries, geographical locations, age, and gender; nonetheless, overall 
overdose was the most common reported cause of death while both HIV and chronic HCV 
infections are significant risk factors for both opioids and stimulant PWID [35, 37, 54, 55]. 
 
In addition to the factors mentioned above, mortality rates and causes of death among people 
in OAT will also vary according to their OAT continuity and retention in treatment [38]. 
OAT patients are aging, in fact, Norway has among the oldest populations in Europe with 
a mean age of almost 45 years in 2017, and it is thus likely that somatic causes of death will 
increase compared to overdoses and other drug-induced causes of death [41, 56, 57]. In a 
Norwegian study of all-cause mortality among OAT patients, somatic diseases accounted 
for 45% of deaths, followed by drug-induced and violent deaths at 42% and 12%, 
respectively [58]. Furthermore, increased somatic comorbidity was found to reduce the odds 
of dying from a drug-induced cause of death [58]. Likewise, retention in OAT treatment, 
with both methadone and buprenorphine, has shown substantial reductions in the risk for 




Of the 11 million people who injected drugs in 2017 almost 6 million of those were living 
with chronic HCV, however, as we shall see next, prevalence globally is much higher with 
the burden of HCV affecting PWID considerably [53, 60]. 
 
1.2.2 Hepatitis C virus infection 
HCV was formerly known as non-A and non-B hepatitis (NANBH), until the isolation of a 
cDNA clone from a hepatitis genome by Choo et. al in 1989 [61]. This newly discovered 
virus was found to be responsible for some 90% of the non-A, non-B hepatitis in the USA, 
and together with hepatitis B the cause of 96% of all hepatitis-related mortality [62, 63]. 
HCV is classified as an RNA virus belonging to the flaviviridae family, with an affinity for 
hepatocytes where the viral replication takes place [63]. The HCV RNA genome mutates 
frequently and has great genetic heterogeneity with at least six known genotypes and more 
than 50 subtypes [64].  
 
The main route of transmission is by exposure to infected blood, such as contaminated 
needles or blood products, however, also the sharing of filters and other user equipment 
among PWID have shown to transmit HCV [65]. There is also a risk for perinatal 
transmission between mother and fetus, sexual transmission or blood contact [65]. Exposure 
to the virus may cause both acute and chronic infections. The former is asymptomatic for 
most, though some 10 to 20% develop jaundice while other signs include mild to severe flu-
like symptoms, malaise, lethargy, abdominal pain, dark urine, pale stool, and increased 
enzymes on liver function tests [65]. Without any treatment, between 15 and 45% of 
infected people achieve spontaneous clearance of the virus, normally within a year, while 
the rest will proceed to develop a chronic HCV with progressing stages of liver fibrosis and 
subsequently cirrhosis [60]. Chronic HCV is defined by the persistence of detectable HCV 
RNA in a person’s blood test at least six months after the onset of the acute HCV infection 
[63]. After 20 years of chronic HCV infection, the prevalence of cirrhosis may be as high 
as 20 to 30% [60, 65]. The prognosis for developing a chronic disease is affected by several 
factors such as age at time of infection, gender, concomitant alcohol consumption; and is 
poorer among individuals with an advanced age, being male, using alcohol, genotype-3 
infections, immunosuppression and having co-infections with hepatitis B and HIV [63, 65]. 
Furthermore, chronic HCV infection may also contribute to extrahepatic comorbidity often 
independent of the stage of liver fibrosis; with the most common being depression (24%), 
diabetes mellitus (15%) and chronic renal disease (10%) [60]. Among patients with 
cirrhosis, around one in forth will develop hepatocellular carcinoma within a 10 year time 




The global prevalence of HCV among the general population varies considerably; high 
prevalence is found in East Asia, North Africa/Middle East (>3.5%), moderate prevalence 
in Southeast Asia, sub-Saharan Africa, Europe and Latin America (1.5-3.5%), low 
prevalence in Asia Pacific and North America (<1.5%) and between 0.5 to 1% in the 
Scandinavian countries of Norway, Sweden and Denmark [65, 66]. However, while 
prevalence may be low to moderate among the general populations, prevalence is 
significantly higher among SUD and PWID populations at more than 50% [41, 67, 68]. 
Injecting drug use and sharing of syringes and needles are the major drivers of HCV 
incidence [69]. Since it was first discovered HCV has become a worldwide epidemic. The 
WHO has estimated that 71 million people around the world are chronically infected with 
the virus and that 399,000 die annually from HCV related complications such as liver 
cirrhosis or hepatocellular carcinoma [60, 66]. Modeling the burden of HCV in Norway 
suggests that HCV-related liver morbidity and mortality are increasing among PWID and 
are likely to continue to rise until 2022; with around 7,000 former and current PWID living 
with chronic HCV at the time of planning this study; with an estimated 400 new cases 
annually, and around 40 HCV-related deaths yearly [70]. 
 
1.2.3 Hepatitis C strategies for control and elimination 
Despite the high burden of HCV among people with SUD, and especially PWID, 
comparatively few have commenced antiviral treatment at the time of study and HCV 
continues to pose a serious health threat [40]. At the World Health Assembly in 2016, the 
WHO recognized the Global Health Sector Strategy, which aims to eliminate viral hepatitis 
(HCV and hepatitis B infection) by 2030 [60]. Eliminating chronic HCV, which is defined 
as a 90% reduction in incidence and a 65% reduction in mortality compared with the 2015 
baseline, requires a significant effort in terms of increasing uptake of testing, diagnosing, 
and antiviral treatment [60]. Ultimately, it requires that 90% of individuals with chronic 
HCV must be identified and diagnosed, and of those, at least 80% must be treated [60]. In 
addition, other preventive strategies have been proposed alongside increasing testing and 
antiviral treatment, such as OAT scale-up, safe injection sites and needle-syringe programs 
to reach the above objectives [60, 71]. 
 
Alongside the decision made at the World Health Assembly in 2016, Norway also endorsed 
a comprehensive national strategy against viral hepatitis in the same year [72]. The initial 
plan was later revised and updated in 2018. Antiviral treatment with direct-acting antiviral 
agents (DAA) was made readily available for all diagnosed with chronic HCV regardless 
of stage of liver fibrosis from February 1, 2018, and the ambitious aim of the national 
strategy was to reduce HCV incidence by 90% by 2023 and stated that nobody should no 
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longer die from HCV related complications [72, 73]. DAA treatment has been offered as 
universal health coverage to all chronic infected HCV patients in Sweden from 2017 [74]. 
 
1.2.4 Treatment of hepatitis C 
The ambition of any antiviral treatment of HCV infection is to eliminate of the virus. Since 
the discovery and development of ribavirin in the 1970s, it was found to be active against 
different DNA and RNA viruses [75]. After the discovery of HCV in 1989, there were a 
few attempts to treat HCV with ribavirin monotherapy in the 1990s, however, while it had 
some effects on serum alanine aminotransferase levels and patients infected with genotype 
2 and 3, little effect was noted on HCV RNA levels and thus not achieving sustained 
virologic response (SVR) [75]. SVR is defined as absence of HCV RNA 12 weeks after end 
of treatment. A major advancement in HCV antiviral treatment came in 1998 when ribavirin 
was added to pegylated-interferon and together played a crucial role the HCV treatment 
preventing relapses and breakthroughs in the years to come [76]. With this drug 
combination, SVR was achieved in approximately 50 to 56% of patients [77, 78]. However, 
the course of treatment was long, 24-48 weeks with weekly injections and sometimes-severe 
side effects with interferon induced bone-marrow depression, flu-like symptoms, 
neuropsychiatric disorders and autoimmune-syndromes [79]. 
 
Further advancements came in 2011 when protease inhibitors, the first generation DAA, 
where approved for treatment, and three years later when the polymerase inhibitor, 
sofosbuvir, came into the market patients were offered interferon-free HCV treatment 
regimens for the first time [65]. As of 2018, the regulatory authorities in USA and Europe 
has approved 13 DAA from the four classes; NS3/4A (protease) inhibitors, NS5A inhibitors, 
NS5B polymerase inhibitor (nucleotide analogue), and NS5B polymerase inhibitor (non-
nucleoside analogue) [60]. Different combinations of DAA are considered to be pan-
genotypic when they achieve high treatment efficacy across all six known genotypes [60]. 
Combining DAA with ribavirin will still be relevant in certain circumstances, for instance 
among hard to treat cirrhotic patients with genotype 3 [76]. HCV policies including DAA 
offer countries an opportunity to eliminate HCV endemics, with less side effects, shorter 
treatment duration and improved adherence as compared to old interferon-based treatment. 
Combining two (or three) DAA can achieve SVR of far beyond 90% including patients who 
have been hard to treat in the past [80-82].  
 
1.2.5 Barriers to hepatitis C treatment and elimination 
The era of DAA treatment creates an opportunity to cure a substantial portion of people 
with chronic HCV among severe SUD populations. However, even if these highly effective 
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medications have become readily available, treatment have been scarce [69, 83]. One reason 
was the initial costs of DAA therapy in high-income countries, which ranged from $83,000 
to $153,000 per treatment course, prompting restrictive access policies in most settings [84, 
85]. Since, costs of DAA therapy has decreased considerably due to increased 
pharmaceutical competition, production of generic DAA and improved pricing models 
among others [86]. Subsequently, many high-income countries such as Norway, now offer 
unrestricted access to DAA treatment [65]. Treatment demand has soared, especially among 
former PWID, while people who are still using drugs have not been able to benefit equally 
from the increased accessibility, suggesting that DAA costs alone is not the only substantial 
barrier to the ambitious elimination targets outlined above [65, 86]. Previous studies have 
addressed the insufficient linkage to HCV care, testing and screening among people with 
SUD, while other studies have identified the lack of knowledge of HCV among risk 
populations as a barrier and demonstrated that psychoeducation may have a positive effect 
on both SVR rates and adherence to HCV treatment [40, 87-89]. Up to two-thirds of people 
with SUD may be unaware that they are actually infected with chronic HCV [90]. 
 
Another significant obstacle to HCV treatment among people with severe SUD is the 
physician-perceived risk factors, especially ongoing substance use, as a contraindication for 
DAA treatment [40]. Despite mounting evidence and the revised HCV treatment guidelines 
from WHO, which recommend treatment regardless of ongoing substance use, many 
clinicians seem to still be reluctant to treat people with injecting drug use [60, 91]. In 
addition to a systematic review that found DAA treatment to be highly favorable among 
people with severe SUD, including PWID and OAT patients, and supported further access 
to HCV treatment despite ongoing substance use; it was the SIMPLIFY study that 
established the efficacy as neither drug use before or during treatment affected the SVR [92, 
93]. Thus, DAA treatment should be offered to people with severe SUD, regardless of 
ongoing substance use [93]. In addition, successful elimination of HCV involves several 
components, from the global to community level, as suggested by Gore (2020) and outlined 











Table 1: Key components for HCV elimination. 
 
Global level 
Expanded WHO viral hepatitis program 
Enhanced global NGO involvement 
Increased global investment 
 
National level 
Political engagement and leadership 
National HCV strategy development 
National HCV-testing policy development 
National surveillance systems to monitor HCV elimination 
Funding for civil-society organizations 
 
Screening level 
HCV-testing strategy  
Targeted screening in high-risk populations 
Universal screening in settings with generalized epidemics 
Ongoing monitoring of level of HCV diagnosis 
 
Diagnostic level 
Low-cost, simple and rapid HCV diagnostics 
Implementation research on new diagnostics 





Access to DAA therapy without restrictions 
Diverse models of HCV care (specialist and non-specialist prescribers) 
Expanded voluntary generic-DAA licenses 
Education of healthcare providers and affected community 
Targeted strategies among high-risk populations 
Monitoring for reinfection, with access to retreatment 
 
Prevention level 
High coverage of harm reduction (NSP and OAT) 
Blood-donor HCV screening in all settings 
Enhanced healthcare infection control 
Antenatal HCV screening and evaluation of DAA therapy in pregnancy 
 
Monitoring and evaluation 
level 
Population-level surveillance monitoring of HCV incidence 
Mathematical modeling 
Monitoring of DAA uptake and outcomes 
Monitoring of HCV-related morbidity and mortality 
Monitoring of HCV-related stigma and discrimination 
 
Community and societal 
level 
Community awareness campaigns 
Enhanced education: school-based, healthcare professional, political 
Drug-law reform 





Source: Dore et.al. Global elimination of hepatitis C by 2030: why not? 
NGO: non-governmental organizations, DAA: direct-acting antiviral agents, HCV: hepatitis C infection, 
PWID: people who inject drugs, NSP: needle-syringe programs, OAT: opioid agonist therapy 
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1.2.6 Prevention and monitoring: Hepatitis C treatment uptake 
The coverage of preventive interventions and harm reduction services varies among people 
with severe SUD. The distribution of needle-syringe programs and OAT are relatively poor 
in many settings; only around 1% of PWID worldwide lives in areas of high coverage of 
these preventive measures [94]. In contrast, opioid treatment programs such as OAT has 
higher coverage in most high-income countries [95]. OAT has shown to reduce the risk of 
HCV acquisition [45], and despite ongoing substance use, patients in OAT are achieving 
high SVR rates as seen above [92]. Hence, OAT may be a critical intervention for achieving 
large reductions in HCV transmissions. Several modeling studies have found that significant 
reductions in HCV prevalence may be achieved with a reasonable increase in HCV 
treatment uptake [96-98]. 
 
Nevertheless, HCV treatment uptake has remained low among people with severe SUD, 
including patients enrolled in OAT programs [99-101]. In Norway, annual HCV treatment 
uptake among OAT patients ranged from 1.3% to 2.6% in the period from 2004 to 2013 
[102]. HCV treatment uptake since, and in particular in the DAA era, is largely unknown. 
The potential for HCV disease elimination by publicly funded DAA policies and the high 
HCV prevalence among OAT populations, it is essential to calculate the DAA treatment 
within an OAT delivery platform. At the time of the study planning, such estimates were 
important for countries aiming for HCV elimination or endemic control in the near future.  
 
1.3 Psychiatric comorbidity among people with substance use disorders 
More than half of the people with a SUD will experience a mental health disorder at some 
point during their lives [12, 13]. Measuring mental distress may be used to predict mental 
health disorders among people with SUD [103]. 
 
1.3.1 A comorbid condition: prevalence and challenges 
On the one hand, ongoing substance use or serious abstinence, may present as symptoms of 
mental health disorders, either as temporary incidents such as stimulant-induced psychosis, 
or long-term when triggering an underlying psychopathology as seen with cannabis and 
schizophrenia [19, 20]. On the other hand, having a mental health disorder such as 
depression, may cause some patients to use for instance stimulants to ease symptoms, and 
thereby progress to a SUD [104]. Thus, the overlap and fluctuations of mental health 
symptoms, ongoing substance use with substance-induced symptoms, abstinence, 
limitations of various assessment methods, and other methodological considerations may 
well complicate the diagnosing of mental health disorders among people with SUD [104]. 
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Nevertheless, it appears to be a strong association between mental health disorders as a risk 
factor for SUD, while having a SUD may affect the presence of mental health disorders 
[104, 105]. Several studies have demonstrated the high co-occurrence of mental health 
disorders among people with SUD [5, 106, 107]. However, the etiological relationship 
between both disorders seem less clear [108]. Whether they present at the same time 
(concurrently) or at different times (successively), mental health disorders and SUD may or 
may not be causally related, even if they could share a common genetic susceptibility and 
pathophysiological evolvement [20, 108, 109]. Early exposure to either stress or trauma 
may also be contributing factors [15, 104]. 
 
Epidemiological studies suggest a prevalence of around 27% for anxiety disorders, 35% for 
affective disorders, 30% for attention-deficit hyperactivity disorder, and 51% for 
personality disorders among SUD populations [110-112]. Prevalence may even be higher 
in clinical studies as people with severe problems are more likely to seek help; studies have 
found prevalence of around 70% for one or more personality disorder and around 66% for 
childhood trauma among people with SUD, and at least one mental health disorder was seen 
in around 80% of patients in a study among OAT patients [13, 15, 113]. This comorbid 
condition may challenge and interfere with treatment of SUD, which seems to be both 
undertreated and underdiagnosed in clinical settings [114]. One study found a direct 
association between quantity of substance use and severity of mental health symptoms 
among patients with schizophrenia [115]. In a follow-up study, both early onset of substance 
use and depression were found to be independent predictors of relapse among people with 
SUD [116]. In addition, several studies have shown that treatment outcomes and prognosis 
may be considerably poorer among patients with comorbid mental health disorders among 
people with SUD [12, 117, 118]. Thus, identifying patients with comorbid conditions is an 
essential precondition in treatment settings, and underlines the importance of diagnostic 
assessment of mental health disorders among people with SUD in order to improve overall 
treatment outcomes [119]. 
 
Integrating treatment approaches of mental health disorders and people with SUD are 
heralded as more effective and superior compared to separate treatment plans [48, 49, 120]. 
However, in spite of the mounting evidence most European countries have opted for a 
separate treatment approach of mental health disorders and SUD, which may cause delayed 
diagnostics and create a barrier to recovery [5, 119]. In Norway, where psychiatry and 
addiction medicine are separate medical specialties; people with SUD and milder comorbid 
mental health disorders, such as mild to moderate depression or anxiety, are treated in a 
12 
 
SUD setting – while people with comorbid severe mental health disorders such as psychosis 
and bipolar disorders, are treated within a psychiatric health care platform [121]. 
 
1.3.2 Identifying mental distress and symptoms of mental health disorders 
The high prevalence of mental health disorders among people with SUD, and given the 
negative impact on treatment outcomes and prognosis; suggest a need for routinely 
screening individuals entering SUD treatment [122]. However, a consistent finding among 
people entering SUD treatment is the lack of routine assessment of mental health disorders, 
which is not always performed as a standard diagnostic procedure upon treatment initiation 
[104]. Early assessment and detection of comorbidity may therefore be favorable for 
individuals in need of further examination or psychiatric treatment, especially for more 
severe mental health disorders such as psychosis, bipolar disorders and severe depression 
[121]. One such screening instrument, the Hopkins symptom check list (SCL-10), may be 
used to identify mental distress and symptoms of mental health disorders among the general 
population and people with SUD [103, 123]. 
 
Hopkins symptom check list SCL-90 was first developed at Johns Hopkins University in 
the 1950s, and originally contained nine primary symptoms dimensions [124]. The SCL-10 
consist of two of the original nine dimension with ten items measuring mental distress and 
symptoms of mental health disorders, and is the short-form of the more comprehensive 
Hopkins symptoms check list SCL-25 [123]. The instrument is psychometrically sound, 
brief and easy to complete, thus recommended for both clinical and research applications 
alike [123, 125]. By introducing a cut-off point one can interpret the proportion of the 
respondents with likely mental health disorders. In the literature, 1.85 is the established 
threshold for mental distress and indicator of mental health disorders, and proposes that 
some 50 to 60% of identified cases above the cut-off will be eligible diagnostically for at 
least one mental health disorders [123, 126]. 
 
Population studies have found that mental distress and symptoms of mental health disorders 
are consistently higher among female gender; in addition to people with poor social support, 
low level of education, having financial difficulties, and belonging to an ethnic minority 
[123, 127-129]. Among people with SUD, being female, receiving prior treatment for 
mental health disorders and extended use of substances predicted a higher level of 






1.3.3 Substance use patterns: predictor of poor mental health? 
Concurrent substance use, including prescription medicine misuse (e.g. without 
prescription, higher frequency or dosage than prescribed), is common and prevalent among 
people with SUD and people enrolled in OAT [130, 131]. Benzodiazepines, which are a 
class of drugs that bind to the GABAA receptor producing anxiolytic, sedative and muscle 
relaxant effects, are not only the most frequent prescribed psychiatric drug, but also among 
the prescription drugs most commonly misused [132, 133]. Thus, the misuse of 
benzodiazepines has emerged as a major public health concern, attributed by a dramatic 
increase in benzodiazepine-related overdoses the last decade [134]. People with SUD, and 
especially among people using opioids, have a much higher misuse of benzodiazepines 
compared to the general population [132]. Moreover, benzodiazepines misuse is also 
prominent among people with alcohol use disorders and people using stimulants, and 
strongly associated with risk for other prescription drug misuse [132, 135, 136]. Among 
people enrolled in OAT, the majority of studies report a benzodiazepines use of over 40%, 
which is similar to findings in Norway among individuals in OAT [131, 132, 137]. There is 
also some evidence that benzodiazepine misuse is related to increased HIV and HCV risk 
behavior, poor quality of life (QoL), and contributes to maintain ongoing substance use 
during SUD treatment [132]. Methamphetamine, amphetamine and cocaine, collectively 
known as stimulants, are another important risk factor for poor mental health and suicidal 
ideation [138]. Furthermore, stimulants are associated with increased risk of cardiovascular 
events and mortality, HIV and HCV infections, injury and violent events [139]. 
 
As there are few population-level studies with a longitudinal design addressing the topic of 
substance use patterns among people with severe SUD, causality remain mostly unknown 
[132, 138]. Thus, assessing potential predictors of mental health symptoms and change in 














1.4 Health-related quality of life among people with opioid dependence 
Knowledge of health-related quality of life (HRQoL) among people with opioid dependence 
and long-term OAT treatment is limited [140]. HRQoL, which is a concept that includes 
both societal perspective and an individual’s subjective physical and mental wellbeing, and 
may be an important outcome measure for SUD treatment programs and patient evolvement 
[141]. 
 
1.4.1 Measuring health-related quality of life among people with opioid dependence 
Traditionally most research and clinical practice on OAT have emphasized on “hard 
outcomes”, such as crude mortality rate, opioid abstinence, retention in treatment and 
reducing concomitant drug use [140]. Amid an opioid epidemic, especially in the USA, 
there has been renewed interest from scholars regarding treatment of opioid dependence, 
yet little attention has been given to studying HRQoL outcomes in opioid treatment 
programs [142]. Several researchers have argued that HRQoL, which is a patient-measured 
outcome and perhaps better reflect overall health and personal wellbeing, should be 
included as an outcome when evaluating substance use and OAT treatment [142-145]. In 
addition, HRQoL and quality adjusted life years are viewed as vital treatment outcomes in 
policymaking when evaluating health economics, such as cost-effectiveness analyses [142]. 
Several institutions advocate and encourage the use of validated HRQoL measures, notably 
The US Food and Drug Administration (USA) and the National Institute for Health and 
Care Excellence (UK) [142]. 
 
A range of several aspects complicates the dynamics of the research. There is a practical 
and academic distinction between QoL and HRQoL domains. Whereas HRQoL aims to 
capture a patient’s subjective physical and mental wellbeing, QoL has accentuate a more 
holistic approach to include features beyond health in a patient’s everyday life. Some 
scholars support the use of QoL instruments in opioid use disorders [146], despite a 
systematic review suggesting that current QoL instruments have limitations that hinders 
accurate and sensitive measurement in this particular subpopulation [1]. Many different 
instruments measuring Qol and HRQoL are available, however comparisons and external 
validity are put into question as different methods are used; among the ten different QoL 
instruments assessed, none scored perfectly on both content and properties and thus viewed 
insufficient when measuring QoL among people with opioid dependence [1]. As seen 
above, others advocate the use of HRQoL as it also allows calculation of quality-adjusted 
life years and being able to compare disease burden across various populations without 
being disease-specific, which is especially important in health priority settings [142]. One 
such HRQoL instrument, which has been validated for opioid use disorders, is the EQ-5D-
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5L [147, 148]. The EuroQol Group, which is a network of international multidisciplinary 
researchers since 1987, has developed both the former EQ-5D-3L and the current EQ-5D-
5L [149]. The instrument is a widely used generic measure of HRQoL, which consists of a 
descriptive (societal) part and a visual analogue scale (self-perceived health) [150]. This is 
vital when evaluating responsiveness and detect meaningful changes in health status [151]. 
 
Measuring HRQoL among patients enrolled in OAT programs represents an opportunity 
beyond calculating quality adjusted life years, economic evaluations and comparisons 
across populations – it also offers a real chance to consider a more patient-centered health 
outcome of OAT treatment [142]. 
 
1.4.2 Health-related quality of life among people with opioid dependence 
There is building evidence that HRQoL is substantially lower among people with opioid 
dependence compared to the general population and people with other mental health 
disorders [142, 152-154]. Factors that seem to be associated with poor HRQoL are age, 
female gender, and symptoms of mental health disorders and physical comorbidity, while 
there is more controversy regarding continued substance use and chronic HCV infection 
[152, 155-157]. As the opioid dependent cohort is aging, they seem to be associated with 
considerably more medical problems and worse overall health compared to younger patients 
under 40, which is likely to put additional burden on SUD treatment programs in the future, 
and to better assess and address the needs of these patients [156, 158, 159]. Similarly, 
females in OAT consistently report worse HRQoL and more symptoms of mental health 
disorders compared to their male counterparts [152, 160]. Substance use patterns and 
HRQoL associations are less clear. In a large cohort of OAT patients, the use of 
benzodiazepines was identified as a factor for lower mental HRQoL and use of stimulants 
with higher physical HRQoL compared to non-users of these substances [140]. While the 
use of stimulants and benzodiazepines are among the most commonly used substances 
among people with opioid dependence, it is not necessarily a predictor of poor HRQoL in 
all settings [140, 152, 153]. 
 
People enrolled in OAT with chronic HCV have reported lower HRQoL compared to people 
without HCV in some studies [140, 157]. Conversely, left untreated; OAT patients with 
chronic HCV were associated with worse HRQoL compared to people with chronic HCV 
outside an OAT treatment program [161]. Whereas mental health assessment and 
intervention prior to HCV treatment seem to be a predictor for improved HRQoL, 
interferon-based treatment of chronic HCV alone seems to either worsen or be non-
significantly associated with HRQoL [157, 161]. The poor reported HRQoL might even 
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persist after achieving SVR with this regimen [162]. In the DAA era, however, when a large 
clinical trial compared treatment with interferon-based and DAA treatment regimens; the 
latter was found superior in achieving both high SVR rates and improvements in HRQoL at 
follow-up [162]. 
 
1.4.3 Effect of opioid agonist therapy on health-related quality of life 
The demand for street heroin have declined in recent years in Western Europe, including 
Norway, as the coverage of preventive measures such as OAT have become more available 
for PWID with opioid dependence [31]. In Western Europe, the estimated coverage of OAT 
is above 40 OAT patients per 100 PWID [94]. In Norway probably even higher at up to 60 
OAT patients per 100 PWID [44]. In contrast, places such as USA and Eastern Europe 
coverage of OAT is poor and vary between 1 and 20 OAT patients per 100 PWID [94]. 
Research has shown that is possible to transfer people with heroin dependence rapidly and 
successfully from low-threshold settings to OAT programs despite the presence of severe 
social problems, and comorbid somatic and mental health disorders [163]. A consistent 
finding in the literature is a considerably lower self-reported HRQoL among these patients 
prior to, and upon, treatment initiation of OAT, as compared to the general population [152, 
154, 164]. However, many of the previous studies are cross-sectional rather than 
longitudinal designs, offers few participants and with non-validated HRQoL measures for 
opioid dependence, which make comparisons challenging across various disease 



















1.5 Rationale for the studies 
As shown in the introduction, people with severe SUD are a marginalized subpopulation 
with risk of serious somatic and mental health comorbidities and an early death. HCV is an 
infectious disease, which in particular impact people with severe SUD who inject or have 
injected drugs. With the emergence of new effective medications for treatment of chronic 
HCV there is an opportunity to eliminate a deadly infectious disease and prevent hepatitis-
related complications and mortality. Elimination strategies at country level demands 
unrestricted access to these new medications and being able to monitor the treatment uptake 
and outcomes. As such, OAT has been proposed to play a key role as delivery platform for 
integrative and upscaling HCV care. At the time of study and study planning, with changing 
national guidelines and restrictive DAA treatment policies, there was a lack of knowledge 
concerning the HCV prevalence and treatment uptake among OAT patients, which paper I 
aimed to fill [166]. 
 
While there is building evidence of the vast co-occurrence of mental health disorders among 
people with severe SUD, considerable less is known about how substances and use patterns 
influence the symptom burden over time. The second paper used a longitudinal design to 
address this question [167]. 
 
OAT is an evidenced based medical intervention for people with opioid dependence and the 
most important preventive measure. HRQoL has emerged as an important outcome measure 
of OAT treatment, however the knowledge is scarce and only infrequently implemented in 
OAT programs [142]. Research have repeatedly shown a substantially lower HRQoL 
among these patients before and upon treatment initiation of OAT, while there is still a large 
gap in the knowledge about long-term OAT patient’s HRQoL. This was the rationale for 
the third paper, which assessed the HRQoL of long-term OAT patients at baseline and after 













2. Aims and objectives of the thesis 
2.1 Aims 
The overall aim of this thesis was to study the burden of disease among people with severe 
substance use disorders (SUD). The first aim was to study the treatment uptake of chronic 
hepatitis C (HCV) among people enrolled in opioid agonist therapy (OAT), secondly to 
assess symptoms of mental health disorders and effect of substance use patterns, and thirdly 
describe the health-related quality of life (HRQoL) among long-term patients in OAT. 
 
2.2 Objectives 
In order to reach the aims of the thesis, the following objectives were addressed: 
• Estimate the prevalence of chronic HCV and calculate HCV treatment annually and 
cumulatively after the introduction of DAA among people in OAT in Sweden and 
Norway, 2014 to 2017 (paper I) 
• Assess symptoms of mental health disorders among people with severe SUD and 
evaluate how substance use patterns, clinical and sociodemographic factors affect these 
symptoms over time (paper II) 
• Assess the HRQoL and self-perceived health in long-term OAT patients at baseline and 



















3. Materials and methods 
In order to answer the research objectives stated above, this thesis has utilized observational 
data from nationwide registries and a nested cohort study, and modeled HCV prevalence from 
both primary and secondary data sources. 
 
3.1 Study settings 
The first study about HCV treatment uptake collected data from the entire Swedish and 
Norwegian populations to identify people with dispensions of OAT (and HCV) treatment 
from 2014 to 2017. The studies for paper II and three took place in Bergen and Stavanger, 
which are cities in southwestern parts of Norway with around 280,000 and 130,000 
inhabitants each. The target population was individuals with opioid dependence who 
received OAT treatment in Sweden and Norway (paper I) and in all together nine OAT 
outpatient clinics (paper II and three) and two low-threshold municipality clinics (paper II) 
in Bergen. Figure 1 provides an overview of the timeline and study settings:
01.01.2014 31.12.2020

























A total of 11.268 individuals included, 7.739 in Norway and 3.529 in Sweden during 
the study period from 2014 to 2017 
Inclusion criteria:OAT* medication >1 DDD/day/year, ≥18 and ≤75 years old
Exclusion criteria:OAT* medication <1 DDD/day/year, <18 and >75 years old
Approximately 900 invited 
from OAT outpatient 
polyclinics
609 recruited at baseline with 
at least one EQ-5D-5L 
assessment
245 included at follow-up 
with two EQ-5D-5L 
assessments
Approximately 1050 invited 
from OAT outpatient and 
municipality clinics
707 recruited at baseline with 
at least one SCL-10 measures
268 included at follow-up 
with least two or more SCL-
10 measures
1042 SCL-10 measures total





 Figure 1: Timeline, settings and papers included in this thesis 
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3.1.1 Opioid agonist therapy in Sweden and Norway 
Sweden and Norway have similar welfare and national healthcare systems where the 
standard is open access to health care for all inhabitants. As such, and in theory, all residents 
with a diagnosed opioid dependence according to International Classification of Diseases 
have free access to opioid agonist therapy (OAT) in Norway, however in Sweden, a 
diagnosis for at least 12 months is required for treatment entry [33, 169]. Pharmacotherapy 
with either buprenorphine or methadone, in an integrated program with psychosocial 
support is the mainstay of treatment even though there are vast intercountry differences to 
this approach [39, 169, 170]. 
 
Whereas the first methadone maintenance treatment program dates back to the 1960s in 
Sweden, modelled after the Dole and Nyswander program, Norway first implemented OAT 
in 1998 into the general health and social security system [33, 171]. In both countries, 
inclusion into the program was strict and thus characterized as high threshold and restrictive. 
However, this practice was abolished in Norway according to the new OAT guidelines from 
2010. Since then, entry requirements have been minimal where opioid dependence has been 
the absolute inclusion criteria, the whole OAT program has expanded and taken over by the 
specialist health services, and patients were no longer subject to involuntary termination 
based on e.g. illicit substance use [33, 39, 41, 172]. This is not the case in Sweden. Even if 
admittance criteria are currently less strict compared to previous ones [171], in cases of 
repeated illicit substance use while receiving OAT, the provision of OAT may be ceased 
and patients referred to other types of treatment [32, 42]. There are currently around 7,500 
individuals on OAT in Norway and 4,400 in Sweden [42, 173]. Attempts to estimate OAT 
coverage among people with opioid dependence have proven difficult due to the criminal 
nature of illicit drug use, difficulties in identifying injecting drug users and people in need 
of treatment. 
 
3.1.2 Opioid agonist therapy in Bergen and Stavanger (Norway) 
The OAT outpatient clinics in Bergen and Stavanger have implemented an integrated 
treatment and care model where patients are followed-up on a near daily basis by general 
and specialized nurses, psychologists and physicians who are under specialization- or 
specialized in addiction medicine. There are around 1,030 enrolled in OAT in Bergen and 
surrounding counties, and around 180 patients enrolled in OAT Stavanger [174]. People 
with severe SUD in the municipality clinics are to some degree overlapping with the OAT 
clinics in Bergen. They are estimated to be around 700 with frequent weekly contact. 
Patients are followed-up by social workers, general nurses and physicians specialized in 
family medicine. The Integrated Treatment of Hepatitis C (INTRO-HCV) study have 
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employed trained research nurses who collected blood samples and completed the structured 
patient interviews, which were recorded in a health register using an electronic data 
collection software (CheckWare®).  
 
3.2 Data sources 
The papers included in this thesis are based on data from four sources; two national health 
registries; The Norwegian Prescription Database (NorPD) and The Swedish Prescribed 
Drug Register (SPDR) (paper I), a mathematical model for estimating HCV prevalence in 
Norway and Sweden (paper I), and one observational cohort from the INTRO-HCV study 
[174] (paper II and III). 
 
3.2.1 The Norwegian Prescription Database 
The Norwegian Prescription Database (NorPD) was established on January 1, 2004 at the 
Norwegian Institute of Public Health. It covers the entire Norwegian population, and 
monitors drugs dispensed by prescription in Norway. Pharmacies are obliged to register 
dispensed drugs made to individuals, and pass the information to NorPD electronically once 
a month. Drugs that are purchased without prescription, such as over the counter, or supplied 
to hospitals and nursing homes are not included in NorPD on individual level [175]. Each 
dispension provides detailed drug information, including Anatomical Therapeutic Chemical 
Classification System code (ATC), patient information (gender, date of birth, date of death, 
county of residence and more), and prescriber information (profession, medical specialty, 
county of occupation). Diagnosis and indication for use is not always evident, however, 
reimbursement codes can be used as guidance for disease after 2008 [175].  
 
3.2.2 The Swedish Prescribed Drug Register 
The Swedish Prescribed Drug Register (SPDR) was established in 2005. As with NorPD, 
the register includes dispensed drugs from all Swedish pharmacies and thereby excludes 
drugs used in hospitals, nursing homes and drugs purchased over the counter. In addition, 
SPDR also follows the WHO ATC Classification system [176]. SPDR contains information 
equal to NorPD in terms of patients and prescriber information. From a research perspective, 
both National registries provide valuable data on exposure to drugs and is useful to study 
patterns of drug utilization [177].  
 
3.2.2.1 Anatomical Therapeutic Chemical (ATC) Classification System 
All dispensed drugs in Norway and Sweden are classified according to ATC developed by 
the WHO Collaborating Centre for Drug Statistics Methodology [178]. The ATC system 
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consists of five levels as shown below, going from a main anatomical or pharmacological 
group to the actual chemical substance(s): 
 
Table 2: Anatomical Therapautic Chemical (ATC) Classification System 
ATC Level 1: The system has 14 main anatomical or pharmacological groups, from A: 
Alimentary tract to V: Various. E.g. J: Antiinfective for systemic use 
ATC Level 2: Pharmacological or Therapeutic subgroup. E.g. J05 Antivirals for 
systemic use 
ATC Level 3: Chemical, Pharmacological or Therapeutic subgroup. E.g. J05 A Direct 
acting antivirals 
ATC Level 4: Chemical, Pharmacological or Therapeutic subgroup. E.g. J05 AP 
Antivirals for treatment of hepatitis C infections 




3.2.2.2 Defined daily doses (DDD) 
By definition the DDD is the assumed average maintenance dose per day for a drug used 
for its main indication in adults according to WHO Collaborating Centre for Drug Statistics 
Methodology [178]. The DDD is only allocated to drugs that are approved and marketed in 
at least one country, and assigned an ATC code. However, since the DDD is a unit of 
measurement it is not always the recommended prescribed daily dose, and especially 
problematic for opioids with dissimilar indications. One example is methadone (DDD of 
25mg/day), which is normally prescribed in doses above 60mg/day as this have better 
treatment outcomes in OAT compared to lower doses [178, 179]. 
 
3.2.3 Modelling the prevalence of chronic hepatitis C 
Prevalence data of chronic HCV among OAT patients were not readily available for either 
Norway or Sweden at the time of study. An estimation from the best available primary and 
secondary sources was thus made. Data was used from the INTRO-HCV study from Bergen 
and Stavanger as a proxy to estimate prevalence among Norwegian OAT patients [174]. 
Among 752 patients, blood samples showed a prevalence of anti-HCV of 81% and HCV 
RNA of 45%. Anti-HCV, which is antibodies to the HCV virus, indicate current infection, 
clearance of the infection, or that anti-viral treatment has been successful. HCV RNA 
indicates current infection. History of injecting drug use was also included. Among OAT 
patients in the cohort, 4.9% answered they have never injected drugs and we subsequently 
counted those as non-PWID. 




Based on the assumption that Norway and Sweden hold similar demographics, including 
drug cultures and behaviors [180], we generalized the proportion of non-PWID from the 
Norwegian cohort to also represent the Swedish cohort. It is assumed that anti-HCV 
prevalence is 0.7% among non-PWID in both Norway and Sweden, which was derived from 
estimates of HCV prevalence among adults in the general population from a comprehensive 
global review of HCV epidemiology [181]. In addition, several studies have pointed 
towards a high prevalence of Anti-HCV among Swedish PWID [182]. For the purpose of 
estimating prevalence among the Swedish patients we used published data from a large 
cohort of PWID in Stockholm, which reported a prevalence of anti-HCV of 82% [183]. 
Moreover, a systematic review have estimated that spontaneous clearance of HCV occurs 
in approximately 26% (95% confidence interval (CI) 22-29%) of acute HCV infections, 
with the remaining proportion of cases becoming chronic [184]. The above assumptions 
enabled us to derive a simple formula to estimate chronic HCV prevalence in Norway and 
Sweden:  
 
𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑐𝑐ℎ𝑛𝑛𝑜𝑜𝑛𝑛𝑟𝑟𝑐𝑐 𝐻𝐻𝐻𝐻𝐻𝐻
= ((1 − 𝛿𝛿) ∗ [𝜙𝜙 ∗ 𝜋𝜋𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 + (1 − 𝜙𝜙) ∗ 𝜋𝜋𝑁𝑁𝑁𝑁𝑁𝑁𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃] ∗ 𝑁𝑁) − 𝜏𝜏 
 
where 𝑁𝑁 is the size of the study population, 𝛿𝛿 is the rate of spontaneous HCV clearance, 𝜙𝜙 
is the proportion of OAT patients who are PWID, 𝜋𝜋𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 and 𝜋𝜋𝑁𝑁𝑁𝑁𝑁𝑁𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 are the anti-HCV 
prevalence estimates among PWID and non-PWID, respectively, and 𝜏𝜏 is the number of 
HCV treatments given (see 3.3.2). 
 
3.2.4 The integrated treatment of hepatitis C cohort 
The INTRO-HCV is a nested cohort study linked to the multicenter randomized controlled 
trial and longitudinal observation study [174]. The data included in this thesis was collected 
from 2016 to 2020, as part of an annual health assessment among people with severe SUD 
in Bergen and Stavanger. The main aim of the main study is to compare the efficacy of 
integrated and standard treatment of HCV. The study design is described in detail in the 










3.3 Study design, sample and assessments 
By design, all studies included in this thesis are observational studies as shown below.  
Table 3: Overview of study samples in the thesis 
 Paper I Paper II Paper III 
Study design Population-based Prospective cohort Prospective cohort 
Study setting Sweden and Norway Western Norway Western Norway 
Data sources NorPD, SPDR, 
modelling 
Intro-HCV cohort Intro-HCV cohort 
Inclusion criteria OAT* medication >1 
DDD/day/year, ≥18 and 




No consent required 
Opioid dependence 
according to ICD-10 or 
having a severe 
SUD/PWID, ≥18 and 





according to ICD-10 ≥18 






Individuals included 11,268: 3,529 in the 
Swedish cohort, 7,739 in 
the Norwegian cohort 
707 609 
Participation rate, % 100 67*  68* 
Follow-up rate, %* 100** 38 40 
Assessments Dispensations 
 
Hopkins SCL-10 EQ-5D-5L and EQ-VAS 
Main outcomes 
studied 
HCV treatment uptake 
among OAT patients 
Symptoms of mental 
health disorders and 
substance use patterns 
Health-related quality of 
life among long-term 
OAT patients 
 
3.3.1 Paper I 
The first study was an observational study among patients in OAT in Sweden and Norway 
from 2014 to 2017. Data were extracted from SPDR and NorPD. The registries cover the 
entire Norwegian and Swedish populations, thus have true population-based coverage. HCV 
prevalence data among OAT patients was unknown, consequently, we employed primary 
and secondary sources to estimate HCV prevalence as described above. The study sample 
included all individuals aged 18 to 75 years who were dispensed at least one DDD per day 
per calendar year of buprenorphine (ATC N07BC01), methadone N07BC02), 
NorPD = Norwegian Prescription Database, SPDR = Swedish Prescribed Drug Register, INTRO-HCV = 
Integrated treatment of Hepatitis C, HCV = hepatitis C, OAT = opioid agonist therapy, SUD = substance 
use disorder, PWID = people who inject drugs, ICD 10 = WHO international classification of disease, SCL-
10 = symptom check list 10 
*The participation rate in OAT Bergen among frequent users is around 90%, the above estimate is for 
Bergen and surrounding counties of all possible invitees. Follow-up is not equal to drop-out since many 
have a delay and not fallen out of the study 
**This is estimated. In case of hospitalization or incarceration there may be periods without dispensations 
captured in the nationwide registries 
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buprenorphine-naloxone (N07BC51), and levomethadone (N07BC05) in Sweden and 
Norway, by summarizing all annually dispensed OAT DDDs divided by 365.25 days. 
Inclusion criteria was set at a dosage at minimum one DDD per day/per annum to avoid 
including other medical indications than OAT. The study sample was thus chosen annually 
for both countries and it was possible for an individual to be included in more than one 
calendar year. Using this inclusion procedure, a total of 11,268 individuals were included 
for the main analysis (Figure 2). 
 
3.3.2 Pharmacoepidemiological assessment 
HCV treatment was defined as being dispensed either one or more pegylated interferon 
alpha (L03AB05 and L03AB11) in combination with ribavirin (J05AP01), or one or more 
of the DAA (group J05AP) per calendar year during the study period. Similarly, considering 
certain drugs as predictors for DAA treatment, dispensations were recorded at the second 
ATC level, except for drugs affecting the nervous system, which was recorded at the third, 
fourth, and fifth ATC levels (Table 2).  
 
3.3.3 Paper II 
The second study was a nested prospective cohort study linked to the multicenter INTRO-
HCV study, and data was collected from May 2017 until July 2020 as part of an annual 
health assessment. The study sample was comprised of two groups of patients; individuals 
diagnosed with opioid dependence (F11.2) according to International Classification of 
Diseases version 10 (ICD-10) [185] where the majority (83% at baseline, 93% of follow-
up) were enrolled in OAT during the study period, and people with severe SUD and 
injecting drug use being cared for at the municipality clinics. All included individuals were 
18 years or older at time of inclusion and signed a written informed consent to partake in 
the study. 
 
3.3.3.1 Assessment: Hopkins symptom check list (SCL-10) 
The SCL-10 is a structured and self-administrated questionnaire, designed to measure 
symptoms of mental health disorders and psychological distress, and is widely used [123, 
125, 186]. The SCL-10 involves ten items (suddenly scared for no reason, feeling fearful, 
faintness, dizziness or weakness, feeling tense, blaming yourself, difficulties falling asleep, 
feeling of worthlessness, feeling blue, feeling hopeless, and feeling everything is an effort), 
which are each scored on four dimensions from not bothered at all (item score = 1) to 
extremely bothered (item score = 4). Scores were summed and divided by the number of 
items answered to derive the mean item score. Mean scores vary between one and four, 
where the latter assumes extremely bothered. SCL-10 mean item scores were used for 
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descriptive analyses while SCL-10 sum scores were used in linear mixed model (LMM) 
analyses. Furthermore, the mean item scores were calculated by gender, age, level of 
education, and living conditions at baseline. By introducing a cut-off point one can interpret 
the proportion of the respondents with symptoms of mental health disorders. A mean score 
of 1.85 for SCL-10 has been recommended as a threshold for indicating substantial mental 
health distress [123]. 
 
3.3.4 Paper III 
Also the third study was nested prospective cohort study linked to the INTRO-HCV study, 
and the data was collected from May 2017 until July 2020. The study sample included 
individuals diagnosed with opioid dependence according to ICD-10 [185], currently 
enrolled in OAT treatment, aged 18 years or older, and had given a written informed consent 
to participate in the study. 
 
3.3.4.1 Assessment: Health-related quality of life: EQ-5D-5L 
The EQ-5D-5L instrument is a widely used generic measure of HRQoL [149] and validated 
for opioid use disorders [147, 148]. It consists of two components. The first descriptive 
system evaluates health in five dimensions (mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression). Each dimension has five levels of response, ranging 
from no problems, slight problems, moderate problems, severe problems, to extreme 
problems [150]. The second part of EQ-5D-5L entails a visual analogue scale (VAS) where 
the respondent rates the self-perceived health from 0 (worst health imaginable) to 100 (best 
health imaginable) [150]. A systematic review have supported the use of the EQ-5D-5L in 
a broad range of patients, and was thus selected to assess the HRQoL among OAT patients 
[187]. 
 
3.4 Statistics analysis 
The quantitative analyses for this thesis have been performed by the author in close 
collaboration with the co-authors. Except for the LMM and expectation-maximization 
analyses for paper II, which were performed in IBM SPSS version 26.0, all other analyses 
used STATA/SE 16.0. Statistical significance was set at the p <0.05 level. 
 
3.4.1 Paper I 
For this study the cumulative treatment uptake of HCV was defined as the proportion of the 
individuals estimated with chronic HCV exposed to treatment at some point during the study 
period from 2014 to 2017. The unadjusted annual HCV treatment, was assessed among all 
patients with dispensed OAT treatment per calendar year (Table 4), and calculated as the 
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number of treated individuals divided by the number of individuals with dispensed OAT 
with confidence intervals (CI). Using the above formula (under 3.2.3), expected number of 
chronic HCV infections were calculated, with uncertainty in this quantity arising only from 
the uncertainty in spontaneous clearance. By dividing the expected number of chronic HCV 
infections by the total population size in that particular year and setting, prevalence was 
estimated. HCV treatment uptake was than estimated by dividing the HCV treatments in 
each year by the estimated number of chronic HCV infections in that same year, yielding a 
percentage of chronic HCV infections that were treated per year. The cumulative HCV 
treatment uptake was then calculated as the sum of HCV treatment uptake across successive 
years. 
 
In this paper we presented the descriptive data as frequencies, percentages, and means, with 
corresponding 95% CI and uncertainty intervals where appropriate. Logistic regression was 
done to assess whether potential predictors, which were determined a priori; methadone vs 
buprenorphine-based OAT medications, stratified age, gender, and various dispensed drugs 
as binary variables (yes vs no) from different therapeutic areas affected the outcome 
variable, which was DAA treatment in 2017, and presented with 95% CI and adjusted odds 
ratio (OR). 
 
3.4.2 Paper II 
In this study we defined baseline as the time when the first SCL-10 measure was completed 
at the first annual health assessment. Additional SCL-10 measures at the next health 
assessment(s) were listed chronologically and included as follow-up. OAT was defined as 
receiving an OAT medication as baseline. Moreover, the OAT ratio, which corresponds to 
the received dose of OAT medication per day divided by expected mean dose 
(buprenorphine 18 mg or methadone 90 mg) according to WHO [188], was calculated per 
OAT patient. Furthermore, injecting substances was defined as having any substance 
injected during last 12 months, while frequent substance use was defined as using a 
substance (alcohol, cannabis, stimulants, non-OAT opioids, and benzodiazepines) more 
than once weekly during the last year. Most of the sociodemographic data was defined as 
categorical variables. Any missing values were assumed to be missing at random when 
performing expectation-maximization imputation. Overall, there were missing values for 
3.4% of these values, which were subsequently replaced with the estimated values by 
expectation-maximization imputation according to Enders (2010) [189].  
 
Descriptive data was presented as frequencies, percentages, means and standard deviations 
(SD), with corresponding 95% CI where applicable. Moreover, in order to evaluate the 
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impact of substance use patterns, clinical and sociodemographic factors at baseline and over 
time, we used a longitudinal LMM analyses where time was defined as years from baseline, 
and impact on the SCL-10 sum score assessed. The model was a random intercept fixed 
slope model with restricted maximum likelihood regression. Based on the full information 
maximum likelihood estimator all available data in the outcome variable were used. This 
was a two-step procedure where first each defined predictor variable was set against time – 
to evaluate if the predictor variable itself changed over time. However, there was no 
clinically significant changes when analyzed separately as outcome variables (time variable 
being the exposure variable). This allowed the model to include the predictor variables as 
time-independent variables in the second step. A new LMM was subsequently made with 
the predictor variables (time-independent) set against the SCL-10 sum score as the outcome 
variable. Furthermore, a time interactional was added to each predictor variable to 
investigate if time impacted changes of SCL-10 given each predictor. The predictor 
variables, on the baseline level and change in SCL-10 sum score, represented as main effects 
and interaction effects with time.  
 
3.4.3 Paper III 
Baseline was defined as the time when the first EQ-5D-5L assessment was completed at the 
first annual health assessment. Additional EQ-5D-5L assessment at the next health 
assessment was included as follow-up. The mean time between the first and second annual 
OAT assessment was 375 days (95% CI: 359-392 days). Responses to the five HRQoL 
dimensions are coded as a five-digit code, which represents a numerical description of a 
health state. The digits have no arithmetic properties and therefore a single summery number 
(an index value) needs to be arrived by applying a formula with an appropriate value set, 
which is a representative sample of the general population. The index value then represents 
how good or bad a health state is according to the preferences of the general population, 
ranging from 1 (full health) to 0 (dead, with negative values indicating health states worse 
than death)  [150]. In the absence of a Norwegian value set, we applied an EQ-5D-5L value 
set for UK to determine the EQ-5D-5L index values for each health state in the OAT cohort 
[190]. 
 
Summary statistics were derived, including proportions and number of patients for the five 
EQ-5D-5L dimensions by age, gender, and OAT medications. The EQ-VAS score was 
summarized descriptively by mean, SD, minimum and maximum. A paired t-test of means 
for the 245 patients with two time points was used in the analysis to investigate whether 
there was any statistical significance in EQ-5D-5L between the measurements. An 
ANCOVA model for EQ-VAS changes from baseline to the next OAT health assessment 
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was conducted where place and treatment were fixed effects and baseline covariate. If data 
were missing from more than one dimension, participants were excluded. Altogether eight 
patients missed data on one dimension at baseline but were included in the analyses. There 
were no missing data from EQ-5D-5L follow-up or EQ-VAS. 
 
To estimate the unbiased treatment effects from baseline to follow-up we used an inverse 
probability weighted method as we had follow-up data for a subgroup. We calculated 
population weights based on age, gender and how many times OAT medication was 
collected during a week in a binominal regression model with follow-up values as the 
dependent variable. More weight was given to cases with valid data, which were associated 
with highest probability of having missing data, and less weight was given to cases with 
lowest probability of missing. The mean for the population weights was 1.0 (SD 0.1) in our 
model. 
 
3.5 Ethical considerations 
All the studies included in this thesis have been approved by the regional committee for 
ethics in medical research in Norway (REK) and the Regional Ethical Review Committee 
in Sweden; paper I (no. 2018/939 and no 2018/2080-31/1), paper II and III for the Integrated 
treatment of hepatitis C virus infection among people who inject drugs: (INTRO-HCV) 
(REK Vest no. 2017/51) [174]. Furthermore, the studies were conducted in accordance with 
the Helsinki Declaration. A written informed consent was obtained for all participants in 
study two and three. In the first study, however, no written informed consent was required 
by the ethical committees as the data received was received pseudo-anonymous and 
encrypted. As the registers include sensitive information, data handling requires some 
caution. Therefore, data have been kept strictly on approved Helse Bergen research servers 
throughout the study period and in accordance with the Data Protection Impact Assessment, 
governed by Krister Kleppe; the data protection officer in Helse Bergen.  
 
Even if all three studies were purely observational by design, and did not present any 
immediate risks or benefits to the participants, their contribution is of utmost importance 
not only to answer research questions, but ultimately contribute to knowledge that will 









4.1 Objective I: Estimate the prevalence of chronic HCV and calculate HCV treatment 
annually and cumulatively after the introduction of DAA among people in OAT in 
Sweden and Norway, 2014 to 2017 (paper I) 
 
4.1.1 Basic characteristics 
Altogether 11,268 individuals were identified with dispensed OAT treatment in Sweden and 
Norway. In Sweden, 3,529 individuals receiving OAT were included during the study 
period from 2014 to 2017, where the majority was male (70%) with a mean age (SD) of 
around 44 (10) and 45 (11) years in 2014 and 2017, respectively. In Norway, 7,739 
individuals were included with OAT treatment during the study period; the majority male 
(70%) with mean age (SD) of 44 (9) in 2014 and almost 46 (9) years in 2017. In both 
countries most of patients received buprenorphine-based OAT medications (up to 55 and 
56% in 2017). Overall, 407 individuals in the Swedish cohort were dispensed HCV 
treatment, and 920 in Norway during the study period. 
 
4.1.2 Main findings 
The main finding from this study was the cumulative treatment uptake; 28% (uncertainty 
interval (UI): 27-30) of the OAT patients in Sweden and 31% (UI: 29-32) of the OAT 
patients in Norway, with estimated chronic HCV, received treatment from 2014 to 2017. 
 
Based on our model HCV prevalence was estimated to range from 56% (UI: 53-59) in 2014, 
to 53 (UI: 51-56) in 2017 for Sweden. In Norway, prevalence was estimated from 54 (UI: 
52-58) in 2014 to 50 (UI: 48-53) in 2017. In Sweden, annual HCV treatment uptake was 
thus calculated to 3.6% (UI: 3.5-3.8) in 2014, and 8.5% (UI: 8.0-8.9) in 2017. In Norway, 
annual HCV treatment uptake was calculated to 4.5% (UI: 4.3-3.7) in 2014, and 13.6% (UI: 
12.8-14.3) in 2017. The proportion of DAA treatment increased throughout the study period 
and reached 99% and 97% in Sweden and Norway in 2017, respectively. Annual and 
cumulative estimated HCV treatment uptake in Norway and Sweden for 2014 and 2017 is 









Table 4: Annual and cumulative estimated HCV treatment uptake in Norway and Sweden 
among OAT patients in 2014 and 2017 
          
  2014 2017 
Country Norway Sweden Norway Sweden 
HCV treatment n (overall) 148 54 378 124 
Study population n, 6057 2663 5545 2739 
HCV treatment  % (95% CI) 2.4 (2.1-2.8) 2.0 (1.5-2.6) 6.8 (6.2-7.5) 4.5 (3.8-5.3) 
Expected proportion of OAT patients who are not 
PWID, n* 303 133 277 137 
Expected Anti-HCV, weighted by PWID status, 
n** 4651 2075 4258 2135 
Expected chronic HCV after spontaneous 
clearance, n (UI)*** 3442 (3303-3628) 1536 (1474-1619) 3151 (3023-3321) 1580 (1516-1665) 
Expected chronic HCV after treatment, n (UI) 3294 (3155-3480) 1482 (1420-1565) 2773 (2645-2943) 1456 (1392-1541) 
Expected chronic HCV after spontaneous 
clearance and treatment, % (UI) 54.4 (52.1-57.5) 55.6 (53.3-58.8) 50.0 (47.7-53.1) 53.1 (50.8-56.3) 
Estimated HCV treatment uptake % (UI) 4.5 (4.3-4.7) 3.6 (3.5-3.8) 13.6 (12.8-14.3) 8.5 (8.0-8.9) 
Estimated HCV cumulative treatment uptake % 











4.1.3 Secondary findings 
Finally, certain predictors, which were determined a priori, were evaluated for any 
association with DAA treatment in both countries. In Sweden, being dispensed DAA 
treatment was associated with increased age (adjusted odds ratio (aOR) 1.8; 95% CI 1.0-
3.2) and dispensation of drugs used in diabetes (aOR 3.2; 95% CI 1.8-5.7). In Norway, 
dispensations of cholesterol modifying medications and antibiotics were associated with 
decreased odds (aOR 0.4; 95% CI 0.2-0.9, aOR 0.8; 95% CI 0.6-1.0) of receiving DAA 
treatment. Being female was associated with decreased odds in both countries (Sweden: 




OAT = opioid agonist therapy, HCV = hepatitis C virus infection, CI = confidence interval, UI = uncertainty 
interval,  
Anti-HCV = antibodies to hepatitis C virus, PWID = people who inject drugs 
Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD), Intro-
HCV = Integrated treatment of hepatitis C study, Kåberg et al. (2017): Prevalence of hepatitis C and pre-testing 
awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program,  
Micallef et al. (2006): Spontaneous viral clearance following acute hepatitis C infection: a systematic review of 
longitudinal studies 
 
*Expected non-PWIDs among OAT patients set to 5% 
**Expected Anti-HCV among PWID in Norway 80.8%, expected Anti-HCV among PWID in Sweden 82%, 
expected Anti-HCV among non-PWID in both Norway and Sweden is 0.7% 
***Expected spontaneous clearance 26% (22-29%) 
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4.2 Objective II: Mental health symptoms and substance use (paper II) 
 
4.2.1 Basic characteristics 
In this study 707 individuals were included from the OAT outpatient clinics and low-
threshold municipality clinics. The study sample was similar in basic characteristics to the 
HCV study; the majority were male (71%), with a mean age of 43 at baseline and 45 years 
at follow-up. The vast majority of the study sample was enrolled in OAT; 82% at baseline 
and 93% at follow-up. More than half had injected substances at least once during the last 
year, while 71% reported frequent substance use; most prevalent substances being cannabis 
(50%), benzodiazepines (38%), stimulants (28%), alcohol (25%) and non-OAT opioids 
(16%). A high proportion of the study sample (88%) reported stable living conditions at 
baseline, while less than half (41%) had a subjective worrying debt situation. 
 
4.2.2 Main findings 
A considerable symptom burden was reported among the study sample; the mean (standard 
deviation, SD) SCL-10 item scores was 2.2 (0.8) at baseline, with 65% of the cohort 
reporting a SCL-10 score above the validated threshold of 1.85 [123]. The solid black line 
show the mean SCL-10 scores of the study sample, while the black dotted line represent the 







Figure 2: Distribution of Hopkins SCL-10 scores at baseline and follow-up. 
HRQoL = Health-related quality of life 
Source for general population comparison: Strand et. al (2003): Measuring the mental health status of the 
Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36) 
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Of the 707 individuals recruited at baseline, 268 (38%) had SCL-10 measures at two data 
points. There was large individual variation in symptoms of mental health disorders and sharp 
changes in symptom burden, in both positive and negative directions, were observed. A linear 
mixed model analysis was subsequently conducted with the SCL-10 sum scores; symptoms 
of health symptoms at baseline were particularly prevalent among females (SCL-10 sum 
score: 1.8, 95% confidence interval (CI): 0.7 to 3.0), people with frequent use of cannabis 
(1.3, CI: 0.2 to 2.5), non-OAT opioids (2.7, CI: 1.1 to 4.2), and benzodiazepines (3.6, CI: 2.4 
to 4.8) compared to males and people with no or less frequent use of these substances at 
baseline. Moreover, people with unstable living conditions (1.7, CI: 0.0 to 3.3) and having a 
worrying debt (2.2, CI: 1.1 to 3.3) had increased mental distress compared to people with 
stable living conditions and non-worrying debt, respectively. On the other hand, frequent use 
of stimulants was associated with lower SCL-10 sum score at baseline (-2.7, CI: -4.1 to -1.4) 
compared with people with no or less frequent use. However, in the time-trend analyses, we 
found no clear associations between substance use patterns, sociodemographic characteristics 
and change in mental health symptoms over time. 
 
4.2.3 Secondary findings 
Overall, many individuals reported considerable mental distress. The mean (SD) SCL-10 
score for all items was 2.2 (0.8) at baseline, which showed that 65% of the cohort had a mean 
score >1.85, the standard reference score for symptoms of mental health disorders. 
 
4.3 Objective III: HRQoL and self-perceived health in long-term OAT patients at baseline 
and follow-up one year later (paper III) 
 
4.3.1 Basic characteristics 
The target study sample was OAT patients. Six hundred and nine patients were included 
from the OAT outpatient clinics with a mean (SD) duration of OAT treatment of 7.9 (5.4) 
years, while total length of OAT treatment ranged from 0 to 25 years for the whole study 
sample. Included individuals were predominantly male (71%) with a mean age of 44 years. 
Most received buprenorphine-based medication (60%) followed by methadone (38%).  
 
4.3.2 Main findings 
Considerable impairments in HRQoL and self-perceived health (EQ-VAS) were found in 
many of the OAT patients at baseline; mean overall scores for the five dimensions were 1.7 
(95% CI: 1.6-1.8) for mobility, 1.3 (95% CI: 1.2-1.3) for self-care, 1.8 (95% CI: 1.7-1.9) 
for usual activity, 2.3 (95% CI: 2.2-2.4) for pain/discomfort and 2.7 (95% CI: 2.6-2.8) for 
anxiety/depression. In addition, females and patients receiving methadone treatment 
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reported more problems across all EQ-5D-5L domains compared to males and patients on 
buprenorphine-based medications, respectively.  
 
Patients in the age group 41-60 reported more problems on every domain except 
pain/discomfort compared to patients under 40 years of age. The mean (SD) EQ-VAS score 
of OAT patients was 57 (22) for the total sample at baseline, meaning their self-perceived 
health was considerably lower compared to the Norwegian reference population of 80 (19) 
[191]. Again, lower scores were observed for females (56, SD 23), patients over 41 years 
old (54, SD 23), and with methadone treatment (53, SD 22). The mean (SD) EQ-5D-5L 
index value for OAT patients was 0.699 (0.250) at baseline. However, 43% had an index 
value above 0.8, meaning they had “no problems” in the five health domains. Thirty-four 
percent of the sample even had an index value above 0.848 (Norwegian reference population 
[191]), meaning their HRQoL was better than that of the Norwegian general population and 
shown in Figure 3 with solid blue line and dotted blue line, respectively. Around five percent 
had an index value below 0.2, meaning they had “extreme problems” in their HRQoL. 
 
4.3.3 Secondary findings 
The large variations in EQ-5D-5L, which were observed between individuals at baseline, 
were also seen at follow-up analysis one year later. Significant improvement in overall 
HRQoL (p=0.004) was observed at one-year follow-up with around half of the OAT patients 
reported some improvement in HRQoL; for both genders (m: p=0.039, f: p=0.016), age 
group 26-40 (p=0.002) and buprenorphine-based patients (p=0.027). The mean (SD) EQ-
5D-5L index value was 0.729 (0.237) at follow-up; 49% had an index value above 0.8 while 
37% of the sample had an index value above the Norwegian reference population. Around 
four percent had an index value below 0.2, as shown in the Pen’s Parade below:  
 
 Figure 3: Distribution of HRQoL index values at baseline and follow-up. 
Sources: HRQoL index values for the Norwegian general population Stavem et al (2018): General 




This thesis has described the immense symptom burden and key challenges facing people with 
severe SUD in Sweden and particularly Norway. There are obvious challenges from a societal, 
clinical and patient perspectives in terms treatment and improving patient care. The discussion 
will start by a short summary of the key study findings before discussing key methodological 
aspect on the basis of research literature and more specific addiction research in light of these 
findings. Finally, it will discuss some of the study implications and recommendations. 
 
5.1 Key findings 
The first study was a population-based observational study assessing the HCV, including 
DAA, treatment uptake among individuals enrolled in OAT in Sweden and Norway from 
2014 to 2017. The study found a cumulative HCV treatment uptake of 28% across all age 
groups in Sweden, and 31% in Norway. Annual treatment uptake was low in the beginning 
of the observation at 3.6% and 4.5%, respectively, but increased steadily towards the end of 
the study period to 8.5% in Sweden and 13.6% in Norway. Our results showed a complete 
shift towards DAA treatment regimens among OAT patients, however there was still a 
considerable gap between those individuals receiving HCV treatment and those estimated 
to being infected with chronic HCV until the end of the study period in both Sweden and 
Norway. Treatment uptake was associated with increasing age, being female and being 
dispensed certain drugs in both countries. By 2018, only a handful of European countries 
were on track to achieve the ambitious elimination target set out by WHO; namely France, 
Italy, United Kingdom, Spain, Switzerland, and among the Nordic countries only Iceland 
[86]. Key components of their HCV effort seem to be a clear national HCV strategy coupled 
with determined political leadership and will, high coverage of preventive measures such as 
needle-syringe programs and OAT, satisfactory monitoring and broad access to affordable 
DAA treatment [86]. Other key components of successful HCV elimination is shown in 
Table 1. Although Norway has several key components in place, such as a comprehensive 
and ambitious national hepatitis strategy since 2016, unrestricted access to DAA therapy 
since 2018 and high coverage of OAT [65, 72], a further essential component is enhanced 
monitoring and evaluation, which is crucial for the tracking of the DAA response on 
prevalence and incidence. Without sufficient surveillance and monitoring of HCV and HCV 
treatment uptake, the efficacy of these programs cannot be fully assessed. It has been 
compulsory to notify The Norwegian Surveillance System for Communicable Diseases 
since 1990, however, since there has been no distinction between anti-HCV, HCV RNA or 
HCV core antigen reporting before 2016, it is impossible to assess whether cases were acute 
or chronic, or whether patients achieved SVR on their own, or how many cases were actually 
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notified [102]. The result is that accurate HCV prevalence and incidence data prior to 2016 
are not readily available, nor is the treatment uptake in the DAA era among people with 
severe SUD. 
 
In the second study on mental distress, SCL-10 was used to assess symptoms of mental 
health disorders among people with severe substance use disorders. The vast majority of 
these individuals, 65%, have symptoms of mental health disorders and psychological 
distress. The mental symptom burden was particularly prevalent among females, people 
with frequent use of cannabis, non-OAT opioids, and benzodiazepines compared to males 
and people with no or less frequent use of these substances. The frequent use of stimulants 
indicated less symptoms of mental health disorders compared to subject with less or no 
frequent use. Hence, our findings are in line with other research that suggests that 
benzodiazepine misuse are associated with other substance use, in addition, worsening 
mental health symptoms and disorders, especially anxiety, mood disorders, and among 
people with personality disorders are observed [132, 192-194]. Correspondingly, having a 
SUD, or a mental health disorder, is also likely to increase the risk for misuse of opioids 
[195, 196]. In addition, substance use patterns of cannabis, especially frequent use, are 
found to be associated with residual cognitive impairment and poor mental health [138, 139, 
197]. While it seems clear that stimulants may exacerbate psychosis in for instance, people 
with underlying schizophrenia, it seems less clear whether they contribute to increase the 
risk of new cases on their own [198, 199]. However, one population based study found that 
people with stimulant use disorder had a higher risk of developing schizophrenia compared 
to people with other SUD (excluding cannabis) [200]. In a systematic review, the odds were 
doubled and tripled for developing psychosis among people with any use of stimulants and 
people with a stimulant use disorder, respectively [138]. This association remained 
significant after adjusting for other substance use and pre-existing mental health disorders 
[138]. Frequency and dosage also seem to play a role. In one of the few studies with a 
longitudinal design, an increase of psychotic symptoms were observed secondary to dose 
and periods with frequent use [200]. On the contrary, no significant associations have been 
found between people with stimulant use disorders and anxiety [138]. Nor is the evidence 
compelling when it comes to major depression, though several studies indicate an 
association with depressive symptoms both among frequent users of stimulants and upon 
entering SUD treatment [138, 201-203]. We found no clear associations between substance 
use patterns and changes in mental health symptoms over time. 
 
The final study assessed the HRQoL in long-term OAT patients. It was among the first 
studies to examine changes in HRQoL in a sample of long-term OAT patients over a one-
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year follow-up period. The literature on HRQoL and OAT patients show improvements in 
HRQoL upon treatment entry, but data on long-term patients’ HRQoL is mostly unknown. 
We found considerable impairments in HRQoL and self-perceived health (EQ-VAS) in 
many of the OAT patients in the cohort. However, large variations in EQ-5D-5L index 
values were observed between individuals, both at baseline and at follow-up. Significant 
improvement in overall HRQoL was observed at one-year follow-up with around half of the 
OAT patients reported some improvement in HRQoL while around one-third experienced 
worse HRQoL at one-year follow up, again, with great individual variations. Only males 
reported significant improvement in their self-perceived health at follow-up. There is 
supporting evidence that HRQoL improves after commencing OAT and during the first few 
months of treatment [152, 154, 204, 205]. For instance, among a cohort of people with 
heroin dependence, which were recruited from a low-threshold setting and subsequently 
initiated OAT, showed a considerable improved HRQoL from baseline to follow-up three 
months after [206]. In a study with longer follow-up, QoL was assessed every three months 
from OAT initiation; found a rapid improvement during the three first months of OAT, 
however, the effect ultimately waned off [207]. Another study on HRQoL found the same 
initial effect upon OAT introduction and until follow-up six months later [208]. However, 
during the next six months of follow-up, HRQoL than unexpectedly declined [208]. In a 
study among a larger OAT cohort with one-year follow up, no improvements in HRQoL 
were observed [209]. In addition, a recent systematic review suggests there is still limited 
knowledge regarding HRQoL outcomes in OAT treatment programs and therefore rarely 
used [142]. Hence, while there is evidence that OAT is effective in improving HRQoL at 
treatment uptake and a few months after treatment, the effect of long-term OAT treatment 
upon HRQoL remains largely unknown except for the study presented in this thesis [140]. 
With the prospect of an aging OAT population in Western Europe, understanding the needs 
of these patients – not only as a whole group, but also including the various subpopulations, 
seem crucial in order to provide suitable care in existing health care systems [1, 165]. 
 
5.2 Research fundamentals – research among a hard-to reach population 
The scientific classification of psychoactive substances and research emerged around the 
same time when morphine addiction was studied by Levinstein (1875) who revealed the 
main drivers for opioid dependence; the fixation and priority over others to take the 
substance and the phenomenon of withdraw that could be cured by simply giving more 
opioids [6, 210]. However, the reality is that research among people with SUD may be very 
challenging for a number of reasons. Research among people from socially disadvantaged 
groups, such as people with SUD, is often labelled hard-to-reach (or hidden) populations, 
secondary to the struggles to get access and keep those participants in studies and in public 
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health programs [211, 212]. The lack of research, and especially quality research with 
designs that can address causality, may lead to decisions and treatment recommendations 
not grounded on evidence-based-medicine, which requires the integration of both the best 
available evidence, clinical judgement and patients value [213]. Within this context, it is 
useful to consider the term best available evidence, which is founded upon certain criteria 
from high to very low to interpret the hierarchy of evidence and how it can be used to guide 







In addition, lack of research and knowledge about substance abuse and people with SUD 
may advocate a reduced amount of interest and even funding. For example, there seems to 
be limited knowledge - and inclusion, of substance abuse and SUD among health personnel 
and medical educations in Norway, and perhaps even viewed as “low status” compared to 
other more prestigious research fields [214, 215]. This is further amplified at country levels 
in the skewness of research on substance abuse and dependencies. In fact, based on number 
of publications and citations, research has shown that approximately two-thirds of all 
publications origin in the USA compared to ten countries in Europe (England, Germany, 
France, Italy, Spain Netherlands and the Nordic countries) [216]. Pending on the external 
validity, research from the USA may arguably benefit beyond American borders, however, 
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Figure 4: The hierarchy of evidence and likelihood of bias. 




Then there is a question about the quality of addiction research. For instance, if we consider 
the prophylactic treatment with thiamin among people with alcohol dependency to prevent 
the onset of Wernicke-Korsakoff syndrome. A search in Cochrane Library database 
suggests that there is only one study in the last 20 years with a randomized, double-blind 
design, which investigated the therapeutic effect of thiamin in this group [218, 219]. This 
could be a coincident, or point toward a systematic lack of quality research among people 
with SUD compared to more “high status” diseases. 
 
Thus, European and Norwegian research is needed to add to the overall knowledge and 
contribute towards best available evidence in the field of substance abuse and dependencies. 
 
5.3 Internal validity 
The key research question is whether, or to which degree, inference can be drawn from 
study findings to represent the “truth” in the real world [220]. Therefore, understanding bias 
is essential for the conduct of quality research studies. In the context of research 
methodology, bias refers to systematic deviation of results or inferences from the truth 
[221]. Bias is defined by Last and Abramson (1995) as any trend in the collection, analysis, 
interpretation, publication, or review of data that can lead to conclusions that are 
systematically different from the truth [222]. A bias can take place at any phase of the 
clinical research process; from the planning phase, to implementation/data collection, and 
publication. The validity, which describes the accuracy of the research, is normally divided 
into internal and external validity. The following subsections will discuss key aspects of the 
internal validity of this thesis. According to the definition of Porta (2008), internal validity 
is the degree to which a study is free from bias and depends on the soundness of study 
design, conduct and analysis [221]. 
 
5.3.1 Study design 
All studies included in this thesis are with an observational design, i.e. the included 
individuals were observed without any controlled interventions. Whereas paper I was a 
register-based cohort study, following large cohorts of OAT patients in Sweden and 
Norway, paper II and three followed a cohort of OAT and SUD patients nested to the 
multicenter INTRO-HCV study. Having a prospective design have some advantages 
compared to retrospective or cross-sectional designs. During the planning process of paper 
I, the exposure (OAT) and outcome (HCV treatment) were clearly defined prior to data 
collection together with inclusion and exclusion criteria of the study. Despite several 
limitations as will be discussed, the study design of paper I was regarded as sufficient to 
answer the research questions in a cost-effective manner. Similarly, the study design of 
40 
 
paper II and III were planned and adopted according to the research questions. Also these 
studies have some limitations, such as an imperfect number of measuring points and lack of 
control groups. Hence, making any causal interpretations difficult and was not the scope of 
these studies. All studies used quantitative data to answer the research questions. Data 
collection methods included the use of national registries for paper I, and a combination of 
semi-structured interviews and questionnaires for the other two papers in this thesis. By 
standardizing the study protocols for data collection, which included trained research nurses 
entering the data into a data management program (Checkware®), is likely to have reduced 
punching (information) errors. Also, by applying validated questionnaires and close follow-
up by the research nurses throughout the study period are likely to have reduced the inter-
observer variability. Blinding of research nurses to the participants exposure (OAT) and 
outcomes (SCL-10 and HRQoL) was not possible in these studies. However, since the 
research nurses did not take part in any clinical evaluations or decisions regarding OAT 
treatment for the participants, this could also decrease bias. 
 
5.3.2 Selection bias 
Selection bias can arise from procedures used to select the subjects or result from factors 
that influence loss to follow-up [223]. In paper I; nationwide registry data from SPDR and 
NorPD was used for Sweden and Norway. Since participation is compulsory in both 
registries, they cover the entire populations of these two countries. Hence, in theory they 
should not be subject to any selection bias. Yet in practice, this is unfortunately not the case. 
Selection bias could arise in the inclusion criteria for dosage, route of drug administration, 
duration of exposure, and the prospect of some patients not being recorded in either SPDR 
or NorPD at all. It is estimated that approximately 10% of OAT patients in Norway and 
40% in Sweden receive their OAT medications from outpatient polyclinics not captured in 
either NorPD or SPDR [41, 224]. Also, we included patients each calendar year with dosage 
criteria based on DDD. Therefore, an individual who commenced OAT treatment late or 
quit early during the year may not obtain sufficient exposure to be included that particular 
year. Similarly, an individual with a low OAT dose below the one DDD/day would not be 
included in the study. In addition, there is also a possibility that individuals on methadone 
mixture in the study were not true OAT patients despite excluding those on tablets and 
injections and setting dosage criteria of minimum one DDD per day per calendar year. Most 
individuals are dispensed OAT medications at pharmacies while some receive the medicine 
at OAT outpatient clinics, which means that the latter may not be fully identified in this 
study. This is also the case for OAT and HCV medications administered directly to 
hospitalized and institutionalized patients, which may not be recorded in the registries. 
Overall, we opted to use these strict selection criteria to make sure those who fulfilled the 
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criteria were reached and in fact true OAT patients. This probably reduced the selection bias 
of including non-OAT patients in the study sample, despite risk of underestimating the total 
OAT samples in both countries. 
 
In paper II and three selection bias could occur both during the identification of the study 
samples and at loss to follow-up, which is a particular concern for studies among hard-to-
reach populations and could thus represent a threat to the internal validity of the estimates 
derived from these studies [211, 220]. We dealt with the former by clearly defining the study 
samples, having continuous access to the patients in the outpatient OAT clinics and low-
threshold municipality clinics for the research nurses during the study period, and 
individuals with increased risk to develop the outcome of interest; measures symptoms of 
mental health disorders and HRQoL. In addition, by having a prospective design of the 
studies, where the outcomes (SCL-10 and EQ-5D-5L) were unknown at the time of 
inclusion, is likely to be less prone to selection bias [225]. Follow-up was conducted on a 
sub-group of the initial samples in both cohort studies. From around 900 patients invited to 
participate in the HRQoL study, a total of 609 (68%) patients completed the EQ-5D-5L 
questionnaire at baseline, and of those, 245 (40%) were included in the follow-up analyses. 
To reduce the selection bias due to the loss-to-follow-up (or more correctly, delayed follow-
up) we performed an inverse probability weighted method as described in the methods 
chapter [226]. The mean for the population weights was 1.0 (SD 0.12) in our model, 
implying few differences between those with valid and missing EQ-5D-5L measurements 
from baseline to follow-up. In the second paper, where the study sample consisted of both 
OAT patients and people with severe SUD, the loss to follow-up was greater in the latter 
group. Individuals enrolled in OAT accounted for 83% and 93% of the study sample at 
baseline and follow-up, respectively. Of the 707 participants with SCL-10 measures at 
baseline and 268 (38%) were included in a follow-up analyses with 67 (10%) having at least 
three annual measuring points. To reduce the potential for selection bias between the sub-
group with follow-up SCL-10 measurements again an inverse probability weighted analysis 
was used and revealed a mean for the population weights similar to paper II (comparing the 
268 patients at follow-up with those at baseline). In addition, secondary to selection bias, 
missing data on entire observations or a subset of variables can distort the effect estimate of 
interest [227]. Missing values of SCL-10, clinical and sociodemographic variables, which 
included substance use, injecting substance use, educational level, worrying debt situation, 
and living conditions were assumed to be missing at random. Hence, the missing values are 
systematically dissimilar from the observed values, however, the systematic differences are 
fully accounted for by measured covariates [227]. There were missing values for 
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approximately 3.4% of these values, which were subsequently replaced with the estimated 
values by expectation-maximization imputation [189]. 
 
5.3.3 Information bias 
Information bias, or sometimes called measurement error, is related to the way information 
is processed and resulting from the problems with the measurement of study variables [223]. 
Such errors are often termed either non-differential (random) or differential information bias 
[228]. The former implies that errors in measurements happen equally across comparison 
groups and tend to lead to an underestimation of effect, while the latter implies there are 
different levels of inaccuracy between the groups and could either over- or underestimate 
the true effect [228]. Such problems may arise for different reasons including recall of 
information among study participants, over- or underreporting, sub-optimal measuring 
tools, or during interviewer interaction with participants. In addition, the use of substances, 
either during an acute intoxication or in a withdrawal phase, can influence all these and 
represent a bias when differentially distributed among the comparison groups [220]. 
 
One of the advantages with prescription databases is that they practically remove the recall 
bias. The dispensations are registered with pharmacies and participants do not need to 
remember them. The information in SPDR and NorPD is consistent with a participant both 
being prescribed the medication and having collected the dispensation at a pharmacy. 
However, the registries do not have information about adherence or compliance. In the 
instances an individual do not choose to collect the prescription, often termed primary non-
compliance, or when an individual collect the dispensation, one cannot be sure if the subject 
actually took the medication as prescribed (secondary non-compliance) [229]. As mention 
above, another source for information bias is that medications administered directly to 
hospitalized and institutionalized patients are not captured by the prescription databases, 
which may underestimate the actual medications used. For instance, it is estimated that 
NorPD captures around 90% of the patients with dispensed OAT from pharmacies [41]. The 
other 10% could represent OAT patients with more need for follow-up in the OAT 
outpatient clinics, and as such, may represent patients with higher disease burden and in 
need of HCV treatment. This could skew our results toward underestimating the HCV 
treatment uptake. On the other hand, our estimates can also be overestimates. OAT patients 
have successfully entered the health care system and therefore more likely to accept medical 
treatment, and thus bias our results toward improved HCV treatment uptake. In regard to 
dispensation of HCV treatment, almost all HCV treatment is initiated in outpatient 
polyclinics and thus are included in the prescription database [102, 230]. 
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Much of the information in the cohort studies in paper II and III are based on self-reporting 
information from study participants with semi-structured interviews with research nurses, 
which challenges several aspects of the information assessment process. Firstly, in the event 
a participant do not remember or inaccurately remember, this may introduce recall bias. The 
outcomes of interest, SCL-10 and HRQoL had a short recall at both baseline and follow-up, 
however many of the other clinical and sociodemographic questions had weeks, months and 
ever recall questions, which may increase the risk of recall bias. The preferred recall period 
seems to be dependent upon the objectives of the study; a longer period implies more 
information and lower recall bias when data analysis are aggregated [231]. We aimed to 
further reduce the risk for recall of information by having a prospective cohort design, and 
by research nurses asking for information at the time of inclusion or around the annual health 
assessments. In addition, questions were carefully selected, using validated questionnaires 
when possible, and balanced toward asking too many extensive question, which could risk 
fatigue response among participants. 
 
A perhaps bigger concern for the cohort studies is the introduction of social desirability bias 
among people with SUD. The core of this bias is on the one hand to underreport socially 
undesirable attitudes and behaviors such as substance use, while on the other over report 
more socially desirable attributes [232]. While this has not been studied well among people 
with SUD, there is some evidence pointing toward social desirability bias being associated 
with severity of substance use and socially desirable changes in the use of both alcohol and 
other substances [233-235]. Another study among cocaine and opioid users found that those 
with high levels of socially desirable responding also report considerably fewer symptoms 
of depression and lower frequency of substance use [232]. Depressive symptoms are 
assessed in both SCL-10 and EQ-5D-5L. This could imply that among participants who 
would answer a more socially desirable response may actually underreport depressive 
symptoms in both studies. While this bias is hard to overcome and fully address in a clinical 
setting, central in the INTRO-HCV study have been to communicate that these studies may 
be potentially useful to the participants. Secondly, by employing independent research 
nurses not being involved in any clinical decisions may have motivated the participants to 
provide more accurate and trustworthy information, especially when asked about substance 
use. However, the research nurses may themselves introduce an interview bias, which refers 
to any systematic difference between how information is asked, stored, or understood [225]. 
The effect of the interviewer may have significant impact on the collected data, in particular 
when sensitive information is asked about for instance substance use, income, risk behavior 
for infectious diseases, or mental health symptoms [236]. The regular training of the 
research nurses is likely to reduce most of these problems. While the exposure was well 
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known to the research nurses, this was not the case for the outcomes in the cohort studies, 
thus, interview bias seem more unlikely when the outcome of interest is unknown to the 
interviewer [225]. Another method to minimize interview bias could perhaps be to have 
sociodemographic interviewer-respondent matching, though there is little evidence 
supporting this to substantially increase response rates or data validity [236]. 
 
5.4 Confounders and causality 
One of the key aims, and challenges, in epidemiological research is to evaluate if the 
exposure is the cause of outcomes of interest. In order for an exposure to be a cause of the 
disease, the exposure must than have preceded the outcome of interest. This condition is 
referred to as the basic temporality criterion in epidemiology [223]. In the opposite event, 
when the disease or outcome of interest has a causal effect on the exposure, a situation of 
reverse causality occurs [223]. As shown in the illustration below; when substance use, as 
the exposure causes mental health disorders, the reverse causality occurs when the outcome 
causes the exposure, in this case, substance use.  






In observational studies, when a prospective cohort observes an association between the 
exposure and outcome, a number of possible explanations need to be addressed before it 
can infer that a cause-effect relationship truly exists. As discussed under the internal 
validity, it may be caused by any systemic errors (biases) or can be simply by chance 
(referred to as random error, which is discussed in the subsection below). A third probability 
is that the observed association may in fact be due to the effects of confounding. A 
confounder affects both the exposure and outcome, thus, distorts the measurement of the 
association between them. Van den Broeck (2013) explains this concept further; 
confounding hinders our ability to see the true casual effect of the exposure on the outcome 
and can mask associations when they truly exist – or indicate spurious associations when in 
fact there are no casual relationships [223]. In other words, several potential situations may 
Figure 6: Temporality and reverse causation 
45 
 
arise. If we add to the illustration above, a confounder can cause both the exposure and the 
outcome, or be non-causally associated with either the exposure or outcome: 











In order to cause confounding, a variable should be either unequally distributed among 
exposure levels, be a cause of the outcome (or strongly associated) or be outside the causal 
pathway between the exposure and outcome [223]. The main prevention of the effect of 
confounding is study design and data analysis (such as regression). The former includes 
randomization and matching, which were not feasible for the studies included in this thesis, 
however, we applied restriction by the introduction of exclusion criteria especially for paper 
I to make sure we were actually capturing true OAT patients in both Sweden and Norway. 
However, since the exposure in most pharmaepidemiological studies is often a drug 
prescription, this may introduce a confounding factor known as confounding by indication, 
since the determinant of the outcome is present, and with HCV medication, which are not 
commonly prescribed, and therefore not likely to be present in any comparison groups [237]. 
Controlling for such an evet is only theoretically possible since we did not have any 
information about the prescriber identity in SPDR and NorPD, and thus not being able to 
adjust for the same prescriber. In the cohort studies included in this thesis known 
confounders were adjusted for in multivariable analyzes, yet, all studies in this thesis are at 
risk for confounding as the effect of any unknown confounders only can be fully adjusted 
by true randomization [225]. 
 
Thus, an observed statistical association between an exposure and outcome in this thesis 
does not necessarily infer a causal relationship. On the other hand, a lack of such association 
does neither imply an absence of such causal relationship taking place. The evaluation of 
whether an observed association represent a true cause-effect seems reliant on certain 
Figure 7: Confounding 
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criteria. One set of such criteria was proposed by Hill (1965), which involves an assessment 
of the strength of association; where a strong association is more likely to be casual 
compared to a weak one; is there temporality as described above, i.e. cause must precede 
outcome, is the findings consistent with other findings, is there a dose-response relationship 
(or biological gradient), specificity of the association – is there a one to one relationship 
between cause and outcome, plausibility and coherence; does the removal of exposure lead 
to altered outcome occurrence [223, 238]. While some of Hill’s criteria were partly met in 
the included papers, such as consistency, coherence of current knowledge and to a certain 
degree dose-relationship in paper I-III, others could be in conflict with both the temporality 
criterion to a certain extent, specificity and one to one relationship between potential cause 
and outcome. However, the scope of these papers were not to conclude strictly on a causal 
interpretation. In line with Hernan and Robins (2020) casual inference framework, where 
there is some hesitation to endow observational associations (unless ideal randomized 
assignments take place), we used a combination of theory and literature review to construct 
our models and analyses [239]. For instance, in paper II where the outcome was mental 
distress (SCL-10), earlier research has shown several sociodemographic factors being 
associated with mental health disorders, such as debt, gender, and living conditions. Other 
factors, such as substance use patterns and injecting behavior are less studied and we 
therefore constructed a priori theory for these selected variables as shown in the figure 
below: 
 
By using a combination of existing knowledge and theory, testing the potential relationship 
between these clinical (and sociodemographic) variables in a casual inference framework 
may contribute to reduce the risk of unfortunate selection of variables and a more reasonable 
interpretations of the findings [239]. 
Figure 8: Causal diagram made with DAGitty for SCL-10 
SCL-10 = Hopkins Symptom Check list 10 
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5.5 External validity 
As illustrated in the figure below, the internal validity is the precondition for external 
validity. Porta (2008) defines external validity to which degree the results of a study may 
apply, be relevant, or be generalized to populations or groups that did not participate in the 
study [221]. If the study design is sound, with an acceptable sample size, when biases and 
confounders are adjusted for, the question remains; is the presented evidence trustworthy? 
[223]. In line with what have been discussed previously regarding both quantity and quality 
of research in addiction medicine, there seems to be another aspect which in particular 
reduces the external validity of many studies according to a systematic review; the high rate 
of exclusion criteria in studies among people with SUD [240]. In paper I we opted for very 
strict inclusion criteria to minimize selection bias among OAT patients, however, this is 
likely to have also influenced the external validity of the study to some degree. In clinical 
and cohort studies, there is also a need to balance the eligibility criteria in order to protect 
the safety of the participants (and to ensure the internal validity), and make sure to include 
the study sample of interest to preserve good external validity [240]. In the cohort studies 
in this thesis, where the target study sample were people with severe SUD and opioid 
dependence we therefore opted for broader inclusion criteria. However, a particular concern 
is the high co-occurrence of SUD and mental health disorders in these cohorts. Since many 
of these patients live a very unstable life, they are difficult to recruit to studies, challenging 
to engage and retain in treatment may lead to the exclusion from controlled studies, resulting 
in limited validity of existing research – which likely also have affected our studies [241-
244]. Thus there seems to be an urgent need to shift research on addiction medicine more 
toward effectiveness studies to facilitate evidence-based interventions in clinical settings 
and improve external validity [241]. 
 
5.6 Strengths of the thesis 
The main strength of this thesis is the relatively large sample sizes among people with severe 
SUD. Paper I presents a very large sample of OAT patients being treated for HCV, which 
was estimated by a model. At the time of the study, there were few papers on HCV treatment 
uptake after the introduction of new medications. By using national registries like SPDR 
and NorPD, with near complete databases with few entry errors, we were able to design a 
time- and cost-effective quality cohort study, which could answer our main research 
questions. Similarly, the major strengths of paper II and three are the relatively large sample 
size of a “hard-to-reach” population of people with severe SUD in an observable clinical 
setting. Both studies were designed as nested prospective cohort studies, avoiding many of 
the biases addressed earlier in this chapter. In addition, a particular strength of paper II is 
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the longitudinal design whereas paper III is the first major study on HRQoL among long-
term OAT patients. 
 
5.7 Other methodological considerations 
5.7.1 Random and other potential errors 
Errors in measurement estimations are normally referred to as either systematic errors, as 
seen above, or errors that incur randomly. A random error, which affects the reliability of 
the study, introduces greater variation in the estimates as it may occur by chance [245]. One 
way to control for random errors is by having a larger sample size. In our first study, which 
was register-based data from NorPD and SPDR which captures the entire Norwegian and 
Swedish populations, effectively reduces the chance for random errors while also increasing 
the precision in measured estimates. While it is not possible to completely eliminate random 
errors, we can assume that for the first paper in this thesis, will limit such errors 
substantially. For the cohort studies from Intro-HCV (paper II and three) with a study 
sample of 707 and 609, respectively, random errors are slightly more prone to random 
errors. Thus, we tried to control for it by efficient statistical analysis and expressed the 
estimations quantitatively with confidence intervals (and p-values where appropriate).  
 
Unlike random errors, systematic errors are not affected by study size alone. Our main 
strategy in dealing with systematic errors were laid out in the study designs of the three 
papers following an observational cohort design and clear data collection strategy in the 
INTRO-HCV project to minimize information, selection and confounding biases as 
described above. 
 
Other common impediments, especially in pharmacoepidemiological studies, are how to 
control for the immortal time bias and left-truncation. Simply put, in study one; the former 
arises when OAT patients included in the study by definition cannot have experienced 
outcome (as they would then have been excluded) during some period of follow-up time 
























The immortal time bias may therefore in particular skew the results in favor of the HCV 
treatment group. Our way of dealing with this was designing the study with clear separation 
of exposure and outcome windows (dispensed OAT with certain DDD during a time period 
to be included, and dispension of HCV treatment as outcome), with the participants in the 
exposure group assigned to that group at time-zero during the start of each calendar year. 
While patients could enter and leave the cohort every calendar year based on inclusion 
criteria, we prevented over-counting individuals in the HCV treatment group by only 
including them once during the whole study period (when the first HCV/DAA dispension 
occurred). Other methods to avoid immortal time bias are time-dependent- or a time-
matched, nested case-control analyses [246]. 
 
The problem with left truncation happens when certain individuals who have already passed 
the milestone, in our study receiving HCV treatment, at the time of study recruitment, are 
not included in the study [247]. In addition, the data presented in study one was cumulative 
data on HCV treatment uptake for the whole period from 2014 to 2017, and was not linked 
between individuals diagnosed with HCV (see section below) and individuals receiving 
HCV treatment. We tried to limit the impact left truncation simply by including only the 
Figure 8: Immortal time bias in cohort studies. 
Sources: Lévesqueet. al (2009) Problem of immortal time bias in cohort studies: example 
using statins for preventing progression of diabetes 
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first dispension of HCV treatment. Although low, there is a risk for patients with several 
treatment courses; secondary to re-infection, non-adherence and therapeutic failure not 
being included. 
 
5.7.2 Unlinked data and model limitations 
One of the key limitations in our first study is the absence of HCV diagnosis on an individual 
level and the linkage of this data to individuals’ actually receiving HCV treatment according 
to NorPD and SPDR. During the study planning and design we opted to not link our data to 
The Norwegian Surveillance System for Communicable diseases due to the low notification 
rate and the uncertainty whether HCV infections were acute, chronic or passed infections. 
In a previous study, when these data was linked, around 40% of the treated individuals 
according to NorPD were not notified in the Norwegian Surveillance System for 
Communicable diseases [102]. Using the above model, we calculated the expected number 
of chronic HCV infections in 2014-2017 for Norway and Sweden, with uncertainty in this 
quantity arising only from the uncertainty in spontaneous clearance. However, our model 
may itself have several limitations. The model has not been adjusted for treatment failure 
or non-adherence. While DAA have a very high curation rate, however, some individuals 
in the study received interferon-based therapies that may only achieve an SVR of less than 
60%. The Norwegian Centre for Addiction Research have estimated prevalence of HCV in 
Norway among OAT patients, based on Anti-HCV and self-reports. [41, 159, 248, 249]. 
Mean prevalence during the study period ranged from 51% in 2014 to 43% in 2017. With 
these estimates, we could calculate a cumulative treatment uptake of HCV of 31.5% in 
Norway and 29.2% for Sweden by 2017. Finally, self-awareness of HCV may be low and 
underreported among PWIDs [183], and thus could represent an underestimate of HCV 
prevalence.  
 
5.8 Study implications and recommendations for future research  
5.8.1 Paper I 
Whereas most previous studies on HCV treatment uptake have focused on smaller cohorts 
of PWID during the interferon-era, our study was among the first evaluating HCV treatment 
uptake among OAT patients at population level after the introduction of DAA therapy. Our 
study has revealed a large increase in DAA treatment uptake among OAT patients in both 
Sweden and Norway from 2014 to 2017, compared to several earlier studies that 
demonstrated continued low treatment uptake among PWIDs and OAT patients [102, 250]. 
In Norway prior to the introduction of DAA, annual HCV treatment uptake among OAT 
patients ranged from 1.3% to 2.6% in the period from 2004 to 2013 [102]. However, despite 
the availability of unrestricted DAA treatment regimen in Norway since 2018, people with 
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SUD in active substance abuse have not been able to benefit from the increased accessibility 
[65]. At the time of study, there was still a considerable “gap” between those estimated to 
be infected with chronic HCV and those receiving treatment. The study implies that there 
are still significant barriers to HCV treatment among OAT patients, which need to be 
addressed. The scale of the HCV endemic among people with severe SUD is tragic and is a 
result of years with failing health policies for vulnerable populations. By 2018, only a 
handful of high-income countries were considered on a pathway to accomplish the WHOs 
HCV elimination targets, and among the Nordic countries only Iceland [86]. In Norway, it 
is estimated that HCV complications will even continue to increase within the next few 
years [70].  
 
The study also revealed that being female was associated with decreased odds for treatment 
in both countries. In addition, increased age and certain pharmacoepidemiological 
associations were identified in Sweden and Norway, respectively. Especially gender and 
increased age, which were also associated with poor HRQoL in the third study, seems to be 
linked to psychosocial vulnerabilities, which requires more research and probably more 
gender and age specific care in OAT clinics. For both Sweden and Norway, which already 
have a unifying and committed political leadership, a sound national hepatitis strategy, in 
addition to unrestricted access to DAA therapies, which are the three main components for 
any country elimination strategy – there seem to be a need for more health policies, which 
will be addressing local epidemiological challenges among affected populations [86]. OAT 
has been suggested to play a vital role in the management of chronic HCV among people 
with opioid dependence and has been shown to reduce the risk of HCV acquisition, and this 
study have provided insight into the relative contribution of HCV treatment in an OAT 
setting. [45]. It will require coordinated efforts to increase the treatment uptake, probably at 
multiple levels of both the primary and secondary health care system. While OAT as an 
integrated delivery platform may seem promising, since the facilities and infrastructure are 
already in place for high levels of HCV screening and linkage to HCV care, at least in some 
places in Norway; however, there still seem to be insufficient evidence [251]. Large clinical 
trials are needed to test these hypotheses in order to rapidly be able to scale-up treatment 
uptake and confirm the best available HCV treatment platform among marginalized and 
vulnerable subpopulations. Finally, enhanced HCV monitoring, including DAA treatment 
uptake, is essential if we are to reach the ambitious hepatitis strategical targets. 
 
5.8.2 Paper II 
The second paper in this thesis assessed symptoms of mental health disorders and impact 
of substance use patterns and other factors among people with severe SUD. Overall, a 
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considerable symptom burden was revealed with two-thirds reporting symptoms of mental 
health disorders. These results are generally in line with multiple studies, both clinical and 
epidemiological, which indicate high rates of co-occurring mental health disorders among 
people with SUD and anxiety disorders (27%) [103, 104, 110-112]. We found that mental 
health symptoms were particularly prevalent among females, people with frequent use of 
cannabis, non-OAT opioids, and benzodiazepines compared to men and people with no or 
less frequent use of these substances. However, there were no changes in time trends 
between use of substances and the burden of mental health symptoms. One assumption 
could be that the associations at baseline might be due to reverse causality, i.e. that 
participants with substantial mental health symptoms use substances to self-medicate 
symptoms [252]. It is also possible that there is a “flattening effect” and that potential 
negative impact of substances are more substantial at an earlier phase and that the change 
in later phases are less pronounced. On the other hand, a study that followed SUD patients 
from treatment entry to discharge found a substantial decrease in symptoms of mental health 
disorders; over 80% reported above the SCL-10 cut-off score at admission, while around 
half the study sample reported above this score at discharge [253]. The more severe 
substance used predicted a larger reduction in symptom burden, which may imply that it is 
the use of the substances attributed by the removal of both intoxication and abstinence, that 
lead to the reduction [103, 253]. Other studies have shown that, especially anxious and 
depressive symptoms, resolve or change rapidly after entry in SUD treatment [254, 255]. 
Nevertheless, the overall symptom burden in our study is still much higher compared to the 
patients with reduced mental distress at discharge. Around 85% of our study sample was 
long-term OAT patients with a mean treatment time of almost eight years, which may 
suggest that symptoms of mental health disorders do persist despite enrollment in an opioid 
treatment program such as OAT. In addition, compared to the general population in 
Norway, were around 11.4% scored above the SCL-10 cut-off, our study found significant 










Our study has exposed that screening for mental health disorders among people with severe 
SUD is important given the high prevalence and co-occurrence of mental health symptoms. 
Mental health disorders are likely to impact the long-term course of SUD, while treatment 
of mental health disorders is likely to impact treatment outcomes in SUD treatment [256, 
257]. For example, depression and opioid use disorders often co-occur, while having a major 
depression in one longitudinal study was the disorder that most regularly impacted treatment 
outcomes negatively for people with opioid dependence, which is of special concern 
attributed by the very questionable efficacy of antidepressants in this subpopulation [116, 
255]. In addition, the presence of comorbid mental health disorders and SUD have been 
found to be associated with poor treatment outcomes and show a higher psychopathological 
severity compared to people with a single disorder [109, 258, 259]. Thus, we advocate the 
assessment of mental health status in clinical settings among people with SUD, not just at 
treatment entry, but also in long-term and maintenance treatment. There is also a need for 
more research, especially clinical trials and studies with longitudinal design evaluating 
impact of substance use patterns, leading toward a better understanding of the dynamics of 
these dual disorders, be age and gender-sensitive and follow and integrated treatment 
approach, which have been found superior compared to separate treatment plans among 









Total Male Female 18-29 30-39 40-49 50-59 ≥60
Norwegian population SUD population
Figure 9: Hopkins SCL-10 scores among the general Norwegian population and people with severe 
substance use disorders, mean per group 
Hopkins SCL-10 = Hopkins symptoms check list 10. Source: Strand et. al (2003). Measuring the 
mental health status of the Norwegian population: A comparison of the instruments SCL-25, SCL-10, 
SCL-5 and MHI-5 (SF-36) 
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5.8.3 Paper III 
The third paper in this thesis studied the HRQoL among OAT patients with a follow-up one 
year later. While many studies have demonstrated a poor HRQoL and QoL among people 
with SUD and opioid dependence, especially at treatment entry, there is a lack of knowledge 
among people in long-term OAT treatment. Our results at baseline were in line with many 
of the findings from other studies; overall we observed a generally poor HRQoL, hereunder 
EQ-5D-5L and EQ-VAS, especially when compared to other chronic disease, and to the 
general reference population. Compared to the latter, OAT patients reported in average 
consistently higher percentages of problems across all EQ-5D-5L domains, especially 
pain/discomfort and anxiety/depression where only 36% and 23% respectively, reported no 
problems. The same was found for both the EQ-5D-5L index value and EQ-VAS. This 
finding is consistent with results from another study among OAT patients in Germany [140]. 
In addition, in line with previous research, females and increased age reported more overall 
problems compared to males and those younger than 40 years [152, 260]. Increased age has 
also been strongly correlated to poor physical HRQoL in another study [140]. In our sample 
the mean age was 44, which is consistent with an aging OAT population in Norway [41, 
159]. Increased age of OAT patients coupled with poorly reported HRQoL, could not only 
lead to increased demand for health care, but also specialized health care in both primary 
and secondary settings.  
 
Previous research has demonstrated that HRQoL improved considerably at OAT treatment 
entry and the first few months [206]. Yet other studies only saw improvements in the 
beginning of observation or even decline [152, 208, 261]. Our study challenges that belief 
and is among the first to show that changes in HRQoL, including positive changes, are 
possible. At one year follow-up, we found significant improvement in overall HRQoL with 
around half of the OAT patients reported some improvement in HRQoL while around one-
third experienced worse HRQoL at one-year follow up, with substantial individual 
variations. Clearly there is a need for more longitudinal studies on OAT patients to either 
confirm or dismiss this finding. While health states of OAT patients are so diverse and 
dynamic, this has implications for personalized patient care, and we belive there is a need 
for regular assessment of HRQoL as an outcome in OAT programs.  
 
Along with more research, especially clinical trials and studies with longitudinal design as 
mention above, we need to better understand what drives the extreme and rapid changes in 
HRQoL in both positive and negative directions among OAT patients. We need to know 
how to best prevent the large drops in index score and how to increase and maintain the 




This thesis has described the immense burden of disease affecting people with severe SUD. The 
first study calculated the HCV treatment uptake in the DAA era among patients enrolled in opioid 
agonist therapy at a population level in both Sweden and Norway. In Sweden annual HCV treatment 
uptake increased from 3.6% in 2014 to 8.5% in 2017, and 4.5% to 13.6% in Norway. The estimated 
cumulative HCV treatment uptake at the end of 2017 was thus 28% in Sweden and 31% in Norway, 
which means that around two-third of OAT patients had yet to receive HCV treatment at the 
beginning of 2018. There seem to be several challenges and still barriers to treatment with the new 
and effective medications.  
 
Overall, many individuals reported considerable mental distress and impaired HRQoL. Among 
people with frequent use of substances, more symptoms of mental health disorders were observed 
amid those using benzodiazepines cannabis, opioids compared to those with no or less frequent use 
of these substances. Overall, 65% of the cohort had a mean score above the threshold for symptoms 
of mental health disorders. Although there were large individual variations in SCL-10 score from 
baseline to follow-up, no consistent time trends indicated change over time for the whole cohort. 
While HRQoL was substantially lower compared to the general population, also this study revealed 
large individual variations in index values, where 43% had a good HRQoL and 5% had extremely 
poor HRQoL at baseline. At follow-up, improvements in HRQoL were observed across almost all 
health dimensions. This shows that people with severe SUD is a very heterogeneous population.  
 
These findings emphasize the urgent need for more research, and perhaps more gender-and age-
adopted treatment. – and arguably there is a need to include screening for mental health disorders 
both at treatment entry and during maintenance of opioid agonist therapy in order to improve 
individualized patient care. In addition, there is a need to implement health-related quality of life as 
an outcome measure when we evaluate the treatment success in both substance use programs and 
opioid treatment programs. Overall, quality research including clinical trials, which can address the 
magnitude of confounders and other biases in this subpopulation, is urgently needed. Only then we 
can start to integrate the recommendations from the best available evidence along with clinical 
judgement, patients’ values and self-perceived health - in what we collectedly know as evidence-
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Abstract
Background: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C
virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT)
programs. The objective of this study was to estimate and to compare HCV treatment uptake after the introduction
of DAAs among patients receiving OAT in Sweden and Norway. We also aimed to evaluate predictors of DAAs
treatment among OAT patients in both countries.
Methods: This observational study was conducted with data from The Swedish Prescribed Drug Register and The
Norwegian Prescription Database. We studied dispensed medications to calculate HCV treatment among OAT
patients from 2014 to 2017 in Sweden and Norway. HCV prevalence was estimated from primary and secondary
sources. Dispensations of medicines from different therapeutic areas, which served as proxy for co-morbidities in
2017, were conditionally adjusted for age, gender, and OAT medications. Logistic regression was used to evaluate
these parameters.
Results: In total 3529 individuals were identified with dispensed OAT in the Swedish cohort and 7739 individuals in
the Norwegian cohort. HCV treatment was utilized by 407 persons in Sweden and 920 in Norway during the study
period. Annual HCV and DAA treatment uptake increased in both countries. The estimated cumulative HCV
treatment uptake at the end of 2017 was 31% in Norway and 28% in Sweden. DAA treatment was associated with
increased age (aOR 1.8; 95% CI 1.0–3.2) and the dispensation of drugs used for diabetes (aOR 3.2; 95% CI 1.8–5.7) in
Sweden. In Norway, lipid modifying agents and antibacterials were associated with decreased odds (aOR 0.4; 95%CI
0.2–0.9, aOR 0.8; 95%CI 0.6–1.0).
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Conclusions: An increase in DAA treatment and HCV treatment uptake was observed among Swedish and
Norwegian OAT patients whilst introducing new direct-acting antiviral treatment regimens. However, more than
two thirds of the OAT population in Norway and Sweden were untreated at the beginning of 2018. A further scale-
up is crucial in order to control and eliminate the HCV endemic among OAT patients.
Keywords: Hepatitis C, Chronic hepatitis C, Treatment uptake, Direct-acting antivirals, Opioid substitution treatment
Background
Treatment of chronic hepatitis C virus (HCV) infection
has been subject to vivid changes in the last few years
with the introduction of direct-acting antiviral agents
(DAAs) [1]. The ambition of any antiviral treatment of
HCV infection is elimination of the virus. In that sense,
standard treatment prior to 2011 was a combination of
pegylated interferon alpha and ribavirin, which saw a
sustained virologic response (SVR) in approximately 50
to 56% of patients [1, 2]. SVR is defined as absence of
HCV RNA 12 weeks after end of treatment. However,
since 2011 various DAAs have become readily available
and should make interferon-based therapies almost ob-
solete. HCV policies including DAA offer countries an
opportunity to eliminate HCV endemics, with less side
effects, shorter treatment periods and improved adher-
ence as compared to old interferon treatment. Combin-
ing two (or three) DAAs have led to a SVR of far
beyond 90% also among patients who have been hard to
treat in the past [3, 4].
The scale of the HCV endemic among people who in-
ject drugs (PWID) is tragic and is a result of years of
failing health policies for vulnerable populations. The
HCV prevalence is around 50%, or more, among PWIDs
[5, 6], and around 50% among patients on opioid agonist
therapy (OAT) [7]. It is estimated that HCV complica-
tions will continue to increase within the next few years
[8]. DAA treatment has been offered as universal health
coverage from 2017 and 2018 in Sweden and Norway,
respectively [9, 10]. It seems, however, that the increased
accessibility has not benefitted active-PWIDs [11].
The coverage of preventive interventions and harm re-
duction services varies among PWIDs. Although the dis-
tribution of needle and syringe programs is relatively poor
[12], opioid treatment programs such as OAT has higher
coverage in many countries [13]. OAT has shown to re-
duce the risk of HCV acquisition [14], and despite on-
going illicit drug use, patients on OAT are achieving high
SVR rates [15]. Hence, OAT programs may be a critical
intervention for achieving large reductions in HCV trans-
missions. Several studies have shown that significant re-
ductions in HCV prevalence can be achieved with an
adequate increase in HCV treatment uptake [16–18].
Nevertheless, HCV treatment uptake has remained low
[19, 20]. In Norway, annual HCV treatment uptake among
OAT patients ranged from 1.3 to 2.6% in the period from
2004 to 2013 [20]. HCV treatment uptake, and in particu-
lar DAA treatment, among OAT patients in Sweden is un-
known. Norway and Sweden share a basic cultural unity,
have a comparable socioeconomic and political structure
with similar health care systems that are based on the
Nordic welfare model [21]. Taking into consideration the
potential for HCV disease elimination by publicly funded
DAA policies in these countries [9, 13] and the high HCV
prevalence among the OAT population, it is essential to
calculate the DAA treatment within an OAT delivery plat-
form. Such estimates are important for countries aiming
for HCV elimination or endemic control in the near
future.
Therefore, this observational study aims to:
1) calculate HCV treatment annually and cumulatively
after the introduction of DAAs among patients
receiving OAT in Sweden from 2014 to 2017
2) compare DAA treatment between Sweden and
Norway among patients receiving OAT from 2014
to 2017 and estimate the HCV treatment uptake
3) evaluate if various dispensed drugs (proxy for
comorbidities), age, gender and OAT medication is
associated with DAA treatment among OAT
patients in Sweden and Norway in 2017
Methods
Study design and data sources
This is an observational study among patients on OAT
in Sweden and Norway from 2014 to 2017. Data were
extracted from The Swedish Prescribed Drug Register
and The Norwegian Prescription Database. The regis-
tries cover the entire Norwegian and Swedish popula-
tions and record all drugs dispensed from pharmacies.
All drugs are classified according to The Anatomical
Therapeutic Chemical (ATC) classification system [22].
HCV prevalence data is not readily available for Norway
and Sweden. Consequently, we employed primary and
secondary sources to model HCV prevalence. Data from
the INTRO-HCV study in Norway [23] was used in
addition to published data on HCV prevalence among a
large cohort of Swedish PWIDs [24]. See additional file 1
for a comprehensive description of methodology and
data sources.
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Study population and definitions
The study population included all individuals aged 18 to
75 years who received OAT in Sweden and Norway.
OAT was defined as being dispensed at least one defined
daily dose (DDD) per day per calendar year of buprenor-
phine, methadone, buprenorphine-naloxone, or levo-
methadone by summarizing all annually dispensed OAT
DDDs divided by 365.25 days.
Moreover, OAT medication per individual was noted
as the last dispensation per calendar year. To avoid in-
cluding other medical indications than OAT, we ex-
cluded methadone preparations on the basis of route of
administration (injections and tablets), and introduced a
dosage criteria in order to make sure that actual patients
on OAT were captured. The dosage criteria was set at
minimum one DDD daily throughout each calendar year
as an inclusion criteria. The study populations were thus
chosen annually for both countries and it was possible
for an individual to be included in more than one calen-
dar year. See additional file 2 for a flow chart. ATC/
DDDs according to 2017 [25] were used to quantify the
dispensed OAT medications. A more detailed descrip-
tion of OAT and HCV treatment in Sweden and Norway
is provided in additional file 3.
Calculating HCV and DAA treatment and estimating
treatment uptake
HCV treatment was defined as being dispensed either
one or more types of pegylated interferon alpha in com-
bination with ribavirin, or one or more of the DAAs per
calendar year during the study period (additional file 4).
For each country, the annual HCV treatment rates were
calculated by dividing the number of individuals with
dispensed HCV treatment by the number of individuals
on OAT. The cumulative HCV treatment frequency,
which is the sum of successive years of treatment, was
then calculated as the proportion of patients with dis-
pensed HCV treatment at some point during the study
period. Similarly, DAA treatment was calculated by div-
iding the number of OAT patients with at least one dis-
pensation of DAA by the total number of OAT patients
per year, which represents the annual prevalence of
DAA use among OAT patients. Using primary and sec-
ondary sources, along with several assumptions, as
described in detail in additional file 1, we derived a for-
mula to estimate the chronic HCV prevalence in Sweden
and Norway as follows;
Expected Number of Chronic HCV
¼ 1−δð Þ ϕπPWIDþ 1−ϕð ÞπNonPWID½ Nð Þ−τ
where N is the size of the study population, δ is the rate
of spontaneous HCV clearance, ϕ is the proportion of
OAT patients who are PWID, πPWID and πNonPWID are
the anti-HCV prevalence estimates among PWID and
non-PWID, respectively, and τ is the number of HCV
treatments given. Using the above formula, we calculate
the expected number of chronic HCV infections in
2014–2017 for Norway and Sweden, with uncertainty in
this quantity arising only from the uncertainty in spon-
taneous clearance. The chronic HCV prevalence was
then calculated by dividing the expected number of
chronic HCV infections by the total population size in
that particular year and setting (i.e. Norway or Sweden).
HCV treatment uptake was then estimated by dividing
the HCV treatments in each year by the estimated num-
ber of chronic HCV infections in that same year, yield-
ing a percentage of chronic HCV infections that were
treated per year. The cumulative HCV treatment uptake
was then calculated as the sum of HCV treatment up-
take across years.
Potential predictors associated with DAA treatment up-
take were determined a priori and included OAT medica-
tion (methadone/levomethadone vs. buprenorphine-based),
age, gender and various dispensed drugs (yes vs. no) from
different therapeutic areas that were used as proxies for co-
morbidities. All dispensations were recorded at the second
ATC level (therapeutic subgroup), except for drugs affect-
ing the nervous system.
Statistical analyses
All data analyses was conducted in STATA SE 16.0 (Sta-
taCorp, TX, USA). Descriptive data was presented as fre-
quencies, percentages, and means, with corresponding
95% confidence intervals where appropriate. Logistic re-
gression was used to estimate whether DAA treatment
uptake was associated with gender, age, OAT medica-
tion, and dispensations of other drugs in 2017. Statistical
significance was set at the p < 0.05 level.
Data handling and ethical considerations
All data were received pseudonymised from registry ad-
ministrators and subsequently analyzed, therefore, no
written consent was obtained from any of the individuals
in the study. The study was approved by the Regional Eth-
ical Review Committee in Stockholm, Sweden, (no 2018/
2080–31/1) and the Regional Committee for Ethics in
Medical Research (no. 2018/939) in Norway. Furthermore,
the study was conducted in accordance with the Helsinki
Declaration and as an observational study in accordance
with international accepted STROBE guidelines [26].
Results
Basic characteristics
In Sweden, 3529 individuals receiving OAT were identi-
fied. Around 70% were male, with a mean age of ap-
proximately 44 years and 45 years in 2014 and 2017,
respectively. See additional file 5. The majority of the
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OAT patients were treated with buprenorphine-based
OAT medication (52% in 2014 and 56% in 2017).
Altogether 407 individuals in the Swedish cohort re-
ceived HCV treatment during the study period. In
Norway, 7739 individuals were identified during the
study period from 2014 to 2017. 70% were male and
mean age was 44 in 2014 and almost 46 years in 2017.
55% received treatment with a buprenorphine-based
OAT medication in 2017. Altogether 920 individuals in
the Norwegian cohort received HCV treatment during
the study period (Table 1).
Estimated HCV prevalence and treatment uptake
For Sweden, chronic HCV prevalence was estimated to
range from 55.6% (uncertainty interval (UI) 53.3 to 58.8)
in 2014, to 53.1 (UI: 50.8–56.3) in 2017. In Norway,
prevalence was estimated from 54.4 (UI: 52.1–57.5) in
2014 to 50.0 (UI: 47.7–53.1) in 2017. The cumulative
HCV treatment uptake was thus projected to be 31% in
Norway and 28% in Sweden for the study period
(Table 2). Unadjusted treatment rates for both countries
are shown in additional file 6, (Fig. 1).
Dispensations and predictors of DAA treatment in 2017
OAT patients in Norway and Sweden were stratified ac-
cording to whether they received DAA treatment or not,
and compared in 2017. In the Norwegian cohort 366 in-
dividuals (6.6%) received DAA treatment whereas in
Sweden, 123 (4.5%) individuals received treatment. Vari-
ations in treatment within countries were few, except for
drugs used for diabetes (Table 3). However, among indi-
viduals receiving DAA treatment in Norway, half were
also dispensed benzodiazepines compared to only 15%
in Sweden. In contrast, 24 and 31% of the Swedish pa-
tients treated with DAA also received dispensations of z-
hypnotics and antidepressants compared to 15 and 20%
in the Norwegian cohort, respectively.
In a logistic regression model (additional file 7), DAA
treatment was associated with increased age (adjusted
odds ratio (aOR) 1.8; 95% CI 1.0–3.2) and dispensation
of drugs used in diabetes (aOR 3.2; 95% CI 1.8–5.7) in
Sweden. Dispensations of lipid modifying agents and an-
tibacterials were associated with decreased odds (aOR
0.4; 95% CI 0.2–0.9, aOR 0.8; 95% CI 0.6–1.0) of receiv-
ing DAA treatment in Norway. Moreover, being female
was associated with decreased odds in both countries (S:
aOR 0.6; 95% CI 0.3–0.9, N: aOR 0.8; 95% CI 0.6–1.0).
Discussion
Amid the hepatitis C endemic among PWIDs and indi-
viduals enrolled in OAT programs in Sweden and
Norway, the study has revealed a large increase in DAA
treatment uptake among OAT patients in both countries
from 2014 to 2017. As such, our findings reflect the im-
mense progress, which has been achieved in HCV treat-
ment during the recent years with almost a complete
shift from interferon-based treatment to solely treatment
with DAAs among OAT patients. The cumulative fre-
quency of HCV treatment in the OAT population be-
tween 2014 and 2017 was estimated to be 28 and 31%%
in Sweden and Norway, respectively.
Despite substantial increase in HCV treatment uptake in
advanced health systems like Sweden and Norway, as found
in our study, the treatment uptake is still too low and pro-
gress too slow globally [20, 28, 29]. Treatment demand has
soared after the introduction of DAAs, especially among
former PWIDs [11], while people who are still using drugs
actively have seemingly not been fully able to benefit from
the increased accessibility [11]. In order to reach universal
health coverage of DAAs and elimination of HCV, more ef-
forts are needed in countries. Coverage of DAAs varied sub-
stantially across European countries, ranging from 0.6 to
10.2% in 2015 [30]. Restrictions in DAA access policies may
explain these variations. Among European countries,
England, Hungary, Croatia and Slovakia experienced one of
the most restricted access policies to DAA treatment com-
pared to Poland, Ireland, the Netherlands, France and
Germany, which had the least restrictions during the study
period [31]. Our findings saw Sweden with a greater DAA
treatment uptake than Norway in 2015, and roughly in the
Table 1 Basic characteristics of patients receiving OAT in 2014
and 2017 in Sweden and Norway
2014 2017
Country Sweden Norway Sweden Norway
OAT studypopulation, n 2663 6057 2739 5545
Gender, n (%)
Male 1911 (72) 4266 (70) 1961 (72) 3870 (70)
Female 752 (28) 1791 (30) 778 (28) 1675 (30)
Age, n (%)
18–35 671 (25) 1219 (20) 647 (24) 878 (16)
36–45 817 (31) 2181 (36) 819 (30) 1747 (32)
46–55 744 (28) 2044 (34) 713 (26) 1998 (36)
56–75 431 (16) 613 (10) 560 (20) 922 (17)
Mean age (SD)
Male 44 (10) 44.1 (9) 45.1 (11) 46.1 (9)
Female 43.5 (11) 43.1 (9) 44.3 (12) 45.2 (10)
OAT medication, n (%)a
Methadone/
levomethadone
1267 (48) 2810 (46) 1198 (44) 2504 (45)
Buprenorphine 875 (33) 2049 (34) 1075 (39) 2190 (40)
Buprenorphine/naloxone 521 (20) 1198 (20) 466 (17) 851 (15)
Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian
Prescription Database (NorPD)
OAT Opioid agonist therapy, SD Standard deviation
aLast registered OAT medication each calendar year
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middle among its European counterparts, similar to the last
Scandinavian country, Denmark, at close to 4% [30]. An-
other reason for the low treatment uptake might be con-
cerns about treatment compliance among PWIDs and OAT
patients; however, this seems unwarranted as both good ad-
herence and high SVR rates in this group have been docu-
mented in several randomized controlled trials [32, 33].
Arguably, poor treatment uptake of DAAs globally and
a hard to reach population opts for countries to consider
alternative health service delivery platforms. Addressing
barriers to HCV treatment and testing are important.
Between 60 and 70% of people enrolled in various opioid
treatment programs are offered onsite testing for HCV
[29], which is too low. OAT programs could thus benefit
from introducing universal HCV testing and linkage to
care in OAT settings. Perhaps OAT programs, together
with infectious disease and gastroenterology/hepatology
specialists, could explore any opportunities for non-spe-
cialists to dispense DAA regimens to increase treatment
uptake. Psychoeducation to improve knowledge among
OAT patients regarding treatment, possible side effects
and HCV infection seems to improve both SVR rates and
adherence to treatment and should also be considered im-
plemented in an OAT setting [34]. Furthermore, current
drug use or any fear of reinfection in patients already
treated for HCV should not hinder treatment with DAA.
Reinfections seems to be low (1–5%), even if treated pa-
tients return to active drug use [35].
The differences between Sweden and Norway are in-
teresting and relevant for other settings. Prevalence of
anti-HCV among PWIDs seems consistently higher in
Sweden compared to Norway [36, 37]. Coverage of OAT
is higher in Norway than Sweden. Waal et al. estimate
an overall OAT coverage of around 60% among people
Fig. 1 Estimated HCV treatment uptake in Norway and Sweden among OAT patients from 2014 to 2017. HCV = hepatitis C virus infection, OAT =
opioid agonist therapy. Sources OAT and HCV treatment: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database
(NorPD). Prevalence: Intro-HCV = Integrated treatment of hepatitis C study, Kåberg et al. [24]: Prevalence of hepatitis C and pre-testing awareness
of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program, Micallef et al. [27]: Spontaneous viral
clearance following acute hepatitis C infection: a systematic review of longitudinal studies. For more comprehensive details on sources and
model calculation, see additional file 1.
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with opioid dependence in Norway [38] compared to 10
to 50% OAT coverage in Sweden [39]. Differences in
OAT eligibility criteria could explain lower coverage of
OAT in Sweden as compared to Norway. Norway
altered its OAT guidelines in 2010, making opioid addic-
tion the absolute criteria for inclusion and being retained
in treatment, and there is a high threshold for dischar-
ging patients from OAT. However in Sweden, current
OAT guideline has lower thresholds for OAT cessation
in the case of repeated illicit drug use [7, 40]. The two
populations may therefore be different and Swedish
OAT patients could have less ongoing drug use, which
could lower the risk of HCV and increase the chance for
HCV treatment success. However, the Norwegian strat-
egy could be more effective at a population level since
hard to reach groups are included and illicit drug use is
not considered as an exclusion criterion for OAT.
With the provision of DAA treatment available for all
Swedish and Norwegian patients, it may be tempting to
argue that this is the beginning of the end for the HCV
endemic. In addition to OAT, maintaining a high cover-
age of needle and syringe availability in these countries,
together with continued scale-up of DAA treatment, it
may be possible to reduce incidence by 90% by 2030 as
shown in a modeling study from the UK [41]. On the
other hand it may still seem embryonic as there may be
shortcomings in current HCV surveillance systems.
HCV has been notified to The Norwegian Surveillance
System for Communicable Diseases since 1990, yet,
there has been no distinction between anti-HCV, HCV
RNA or HCV core antigen reporting before 2016 [20].
Hence, accurate HCV prevalence and incidence data
prior to 2016 are not readily available. Furthermore, in
order to eliminate HCV as a public health threat by
2030, which both countries have embraced, a coherent
and structured national plan is essential. The Norwegian
Health Ministry introduced a national hepatitis C strat-
egy in 2016, and was later revised in 2018, which focuses
on DAA treatment, HCV surveillance, and prevention,
and aims to reduce HCV incidence by 90% within 2023
[42]. On the contrary, an ambitious national Swedish
hepatitis C plan has not yet been established [43].
Our findings suggest few inter-country differences in dis-
pensed drugs among those treated with DAAs and those
not, except for drugs used for diabetes in the Swedish co-
hort, which was significantly higher and demonstrated a
Table 3 Dispensed drugs to patients receiving OAT and OAT/DAAs in Norway and Sweden in 2017
Year 2017 2017
Country Norway Sweden
OAT study population, n 5543 2739
Only OAT DAA + OAT Only OAT DAA + OAT
5177 366 2616 123
Drugs No. (%) No. (%) No. (%) No. (%)
Drugs used in Diabetes 197 (4) 14 (4) 161 (6) 18 (15)
Antithrombotic agents 529 (10) 35 (10) 217 (8) 8 (7)
Cardiovascular system drugs a 842 (16) 67 (18) 622 (24) 37 (30)
Lipid modifying agents 271 (5) 10 (3) 121 (5) 4 (3)
Sex hormones and modulators of genital system 654 (13) 51 (14) 430 (16) 14 (11)
Antibacterials for systemic use 1901 (36) 112 (31) 915 (35) 33 (27)
Anti-inflammatory and ant-rheumatic products 1155 (22) 69 (19) 570 (22) 25 (20)
Drugs for obstructive airway diseases 1048 (20) 68 (19) 410 (16) 14 (11)
Benzodiazepinesb 2368 (46) 181 (50) 402 (15) 19 (15)
Hypnotics and sedativesc 797 (15) 54 (15) 691 (26) 30 (24)
Antiepilepticsd 823 (16) 57 (16) 629 (24) 25 (20)
Antidepressantse 960 (19) 73 (20) 1008 (39) 38 (31)
Antipsychoticsf 1401 (27) 85 (23) 602 (23) 28 (23)
Source: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). All drugs on ATC Level 2, except under Nervous system. See
Supplement Table S2
OAT Opioid agonist therapy, DAA Direct-acting antiviral agents
aC01, C02, C03, C07, C08, C09
bN05BA01, N05BA04, N05BA06, N05BA12, N05CD02, N05CD03, N05CD08, N03AE01
cN05CF01 and N05CF02
dN03AA, N03AB, N03AF, N03AG, N03AX
eN06AA, N06AB, N06AF, N06AG, N06AX
fN05AA, N05AB, N05AC, N05AD, N05AE, N05AF, N05AG, N05AH, N05AL, N05AN, N05AX
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strong association with DAA treatment. Chronic HCV
might be a risk factor for developing immune system disor-
ders, heart disease and diabetes, especially diabetes type II
as the viral infection may increase insulin resistance [44,
45]. This finding was not mirrored in the Norwegian co-
hort. Dispensed drugs can serve as a proxy for co-
morbidity and it is well-established that both somatic and
especially mental illness are underdiagnosed and under-
treated among individuals with substance use disorders
[46]. This does not explain the vast differences we observed
among dispensations of benzodiazepines, z-hypnotics, and
antidepressants comparing Sweden and Norway. Older pa-
tients are more likely to have cirrhosis and longer HCV
treatment courses compared to younger patients. A reason
for the observed age difference may be that the younger pa-
tients are usually harder to reach due to an unstable life
situation and drug abuse related behavior. Similarly, the
analyses point toward women being less likely to be treated
for HCV, however, this could be due to women being un-
derrepresented in services.
Strengths and limitations
The national prescription registries capture large popu-
lations, and as such, provide researchers with precise
and near complete databases. The main strength of this
study is that it offers a large sample of OAT patients be-
ing treated for HCV.
However, this study has several limitations. As the pa-
tients were included each calendar year with a dosage
criteria, a patient who commenced treatment late or quit
early during the year may not obtain sufficient exposure
to be included in that particular year. Moreover, OAT
treatment in Norway and Sweden is not uniform. Most
individuals are dispensed OAT medications at pharma-
cies while others receive the drugs at OAT outpatient
clinics, which means that those latter patients are not
identified in this study. OAT and HCV treatment ad-
ministered to hospitalized and institutionalized patients
are also not recorded in the registries. In addition, DDD
does not necessarily reflect the prescribed daily dose.
Furthermore, HCV treatment uptake data was not linked
on an individual level to diagnosis codes of HCV according
to International Statistical Classification of Diseases and Re-
lated Health Problems version 10 (ICD-10) or the Inter-
national Classification of Primary Care (ICPC), rather, it
was estimated from published reports and modelled where
adequate data sources were missing. Thus, there is some
uncertainty in the denominator of people with HCV in
need of treatment. The predictors for DAA treatment were
limited to the main dispensed drugs and sociodemographic
variables and so did not fully acknowledge that there could
be other vital reasons why access to DAAs would be limited
in this group of patients.
Finally, PWID are a heterogeneous group of individ-
uals, and one should be careful not to generalize OAT
patients to include all PWIDs.
Conclusion
This study indicates a large scale-up in DAA treat-
ment among Swedish and Norwegian OAT patients.
Cumulative HCV treatment uptake was around one-
third from 2014 to 2017 in both countries, attributed
by a complete shift to DAA treatment regimens.
Amidst a HCV endemic among PWIDs, it seems that
two-thirds of OAT patients in need of treatment were
untreated in the beginning of 2018. Coupled with the
prospect of HCV elimination, there is a need for fur-
ther scale-up of the most effective HCV treatment
strategies, by identifying possible predictors of treat-
ment and to establish more accurate surveillance sys-
tems in order to provide better care to this group of
marginalized people.
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Abstract
Background: There is high co-occurrence of substance use disorders (SUD) and mental health disorders. We aimed
to assess impact of substance use patterns and sociodemographic factors on mental health distress using the ten-
item Hopkins Symptom Checklist (SCL-10) over time.
Methods: Nested prospective cohort study of 707 participants with severe SUD across nine opioid-agonist-therapy
outpatient clinics and low-threshold municipality clinics in Norway, during 2017–2020. Descriptive statistics were
derived at baseline and reported by means and standard deviation (SD). A linear mixed model analysis was used to
assess the impact of substance use patterns and sociodemographic factors on SCL-10 sum score with beta
coefficients with 95% confidence intervals (CI).
Results: Mean (SD) SCL-10 score was 2.2 (0.8) at baseline with large variations across patients. We observed more
symptoms of mental health disorders among people with frequent use of benzodiazepines (beta 3.6, CI:2.4;4.8),
cannabis (1.3, CI:0.2;2.5), opioids (2.7, CI:1.1;4.2), and less symptoms among people using frequent stimulant use (−
2.7, CI:-4.1;-1.4) compared to no or less frequent use. Females (1.8, CI:0.7;3.0) and participants with debt worries (2.2,
CI:1.1;3.3) and unstable living conditions (1.7, CI:0.0;3.3) had also higher burden of mental health symptoms. There
were large individual variations in SCL-10 score from baseline to follow-up, but no consistent time trends indicating
change over time for the whole group. 65% of the cohort had a mean score > 1.85, the standard reference score.
(Continued on next page)
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Conclusions: People with SUD have a considerable burden of mental health symptoms. We found no association
between substance use patterns and change in mental health symptoms over time. This could suggest that the
differences observed were indicating flattening of effects or self-medication to a larger degree than medication-
related decline in mental health. This call for better individualized mental health assessment and patient care.
Keywords: Substance use disorder, Substance abuse, Mental disorder, Psychological distress, Mental health
problems, Opioid substitution treatment, Opioid dependence
Background
Substance use disorders (SUD) contribute to 11.8
million deaths globally per year and 1.5% of the global
disease burden [1]. It is estimated that 2% of the world
population has a SUD, with some countries reporting a
prevalence of SUD greater than 5% [1]. More than half
of the people with a SUD will experience a mental health
disorder at some point during their lives [2, 3], yet it is
less clear whether mental health disorders develop
mostly as a consequence of substance use or vice versa
[4]. The co-occurrence of SUD and mental health disor-
ders may be attributed to shared genetic vulnerability
and pathophysiological processes possibly related to spe-
cific neurotransmitter systems [5, 6]. Even though most
research has been in relation to amphetamines, cannabis
and alcohol, comorbid mental health symptoms are
probably also the case for the more severe forms of SUD
like opioid dependence. However, less is known about
the prevalence, predictors and change over time of
mental health symptoms in these patient groups,
limiting optimal clinical care. It has been suggested that
these comorbidities often are under-recognized in clin-
ical settings [7, 8].
Among people with SUD in Europe, the most preva-
lent mental health disorders in epidemiological studies
are personality disorders (51%), mood disorders (35%),
attention-deficit hyperactivity disorder (30%) and anxiety
disorders (27%) [9–12]. Poor quality of life [13], concur-
rent drug use, including benzodiazepine misuse (e.g.
without prescription, higher frequency or dosage than
prescribed), is common and prevalent among SUD and
people enrolled in opioid agonist therapy (OAT) [14,
15]. Some research suggest that benzodiazepine misuse
are associated with other substance use, aggressive
behavior and worsening mental health symptoms and
disorders [16, 17]. Having a SUD, or a mental health dis-
order, is also likely to increase the risk for misuse of opi-
oids [18, 19]. Opioid dependence is the most severe
SUD, and of all illegal drugs, opioids represents the most
fatal risk factor, the highest disease burden and most ur-
gent demand for treatment [20, 21]. In addition, sub-
stance use patterns of cannabis and simulants especially
frequent use, are found to be associated with residual
cognitive impairment and poor mental health [22–24].
Attention to mental health symptoms could perhaps
better facilitate and optimize individualized mental health
care and SUD treatment to these marginalized and vulner-
able populations in low-threshold settings and OAT pro-
grams. It is therefore vital to identify and assess mental
health among the SUD population, as the co-occurrence
of SUD and mental health disorders are likely to be under-
served by current mental health systems [25, 26].
The aims of this prospective cohort study was to
examine prevalence and change over time of mental
health symptoms using the ten-item Hopkins Symptom
Checklist (SCL-10) among people with severe substance
use disorders (SUD) in Norway. In addition, the study
aimed to assess potential predictors of mental health
symptoms and change in symptom burden over time
from substance use patterns and injecting use while also
adjusting for level of education, living conditions, age
and gender.
Methods
Study design and setting
This study is a nested prospective cohort study linked to
the multicenter INTRO-HCV study [27]. The data was
collected from May 2017 until July 2020 as part of an an-
nual health assessment among people with SUD in nine
OAT outpatient clinics in Bergen and Stavanger and two
low-threshold municipality clinics in Bergen. The OAT
clinics have implemented an integrated treatment and
care model where patients are followed-up on a near daily
basis by general and specialized nurses, psychologists and
physicians who are under specialization- or specialized in
addiction medicine. Buprenorphine-based and methadone
are the two main OAT medications [28]. People with
SUD in the municipality clinics are followed-up by social
workers, general nurses and physicians specialized in fam-
ily medicine. The INTRO-HCV study have employed
trained research nurses who collected and completed the
structured patient interviews, which were recorded in a
health register using an electronic data collection software
(CheckWare).
Study sample
The study sample was comprised of two groups of pa-
tients; individuals diagnosed with opioid dependence
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(F11.2) according to World Health Organization’s Inter-
national Classification of Diseases version 10 (ICD-10)
[29], which were enrolled in OAT during the study
period and accounted for 83% of the total study sample
at baseline. The other participants were recruited from
low-threshold municipality clinics among people who in-
ject drugs. For the purpose of this paper, a SUD was de-
fined as harmful use of, or dependency of a substance,
and a severe SUD was defined as dependency of one or
more substances. All included individuals were 18 years
or older at time of inclusion and signed a written in-
formed consent to partake in the study. Altogether 1042
SCL-10 measurements were included from 707 partici-
pants. Of the 707 participants with SCL-10 measures at
baseline and 268 (38%) were included in a follow-up as-
sessment with 67 (10%) having at least three annual
measuring points. The mean time between SCL-10 mea-
surements was 364 days (standard deviation (SD) 133).
Table 1 shows details on clinical and sociodemographic
characteristics of the study sample.
Assessment
Measuring mental health status: Hopkins symptom
check list (SCL-10).
Table 1 Basic characteristics of study sample
Participants, n (%) Baseline (n = 707) Follow-up (n = 268)
Gender
Male 500 (71) 208 (78)
Female 207 (29) 60 (22)
Age, n (%)
18–29 83 (12) 25 (9)
30–39 203 (29) 71 (26)
40–49 217 (31) 87 (32)
50–59 161 (23) 71 (26)
≥ 60 43 (6) 14 (5)
Mean (SD) 43 (11) 45 (10)
Highest education completed, n (%)
Not completed lower secondary school 41 (6) 15 (6)
Completed lower secondary school (9 years) 309 (44) 128 (48)
Completed upper secondary school (12 years) 285 (40) 99 (37)
Completed under or postgraduate studies (≥ 12 years) 72 (10) 26 (10)
Current living conditions, n (%)
Stable (owned, rented or incarcerated) 619 (88) 242 (90)
Unstable (homeless, with family/friends) 88 (12) 26 (10)
Worrying debt situation 292 (41) 116 (43)
Participants enrolled in OAT, n (%) 590 (83) 248 (93)
OAT medications of those; n (%)
- Methadone 224 (38) 110 (44)
- Buprenorphine-based 357 (61) 134 (54)
OAT treatment ratio*, mean (SD) 0.9 (0.4) 0.9 (0.3)
Injecting and frequent substance use past 12months, n (%)
Injected at least once 352 (54) 142 (53)
Alcohol 165 (25) 67 (25)
Cannabis 329 (50) 145 (55)
Stimulants (amphetamine/methamphetamine/cocaine) 183 (28) 73 (27)
Opioids (other than OAT) 103 (16) 29 (11)
Benzodiazepines 248 (38) 104 (39)
SD = standard deviation, OAT = Opioid agonist therapy,
*OAT ratio = ratio between daily OAT medication dose divided by expected mean daily dose; for buprenorphine 18 mg, buprenorphine-naloxone 18/4.5 mg or
methadone 90 mg
Frequent substance use was defined as using substance at least weekly during the past 12months
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The SCL-10 is a structured and self-administrated
questionnaire, designed to measure symptoms of mental
health disorders and psychological distress, and is widely
used for both clinical and epidemiological purposes [30–
32]. The SCL-10 involves ten items (suddenly scared for
no reason, feeling fearful, faintness, dizziness or weak-
ness, feeling tense, blaming yourself, difficulties falling
asleep, feeling of worthlessness, feeling blue, feeling
hopeless, and feeling everything is an effort), which are
each scored on four dimensions from not bothered at all
(item score = 1) to extremely bothered (item score = 4).
Scores were summed and divided by the number of
items answered to derive the mean item score. Mean
scores vary between one and four, where the latter as-
sumes extremely bothered. SCL-10 mean item scores
were used for descriptive analyses while SCL-10 sum
scores were used in linear mixed model (LMM) analyses.
Furthermore, the mean item scores were calculated by
gender, age, level of education, and living conditions at
baseline. By introducing a cut-off point one can interpret
the proportion of the respondents with symptoms of
mental health disorders. A mean score of 1.85 for SCL-
10 has been recommended as a threshold for indicating
substantial mental health distress [31].
Study variables; baseline, OAT, clinical and
sociodemographic factors
Baseline was defined as the time when the first SCL-10
measure was completed upon the participant’s first an-
nual health assessment. Subsequent SCL-10 measures at
the next health assessment(s) were listed chronologically
and included as follow-up. Being on OAT was defined
as receiving either buprenorphine-based or methadone
medication at baseline. Moreover, the OAT ratio,
which corresponds to the received dose of OAT
medication per day divided by expected mean dose
(buprenorphine 18 mg or methadone 90 mg) according
to World Health Organization [33], was calculated
per OAT patient. For the clinical factors we defined
injecting substances as having injected any substance
during the last 12 months, and frequent substance use
as using a substance more than once weekly during
the last 12 months according to the subcategories of
alcohol, cannabis, stimulants (amphetamine/metham-
phetamine/cocaine), opioids (non-OAT), and benzodi-
azepines (including z-hypnotics).
Statistical analysis
All descriptive analyses were performed using STATA/
SE 16.0. Expectation-maximization (EM) imputation and
LMM analyses were performed in IBM SPSS version
26.0. Statistical significance was set at the p < 0.05 level.
Missing values of SCL-10, clinical and sociodemographic
variables, which included substance use, injecting sub-
stance use, educational level, worrying debt situation,
and living conditions were assumed to be missing at ran-
dom when performing EM imputation. There were miss-
ing values for 3.4% of these values, which were
subsequently replaced with the estimated values by EM
imputation according to Enders (2010) [34].
A LMM analyses were used to evaluate the impact of
clinical and sociodemographic factors on the SCL-10
sum score. Time was defined as years from baseline
Firstly, we ran a LMM analysis where each defined pre-
dictor variable was set against time, to assess whether
the predictor variable changed over time. There were no
clinical significant changes in these variables when ana-
lyzed separately as outcome variables – with the time
variable being the exposure variable (data not shown).
Thus, these predictor variables were included as con-
stant and time-independent variables in further analyses.
Secondly, a new LMM analysis was generated where
these time-independent predictor variables were set
against the SCL-10 sum score being the outcome vari-
able. In addition, we added a time interactional to each
predictor variable to investigate if time impacted
changes of SCL-10 given each predictor. The predictor
variables, on the baseline level and change in SCL-10
sum score, represented as main effects and interaction
effects with time. The model was a random intercept
fixed slope model with restricted maximum likelihood
set as the estimator. This model uses all available data in
the outcome variable.
Results
Basic characteristics of the study sample
Seventy-one percent of the study sample were male,
mean (SD) age of 43 (11) at baseline and 45 (10) at
follow-up for the whole cohort (Table 1). Approximately
40% had completed upper secondary school. Most par-
ticipants (88%) had a stable living condition and 41%
had a concerning debt situation. Eighty-two percent of
the study sample was in OAT, of which 61 and 38% re-
ceived buprenorphine-based medication and methadone,
respectively. Over half had injected substances at least
once during the last year, while 71% reported frequent
substance use; most prevalent substances being cannabis
(50%) and benzodiazepines (38%).
SCL-10 scores at baseline and follow-up
The mean (SD) of the SCL-10 item scores was 2.2 (0.8)
(Table 2) at baseline. The distribution was sharply-
peaked (kurtosis: 2.2) and slightly right-skewed (skew-
ness: 0.4). The lowest mean (SD) item score (SD) was
found for suddenly scared for no reason at 1.9 (1.1) and
the highest score 2.5 (1.2) for difficulty in falling asleep
(Fig. 1 and Additional File 1). Overall, females reported
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mean (SD) SCL-10 item score of 2.3 (0.8) and men 2.2
(0.8) [31].. People with unstable living conditions re-
ported more symptoms of mental disorders than people
with stable living conditions. Among OAT treatment,
people on methadone reported mean (SD) SCL-10 of 2.3
(0.7) and buprenorphine-based medications at 2.2 (0.8).
SCL-10 = Symptoms checklist 10; ten items scale for
measuring mental health status/psychological distress.
The figure displays the proportion of patients re-
sponses on the ten item scale, from not bothered at all
(item score = 1) to extremely bothered (item score = 4).
We found vast individual dissimilarities in subjective
mental health symptoms at baseline (Additional File 2);
minimum and maximum mean SCL-10 item score was
one and four, respectively. Thirty-three participants
(4.7%) reported a mean of one; meaning not bothered at
all on any items, while three participants (0.4%) were ex-
tremely bothered on all items. Sixty-five percent of the
cohort reported a mean SCL-10 above the 1.85 cut-off
point, which is recommended as a predictor of mental
disorder [31] as shown in the Pen’s Parade below.
Pen’s Parade: SCL-10 = Symptoms checklist 10; ten
items scale for measuring mental health status/psycho-
logical distress.
The figure displays distribution in SCL-10 mean values
at baseline (n = 707) and follow up (n = 268), represented
by fixed black line and vertical grey lines. The dotted
lines represent the mean reported SCL-10 score of the
Norwegian reference population (1.36) and standard ref-
erence of 1.85 indicating one or more mental disorders
above this cut-off, respectively. Source: Strand BH, Dal-
gard OS, Tambs K, Rognerud M: Measuring the mental
health status of the Norwegian population: a comparison
of the instruments SCL-25, SCL-10, SCL-5 and MHI-5
(SF-36). Nordic journal of psychiatry 2003 [31].
Altogether 268 (38%) of the 707 participants at base-
line had SCL-10 measures at two data points. As shown
in Fig. 2, individual SCL-10 score at first follow-up are
indicated with grey points and individual changes from
baseline with vertical lines. Sharp changes go in both
positive and negative directions and appear considerable
for some.
Impact of substance use patterns, clinical and
sociodemographic factors on baseline level and change in
SCL-10 sum score
Using a LMM analysis, we found higher SCL-10 sum
scores at baseline for females (SCL-10 sum score: 1.8,
95% confidence interval (CI): 0.7 to 3.0) compared to
men, people with unstable living conditions (1.7, CI: 0.0
to 3.3) and having a worrying debt (2.2, CI: 1.1 to 3.3)
compared to people with stable living conditions and
non-worrying debt, respectively. For substances, fre-
quent use of cannabis (1.3, CI: 0.2 to 2.5), other opioids
(2.7, CI: 1.1 to 4.2) and benzodiazepines (3.6, CI: 2.4 to
4.8) were associated with higher SCL-10 scores at base-
line compared to people with no or non-frequent use of
these substances (Table 3). On the other hand, frequent
use of stimulants was associated with lower SCL-10 sum
score at baseline (− 2.7, CI: − 4.1 to − 1.4) compared with
people with no or less frequent use. There were no sig-
nificant time interactions between any of the substance
use patterns and changes in the SCL-10 sum score, nor
were there any significant time interactions with socio-
demographic characteristics.
Discussion
In this study, we found that 65% of people with SUD
have symptoms of mental health disorders and psycho-
logical distress. Mental health symptoms were particu-
larly prevalent among females, people with frequent use
of cannabis, non-OAT opioids, and benzodiazepines
compared to men and people with no or less frequent
use of these substances. Interestingly, there were no
clear associations between substance use patterns and
Table 2 Baseline SCL-10 mean item scores and standard
deviation (SD) by gender, age and sociodemographic factors












Highest level of education, n 705
Not completed lower secondary school 2.46 0.78
Completed lower secondary school (9 years) 2.24 0.78
Completed upper secondary school (12 years) 2.14 0.72
Completed undergraduate studies (≤ 15 years) 2.28 0.77
Completed postgraduate studies (≥ 15 years) 2.16 0.66
Current living conditions, n 705
Stable (owned, rented or incarcerated) 2.19 0.74
Unstable (homeless, with family/friends) 2.40 0.84
Enrolled in OAT and by medication, n 583
Methadone 2.28 0.71
Buprenorphine 2.15 0.77
SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health
status/psychological distress, SD =standard deviation, OAT = opioid
agonist therapy
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Fig. 1 Proportion of SCL-10 item scores at baseline. SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/
psychological distress. The figure displays the proportion of patients responses on the ten item scale, from not bothered at all (item score= 1) to
extremely bothered (item score = 4)
Fig. 2 Pen’s Parade: Distribution of mean SCL-10 item scores at baseline and follow-up. Pen’s Parade: SCL-10 = Symptoms checklist 10; ten items
scale for measuring mental health status/psychological distress. The figure displays distribution in SCL-10 mean values at baseline (n=707) and
follow up (n=268), represented by fixed black line and vertical grey lines. The dotted lines represent the mean reported SCL-10 score of the
Norwegian reference population (1.36) and standard reference of 1.85 indicating one or more mental disorders above this cut-off, respectively.
Source: Strand BH, Dalgard OS, Tambs K, Rognerud M: Measuring the mental health status of the Norwegian population: a comparison of the
instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nordic journal of psychiatry 2003 [31]
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change in mental health symptoms over time. This could
suggest that the differences observed were indicating
self-medication to larger degree than medication-related
decline in mental health.
People with SUD are a heterogeneous population; fif-
teen and 35 % reported lower mean SCL-10 item scores
compared to the general population and the standard
reference score for symptoms of mental health disorders,
respectively. Despite vast intra-individual variations in
SCL-10 score from baseline to first follow-up, going in
both directions, there were no time trends indicating
change over time for the total study sample. This indi-
cates that mental health disorders and psychological dis-
tress persist over time for this group and we are not able
to explain the huge shift, positive and negative, in mental
status of many individuals.
The mean SCL-10 for our cohort was 2.2, which is
considerable lower compared to the general Norwegian
population at 1.4, estimated to be around 11% of the
population [31]. Around two-thirds of the total study
sample reported symptoms of mental health disorders.
This was somewhat higher symptom burden compared
to cohort among people with SUD in Sweden [35], how-
ever, lower compared to a study among people entering
SUD treatment in Norway, which found that over 80%
had a level of mental distress above the 1.85 cut-off for
SCL-10 at admission [36]. This could reflect that initiat-
ing SUD treatment, often combined with strict detoxifi-
cation, is a very stressful event, whereas most of the
patients included in our cohort were long-term OAT pa-
tients with a mean treatment time of almost eight years
[13]. Correspondingly, follow-up studies have shown
that there may be a significant reduction in SCL-10
symptoms when these individuals are discharged from
inpatient treatment, however, presence of mental health
disorders and severity of substance use seem to be inde-
pendent predictors of considerable symptoms of mental
health disorders in the long-term [37, 38]. We found
that mental health symptoms at baseline were associated
with a worrying debt situation, unstable living conditions
and a frequent use of some of the substances. Severe
debt has been found to correlate with poor mental
health in a systematic review summarizing a number of
studies [39]. There are also several studies suggesting a
strong relationships between substance use and psycho-
logical distress, despite hardship to establish exact caus-
ality [40–42]. In the above study among people entering
SUD treatment, severity of substance use, although
stratified into alcohol use, illicit drug use and number of
substances used– but not the actual substances used;
was the most significant predictor of symptoms of men-
tal health disorders [36]. However, again the question
Table 3 Linear mixed model of SCL-10 adjusted for clinical and sociodemographic factors
Fixed effects
Baseline Change per year
n = 707 Estimate (95% CI) Slope (95% CI)
Factor impact* on SCL-10 sum score at baseline and changes per year from baseline
SCL-10 sum score 18.1 (15.9 to 20.2) 0.6 (−1.6 to 2.9)
Female 1.8 (0.7 to 3.0) 0.4 (−0.9 to 1.8)
Age per 10 years 0.0 (−0.1 to 0.0) 0.0 (0.0 to 0.1)
Clinical factors
Injecting substance use
Injecting at least once last 12 months 0.6 (−0.7 to 1.8) −0.3 (−1.6 to 1.0)
Frequent use of substances
Alcohol 0.7 (−0.6 to 1.9) 0.1 (−1.2 to 1.4)
Cannabis 1.3 (0.2 to 2.5) 0.3 (−0.9 to 1.4)
Stimulants (amphetamines/ cocaine) −2.7 (−4.1 to − 1.4) − 0.2 (−1.6 to 1.3)
Opioids (other than opioid dispensed on OAT) 2.7 (1.1 to 4.2) −2.6 (− 4.7 to − 0.4)
Benzodiazepines 3.6 (2.4 to 4.8) − 0.4 (− 1.7 to 0.8)
Sociodemographic factors
Level of education −0.1 (− 0.7 to 0.6) −0.6 (− 1.3 to 0.1)
Unstable living conditions 1.7 (0.0 to 3.3) 1.1 (−1.0 to 3.3)
Worrying debt situation 2.2 (1.1 to 3.3) 0.4 (−0.7 to 1.6)
SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/psychological distress, CI = confidence interval
*Age per 10 years (centered according to mean age 43 years), level of education was coded 0–4 with 4 as the highest educational level, living conditions; unstable
situation homeless or non-permanent residence, worrying debt situation: including any legal or illegal fees and debt, injecting substance use: during
last 12months
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arises whether these symptoms are the direct result of
the substance use or symptoms of mental distress pre-
senting upon treatment admission [36].
In our study, use of cannabis, non-OAT opioids and
benzodiazepines were co-occurring with mental health
distress at baseline, while the opposite was seen for stim-
ulants. There were no changes in time trends between
use of substances and mental health symptoms. One hy-
pothesis for these findings could be that the associations
at baseline might be due to reverse causality, i.e. that
participants with substantial mental health symptoms
use substances to self-medicate symptoms [43]. It is also
possible that there is a “flattening effect” and that poten-
tial negative impact of substances are more substantial
at an earlier phase and that the change in later phases
are less pronounced. Other research indicate that high
doses of benzodiazepines reduce social functioning, and
that it may also increase psychological distress and
worsen mental health [16, 44], and misuse of benzodiaz-
epines is seen among both SUD and psychiatric popula-
tions alike [45]. Similarly, the use of stimulants, in
particular methamphetamine, has been associated with
poor mental health outcomes [23]. Self-medication of at-
tention deficit hyperactivity disorder (ADHD) with stim-
ulants could be one explanation for these findings. Yet
one study found that high ADHD symptom burden was
associated with higher mental distress and use of simu-
lants among OAT patients [46]. It is estimated that up
to a third of patients in OAT have ADHD and previ-
ously we have found that coverage of central acting
stimulants in this patient group is very low [12, 47, 48].
An alternative explanation could be that stimulants have
a direct positive impact on mental health symptoms
among these patients. However, the time trend analyses
does not support these hypotheses.
Although prevalence of mental disorders and SUD co-
morbidity has been found to vary among European
countries; research consistently shows a high total preva-
lence of around 50%, with depression, anxiety disorders
and personality disorders being the most frequent [9].
However, some facility based studies indicate an even
higher comorbidity prevalence as people with severe
symptoms are more likely to seek support; 70% for
personality disorders [3] and a lifetime substance-
independent mental disorder was found in nine out of
ten patients enrolled in treatment facilities [49]. Comor-
bid mental health disorders and SUD have been found
to be associated with poor treatment outcomes and
show a higher psychopathological severity compared to
people with a single disorder [50–52], and this under-
lies the importance of assessing mental health status
in clinical settings among people with SUD. We en-
dorse that evaluation of mental health and linkage to
mental health care services should be included in
OAT programs and low-threshold SUD clinics; be
gender-sensitive and follow and integrated treatment
approach, which have been found superior compared
to separate treatment plans [53–55].
The major strength of this study is the relatively large
sample size of a “hard-to-reach” population of people
with SUD as well as a cohort design. However, there are
some limitations. Firstly, only a minority contributed to
the prospective analyses (268/707). To reduce the poten-
tial for selection bias between the sub-group with
follow-up SCL-10 measurements presented in Fig. 2 and
the baseline cohort, we conducted an inverse probability
weighted analysis. Our study sample is also mainly rele-
vant for people with opioid dependence being enrolled
in OAT treatment as most were in this group. Thus, our
research might not be generalized to other groups with
SUD. Moreover, both in the OAT and low-threshold
SUD clinics, patient- and system delays contributed to
non-accurate annual health assessments, which could in
turn affect both answers and results. Thirdly, the SCL-
10 has limitations. It is not a diagnostic tool for mental
health disorders and is no replacement for clinical inter-
views and more comprehensive psychiatric instruments
among people with SUD. Literature also suggests that
the SCL-10 predicts depression and anxiety better than
other diagnosis, and that some 50–60% of the patients
identified with symptoms of mental disorders qualify for
at least one or more mental disorders when assessed
clinically [31, 56, 57].
Conclusion
People with SUD have considerable symptoms of mental
health disorders and psychological distress. However,
this is a diverse and dynamic population with extreme
individual variations. Around one-third have few symp-
toms of mental health disorders. This emphasizes the
importance of consideration and evaluation of symptoms
of mental health disorders and psychological distress in
both OAT and low-threshold SUD clinics to further im-
prove personalized patient care. Mental health problems
were particularly observed among females, people with
frequent use of cannabis, opioids, and benzodiazepines,
and less among people using amphetamines. Time trend
analyses could suggest that the differences observed in-
dicates self-medication or a flattening effect rather than
medication-related decline in mental health. Studies with
long term follow-up or experimental design is needed to
confirm these potential effects better.
Abbreviations
ADHD: Attention deficit hyperactivity disorder; EM: Expectation-maximization
imputation; INTRO-HCV: Integrated treatment of hepatitis C virus infection;
HCV: Hepatitis C virus infection; LMM: Linear mixed model; OAT: Opioid
agonist therapy; SCL-10: Hopkins Symptom Check List 10; SCL-25: Hopkins
Symptom Check List 25; SUD: Substance use disorder
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:20 Page 8 of 10
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13011-021-00354-1.
Additional file 1. SCL-10 = Symptoms checklist 10; ten items scale for
measuring mental health status/psychological distress, SD = standard
deviation,
Additional file 2. Pen’s Parade: SCL-10 = Symptoms checklist 10; ten
items scale for measuring mental health status/psychological distress. The
figure shows distribution in SCL-10 mean values at baseline (n = 707) by
fixed black line. The dotted lines represent the mean reported SCL-10
score of the Norwegian reference population (1.36) and standard refer-
ence of 1.85 indicating one or more mental disorders above this cut-off,
respectively. Source: Strand BH, Dalgard OS, Tambs K, Rognerud M: Measur-
ing the mental health status of the Norwegian population: a comparison of
the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nordic journal of
psychiatry 2003.
Acknowledgements
Christer Kleppe, data protecting officer, Helse Bergen for his valuable
contribution and guidance in data management. We also thank Nina
Elisabeth Eltvik for valuable help and input during the planning and
preparation phases.
INTRO-HCV Study Group participating investigators:
Bergen: Christer Frode Aas, Vibeke Bråthen Buljovcic, Fatemeh Chalabianloo, Jan
Tore Daltveit, Silvia Eiken Alpers, Lars T. Fadnes (principal investigator), Trude
Fondenes Eriksen, Per Gundersen, Velinda Hille, Kristin Holmelid Håberg, Kjell
Arne Johansson, Rafael Alexander Leiva, Siv-Elin Leirvåg Carlsen, Martine Lepsøy
Bonnier, Lennart Lorås, Else-Marie Løberg, Mette Hegland Nordbotn, Cathrine
Nygård, Maria Olsvold, Christian Ohldieck, Lillian Sivertsen, Hugo Torjussen, Jørn
Henrik Vold, Jan-Magnus Økland.
Stavanger: Tone Lise Eielsen, Nancy Laura Ortega Maldonado, Ewa Joanna Wilk.
proLAR: Ronny Bjørnestad, Ole Jørgen Lygren, Marianne Cook Pierron.
Oslo: Olav Dalgard, Håvard Midgard, Svetlana Skurtveit.
Bristol: Peter Vickerman.
(In alphabetical order of surname)
Ethical approval and consent to participate
The study was approved by the Regional committee for medical and health
research ethics (no. 2017/51/REK vest). It was conducted in accordance with
the Helsinki Declaration and STROBE guidelines All included participants
signed a written consent to partake in the study.
Authors’ contributions
This observational study was led by CFA in terms of study design, analyzes,
drafting and writing the article. JHV, RG and AGL were particularly involved
with acquisition of data, analyses and interpretation. Figures were made by
AGL. KAJ, LTF, SS, JHV, AGL, KVG, RG and EML contributed to the conception,
writing, and revising the draft(s) critically. All authors have read and
approved the version to be published.
Authors’ information
Christer F. Aas, MD MA, Department of Addiction Medicine, Haukeland
University Hospital, and Department of Public Health and Primary Care,
University of Bergen. Mailing address: Department of Addiction Medicine,
Haukeland University Hospital, Østre Murallmenningen 7, N-5012 Bergen,
Norway. E-mail: christer.frode.aas@helse-bergen.no.
Funding
This study is part of the main INTRO-HCV study, which was funded by The
Norwegian Research Council (no. 269855) and the Western Norway Regional
Health Authority (“Åpen prosjektstøtte) with Department of Addiction Medi-
cine, Haukeland University Hospital as responsible institution. The funders
had no role in the study design, data collection and analyzes, decision to
publish, nor preparation of any content in the manuscript. Two of the au-
thors, CFA and JHV, are funded from the above research grant, whereas the
other authors are funded by their respective affiliations.
Availability of data and materials
Dataset used for SCL-10 for this publication may be available in an anonym-
ous and shortened version upon contacting the corresponding author.
Consent for publication
Not applicable. No personal details on any of the participants are reported in
the manuscript, tables or figures.
Competing interests
None of the authors have competing interests.
Author details
1Bergen Addiction Research group, Department of Addiction Medicine,
Haukeland University Hospital, Bergen, Norway. 2Department of Global Public
Health and Primary Care, University of Bergen, Bergen, Norway. 3Division of
Psychiatry, Haukeland University Hospital, Bergen, Norway. 4Norwegian
Centre for Addiction Research, University of Oslo, Oslo, Norway. 5Department
of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.
6Population Health Sciences, Bristol Medical School, University of Bristol,
Bristol, UK. 7Department of Clinical Psychology, University of Bergen, Bergen,
Norway.
Accepted: 16 February 2021
References
1. Global Burden of Disease Collaborative Network. The global burden of
disease attributable to alcohol and drug use in 195 countries and territories,
1990-2016: a systematic analysis for the global burden of disease study
2016. The lancet Psychiatry. 2018;5(12):987–1012.
2. Santucci K. Psychiatric disease and drug abuse. Curr Opin Pediatr. 2012;
24(2):233–7.
3. Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between
mental distress and poly-drug use: a ten year prospective study of patients
from substance abuse treatment. Addict Behav. 2015;48:71–8.
4. Chassin L, Sher KJ, Hussong A, Curran P. The developmental
psychopathology of alcohol use and alcohol disorders: research
achievements and future directions. Dev Psychopathol. 2013;25(4 Pt 2):
1567–84.
5. Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Løberg
EM, Medhus S, Tanum L, Franck J. Amphetamine-induced psychosis--a
separate diagnostic entity or primary psychosis triggered in the vulnerable?
BMC Psychiatry. 2012;12:221.
6. Løberg EM, Helle S, Nygård M, Berle JO, Kroken RA, Johnsen E. The
Cannabis pathway to non-affective psychosis may reflect less
neurobiological vulnerability. Front Psychiatry. 2014;5:159.
7. European Monitoring Centre for Drugs and Drug Addiction: Komorbiditet
— samförekomst av narkotikamissbruk och psykisk störning. Ett
underskattat tillstånd. In.; 2004.
8. Global, regional, and national age-sex specific all-cause and cause-specific
mortality for 240 causes of death, 1990–2013: A systematic analysis for the
global burden of disease study 2013. Lancet (London, England). 2015;
385(9963):117–71.
9. European Monitoring Centre for Drugs and Drug Addiction: Co-
morbid substance use and mental disorders in Europe: a review of
the data. In.; 2013.
10. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W,
Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use
disorders and independent mood and anxiety disorders: results from the
National Epidemiologic Survey on alcohol and related conditions. Arch Gen
Psychiatry. 2004;61(8):807–16.
11. Hall W. What have population surveys revealed about substance use
disorders and their co-morbidity with other mental disorders? Drug and
alcohol review. 1996;15(2):157–70.
12. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F,
Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit
hyperactivity disorder in substance use disorder patients: a meta-analysis
and meta-regression analysis. Drug Alcohol Depend. 2012;122(1–2):11–9.
13. Aas CF, Vold JH, Skurtveit S, Lim AG, Ruths S, Islam K, Askildsen JE, Løberg
EM, Fadnes LT, Johansson KA: Health-related quality of life of long-term
patients receiving opioid agonist therapy: a nested prospective cohort
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:20 Page 9 of 10
study in Norway. Substance abuse treatment, prevention, and policy 2020,
15(1):68.
14. Franklyn AM, Eibl JK, Gauthier G, Pellegrini D, Lightfoot NE, Marsh DC. The
impact of benzodiazepine use in patients enrolled in opioid agonist therapy
in northern and rural Ontario. Harm Reduct J. 2017;14(1):6.
15. Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Reutfors J, Halmøy A,
Johansson KA, Fadnes LT. Potentially addictive drugs dispensing to patients
receiving opioid agonist therapy: a register-based prospective cohort study
in Norway and Sweden from 2015 to 2017. BMJ Open. 2020;10(8):e036860.
16. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of
benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;
200:95–114.
17. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine
use and aggressive behaviour: a systematic review. The Australian and New
Zealand journal of psychiatry. 2014;48(12):1096–114.
18. Davis MA, Lin LA, Liu H, Sites BD. Prescription opioid use among adults with
mental health disorders in the United States. JABFM. 2017;30(4):407–17.
19. Cragg A, Hau JP, Woo SA, Kitchen SA, Liu C, Doyle-Waters MM, Hohl CM.
Risk factors for misuse of prescribed opioids: a systematic review and meta-
analysis. Ann Emerg Med. 2019;74(5):634–46.
20. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden
of opioid-related mortality in the United States. JAMA Netw Open. 2018;
1(2):e180217.
21. European Monitoring Centre for Drugs and Drug Addiction: European Drug
Report. Trends and Developments. In.; 2019.
22. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use.
Drug testing and analysis. 2014;6(1–2):39–45.
23. McKetin R, Leung J, Stockings E, Huo Y, Foulds J, Lappin JM, Cumming C,
Arunogiri S, Young JT, Sara G, et al. Mental health outcomes associated with
of the use of amphetamines: a systematic review and meta-analysis.
EClinicalMedicine. 2019;16:81–97.
24. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran
LT, Rehm J, Torrens M et al: Responding to global stimulant use: challenges and
opportunities. Lancet (London, England) 2019, 394(10209):1652–1667.
25. Đào GJ, Brunelle C, Speed D. Impact of substance use and mental health
comorbidity on health care access in Canada. J Dual Diagn. 2019;15(4):260–9.
26. Sheidow AJ, McCart M, Zajac K, Davis M. Prevalence and impact of
substance use among emerging adults with serious mental health
conditions. Psychiatr Rehabil J. 2012;35(3):235–43.
27. Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S,
Lygren OJ, Dalgard O, Vickerman P, et al. Integrated treatment of hepatitis C
virus infection among people who inject drugs: study protocol for a
randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):943.
28. Waal H BK, Clausen T, Lillevold PH, and Skeie I.: SERAF Report: Status 2017.
MAR 20 years. Status, evaluations and perspectives. In.: The Norwegian
Centre for Addiction Research (SERAF); 2018.
29. The World Health Organization. International Statistical Classification of
Diseases and Related Health Problems (ICD). 2020. [https://www.who.int/cla
ssifications/icd/icdonlineversions/en/]. Accessed 21 Sept 2020.
30. Schmalbach B, Zenger M, Tibubos AN, Kliem S, Petrowski K, Brähler E.
Psychometric properties of two brief versions of the Hopkins symptom
checklist: HSCL-5 and HSCL-10. Assessment. 2019;1073191119860910.
31. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health
status of the Norwegian population: a comparison of the instruments SCL-25,
SCL-10, SCL-5 and MHI-5 (SF-36). Nordic journal of psychiatry. 2003;57(2):113–8.
32. Kleppang AL, Hagquist C. The psychometric properties of the Hopkins
symptom Checklist-10: a Rasch analysis based on adolescent data from
Norway. Fam Pract. 2016;33(6):740–5.
33. World Health Organization: Guidelines for the Psychosocially Assisted
Pharmacological Treatment of Opioid Dependence. In.; 2009.
34. Enders CK. Applied missing data analysis. New York: The Guilford Press;
2010.
35. Richert T, Anderberg M, Dahlberg M: Mental health problems among young
people in substance abuse treatment in Sweden. Substance abuse
treatment, prevention, and policy 2020, 15(1):43.
36. Hoxmark E, Nivison M, Wynn R: Predictors of mental distress among
substance abusers receiving inpatient treatment. Substance abuse
treatment, prevention, and policy 2010, 5:15.
37. Hoxmark E, Benum V, Friborg O, Wynn R. Reduction in mental distress
among substance users receiving inpatient treatment. Int J Ment Health
Syst. 2010;4:30.
38. Bakken K, Landheim AS, Vaglum P. Axis I and II disorders as long-term
predictors of mental distress: a six-year prospective follow-up of substance-
dependent patients. BMC psychiatry. 2007;7:29.
39. Richardson T, Elliott P, Roberts R. The relationship between personal
unsecured debt and mental and physical health: a systematic review and
meta-analysis. Clin Psychol Rev. 2013;33(8):1148–62.
40. Kelly AB, Chan GC, Mason WA, Williams JW. The relationship between
psychological distress and adolescent polydrug use. Psychol Addict Behav.
2015;29(3):787–93.
41. Sopheab H, Suy S, Chhea C, Chhit S, Mun P, Bui TC. Psychological distress
among Cambodian people who use drugs. Drug and alcohol review. 2020;
39(1):66–70.
42. Booth BM, Curran G, Han X, Wright P, Frith S, Leukefeld C, Falck R, Carlson
RG. Longitudinal relationship between psychological distress and multiple
substance use: results from a three-year multisite natural-history study of
rural stimulant users. J Stud Alcohol Drugs. 2010;71(2):258–67.
43. Turner S, Mota N, Bolton J, Sareen J. Self-medication with alcohol or drugs
for mood and anxiety disorders: a narrative review of the epidemiological
literature. Depress Anxiety. 2018;35(9):851–60.
44. Lugoboni F, Mirijello A, Faccini M, Casari R, Cossari A, Musi G, Bissoli G,
Quaglio G, Addolorato G. Quality of life in a cohort of high-dose
benzodiazepine dependent patients. Drug Alcohol Depend. 2014;142:105–9.
45. McHugh RK, Peckham AD, Björgvinsson T, Korte FM, Beard C.
Benzodiazepine misuse among adults receiving psychiatric treatment. J
Psychiatr Res. 2020;128:33–7.
46. Fiksdal Abel K, Ravndal E, Clausen T, Bramness JG. Attention deficit
hyperactivity disorder symptoms are common in patients in opioid
maintenance treatment. Eur Addict Res. 2017;23(6):298–305.
47. Subramaniam GA, Stitzer MA. Clinical characteristics of treatment-seeking
prescription opioid vs. heroin-using adolescents with opioid use disorder.
Drug Alcohol Depend. 2009;101(1–2):13–9.
48. Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Halmøy A, Johansson
KA, Fadnes LT. Dispensation of attention deficit hyperactivity disorder
(ADHD) medications in patients receiving opioid agonist therapy; a national
prospective cohort study in Norway from 2015 to 2017. BMC psychiatry.
2020;20(1):119.
49. Bakken K, Landheim AS, Vaglum P: Primary and secondary substance misusers:
do they differ in substance-induced and substance-independent mental
disorders? Alcohol and alcoholism (Oxford, Oxfordshire) 2003, 38(1):54–59.
50. Stahler GJ, Mennis J, Cotlar R, Baron DA. The influence of neighborhood
environment on treatment continuity and rehospitalization in dually
diagnosed patients discharged from acute inpatient care. Am J Psychiatry.
2009;166(11):1258–68.
51. Langås AM, Malt UF, Opjordsmoen S. Comorbid mental disorders in
substance users from a single catchment area--a clinical study. BMC
psychiatry. 2011;11:25.
52. Szerman N, Lopez-Castroman J, Arias F, Morant C, Babín F, Mesías B, Basurte
I, Vega P, Baca-García E. Dual diagnosis and suicide risk in a Spanish
outpatient sample. Substance use & misuse. 2012;47(4):383–9.
53. Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric
disorders. Social work in public health. 2013;28(3–4):388–406.
54. Donald M, Dower J, Kavanagh D. Integrated versus non-integrated
management and care for clients with co-occurring mental health and
substance use disorders: a qualitative systematic review of randomised
controlled trials. Soc Sci Med. 2005;60(6):1371–83.
55. Rezansoff SN, Moniruzzaman A, Somers JM. Temporal associations between
medication adherence for patients with schizophrenia and opioid dependence: a
17-year Canadian cohort study. Schizophr Res. 2019;210:157–63.
56. Syed HR, Zachrisson HD, Dalgard OS, Dalen I, Ahlberg N. Concordance
between Hopkins symptom checklist (HSCL-10) and Pakistan anxiety and
depression questionnaire (PADQ), in a rural self-motivated population in
Pakistan. BMC psychiatry. 2008;8:59.
57. Sandanger I, Moum T, Ingebrigtsen G, Dalgard OS, Sørensen T, Bruusgaard
D. Concordance between symptom screening and diagnostic procedure:
the Hopkins symptom Checklist-25 and the composite international
diagnostic interview I. Soc Psychiatry Psychiatr Epidemiol. 1998;33(7):345–54.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:20 Page 10 of 10
The burden of disease among people with severe substance use disorders 
   
Article 3 
Aas CF, Vold JH, Skurtveit S, Lim AG, Ruths S, Islam K, Askildsen JE, Løberg EM, Fadnes 
LT, Johansson KA: Health-related quality of life of long-term patients receiving opioid 
agonist therapy: a nested prospective cohort study in Norway. Substance abuse treatment, 
prevention, and policy 2020, 15(1):68 
 
 
Christer F. Aas 
RESEARCH Open Access
Health-related quality of life of long-term
patients receiving opioid agonist therapy: a
nested prospective cohort study in Norway
Christer Frode Aas1,2* , Jørn Henrik Vold1,2, Svetlana Skurtveit3,4, Aaron G. Lim5, Sabine Ruths2,6, Kamrul Islam7,8,
Jan Erik Askildsen8, Else-Marie Løberg1,9,10, Lars Thore Fadnes1,2, Kjell Arne Johansson1,2 and for the INTRO-HCV
Study Group
Abstract
Background: Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy
(OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge
on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-
perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and
assesses changes in these scores at 1-year follow up.
Methods: We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT
patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-
perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from “no problems” to
“extreme problems”). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and
compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100).
Results: Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22)
compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L
index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for
female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were
observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index
value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively.
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Conclusion: The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the
general population, and lower than what has been found among other severe somatic and psychiatric conditions.
Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor
HRQoL.
Keywords: Health related quality of life, Quality of life, EQ-5D, Opiate substitution therapy, Opioid agonist therapy,
Opioid dependence, Epidemiology
Background
Opioid dependence is a severe chronic relapsing disorder
consisting of a cluster of physiological, behavioral, and
cognitive phenomena [1]. Worldwide, opioid use disor-
ders affect over 16 million people and are responsible
for over 120.000 deaths per year [2]. Of all illegal drugs,
opioids denote the highest disease burden, have the
highest demand for treatment, contribute to substantial
increased healthcare costs, and have given rise to a
marked increase in opioid related deaths in the last dec-
ade [3–5]. People with opioid use disorders suffer not
only from a shorter life-span as compared to the general
population, but also severe social marginalization and
long-term impairments in most aspects of their lives [6].
Research consistently shows that people with opioid use
disorders have inferior quality of life (QoL) compared to
the general population [7, 8]. This is partly explained by
the extensive co-occurrence of substance use disorder
and mental disorders, which both seem underdiagnosed
and undertreated [9], in addition to high prevalence of
somatic disorders such as chronic hepatitis C of almost
50% [10]. Epidemiological studies suggest a prevalence
of around 27% for anxiety disorders, 35% for affective
disorders, 30% for attention-deficit hyperactivity dis-
order, and 51% for personality disorders in patients with
substance use disorders [11–13]. However, prevalence
may be even higher in clinical studies as people with se-
vere problems are more likely to seek help; studies have
found prevalence of around 70% for one or more per-
sonality disorder [14] and around 66% for childhood
trauma among people with substance use disorders [15],
and at least one comorbid psychiatric disorder in ap-
proximately 80% of patients on opioid agonist therapy
(OAT) [16].
Increased focus on, and availability of harm reduction
programs, such as OAT have lowered the demand for
heroin in Western Europe including Norway [5]. OAT is
an evidence-based medical intervention that reduces
illicit opioid use, improves patients’ health and reduces
crude mortality rates significantly [3, 17–20]. For in-
stance, results of 22 pooled longitudinal cohort studies
showed a crude mortality rate for patients on OAT of
0.90 per 100 person years, compared to 1.63 when OAT
was ceased and 4.91 for untreated periods [21]. Most
research on OAT has emphasized on crude mortality
rate, abstinence and retention in treatment, rather than
what may be most important for each individual patient;
personal wellbeing. In turn, several researchers argued
that health related quality of life (HRQoL) should be in-
cluded as an outcome when evaluating substance use
and OAT treatment [22–25]. Thus, to evaluate real life
outcome of OAT, changes in objective and self-
perceived health, including the individual’s own experi-
ence, should be examined. In addition, for more individ-
ualized OAT treatment and management, it is important
to understand the relationship between clinical and
demographic characteristics and HRQoL.
Factors associated with poor HRQoL among OAT pa-
tients are older age, female gender, and mental and phys-
ical comorbidity [7, 26, 27]. There is building evidence
that HRQoL is substantially lower among people with opi-
oid dependence and that HRQoL improves at OAT initi-
ation and during the first few months of treatment [27–
30]. However, a recent systematic review suggests there is
still limited knowledge regarding HRQoL outcomes in
OAT treatment programs and HRQoL outcomes are
rarely used [22]. Many of the previous studies are cross-
sectional rather than longitudinal designs, offers few par-
ticipants and with non-validated HRQoL measures for
opioid dependence, which make comparisons difficult
across opioid dependence and other diseases.
The principal aim of this study is to evaluate the
HRQoL and self-perceived health of a large cohort of
long-term patients with opioid dependence enrolled in
an integrated OAT program in Norway. The HRQoL of
OAT patients will also be compared to that of the gen-
eral population in Norway. Finally, an assessment of
changes in HRQoL and self-perceived health at one-year
follow-up will be conducted.
Methods
Study design and setting
This study is a nested prospective cohort study linked to
the Integrated Treatment of Hepatitis C study (INTRO-
HCV) [31]. The observational study recruited partici-
pants from May 2017 until January 2020 [31]. HRQoL
baseline data was collected at the first OAT health as-
sessment, and follow-up data was collected one-year
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after baseline for each patient. Trained research nurses,
who were not responsible for clinical patient follow-up,
collected the research data via structured patient inter-
views. The data was recorded directly in an electronic
data entry system (CheckWare). The study took place in
Bergen and Stavanger, which are cities in southwestern
parts of Norway with around 280,000 and 130,000 in-
habitants each. The target population was individuals
with opioid dependence who received OAT treatment
and care in all together nine OAT outpatient clinics.
The clinics have adopted an integrated treatment and
care model where patients are charted on a nearly daily
basis by health professionals; including social workers,
specialized and general nurses, psychologists, and physi-
cians specialized in addiction medicine. OAT medica-
tions include mostly methadone or buprenorphine-based
medications, often with directly observed intake [32].
Study sample
The study sample included individuals diagnosed with
opioid dependence according to International Classifica-
tion of Diseases version 10 (ICD-10) [33], currently en-
rolled in OAT treatment, aged 18 years or older, and
have given a written informed consent to participate in
the study. Individuals were eligible for inclusion regard-
less of the type of OAT medication or administration
form. Remuneration, of around euro 20, was provided
once for the participants upon inclusion to participate in
the study. Of the 900 patients invited, a total of 609
(68%) patients completed the EQ-5D-5L questionnaire
at baseline, and of those, 245 (40%) were followed up
with a follow-up questionnaire approximately 1 year
after the first visit. Nineteen patients (2%) were excluded
because they did not complete the interview or due to
missing data of the EQ-5D-5L instrument The mean
time between the first and second annual OAT assess-
ment was 375 days (95% confidence interval (CI): 359–
392 days). See Table 1 for details on clinical and demo-
graphic characteristics and additional file 1 for flowchart
of study sample.
Instruments
Health related quality of life: EQ-5D-5L
The EQ-5D-5L instrument is a widely used generic
measure of HRQoL [34] and validated for opioid use dis-
orders [35, 36]. It consists of two components. The first
descriptive system evaluates health in five dimensions
(Mobility, Self-care, Usual activities, Pain/Discomfort,
Anxiety/Depression). Each dimension has five levels of
response, ranging from no problems, slight problems,
moderate problems, severe problems, to extreme prob-
lems [37]. The second part of EQ-5D-5L entails a visual
analogue scale (VAS) where the respondent rates the
self-perceived health from 0 (worst health imaginable) to
100 (best health imaginable) [37]. A systematic review
supports the use of the EQ-5D-5L in a broad range of
patients [38]. We therefore selected this instrument to
assess the HRQoL of patients in OAT and to compare
their HRQoL to the general population.
Statistical analysis
Responses to the five HRQoL dimensions are coded as a
five-digit code, which represents a numerical description
of a health state. The digits have no arithmetic proper-
ties and therefore a single summery number (an index
value) needs to be arrived by applying a formula with an
appropriate value set, which is a representative sample
of the general population. The index value then repre-
sents how good or bad a health state is according to the
preferences of the general population, ranging from 1
(full health) to 0 (dead, with negative values indicating
health states worse than death) [37]. In the absence of a
Norwegian value set, we applied an EQ-5D-5L value set
for UK, i.e. the societal preference weights for the health
state, to determine the EQ-5D-5L index values for each
health state in the OAT cohort [39]. Summary statistics
were derived, including proportions and number of pa-
tients for the five EQ-5D-5L dimensions by age, gender
and OAT medications. The EQ-VAS score was summa-
rized descriptively by mean, standard deviation (SD),
minimum and maximum as the data was not particularly
skewed. A paired t-test of means for the 245 patients
with two time points was used in the analysis to investi-
gate whether there was any statistical significance in EQ-
5D-5L between the measurements. An ANCOVA model
for EQ-VAS changes from baseline to the next OAT
health assessment was conducted where place and treat-
ment were fixed effects and baseline covariate. If data
were missing from more than one dimension partici-
pants were excluded. Altogether eight patients missed
data on one dimension at baseline but were included in
the analyses. There were no missing data from EQ-5D-
5L follow-up or EQ-VAS. To estimate the unbiased
treatment effects from baseline to follow-up we used an
inverse probability weighted method as we had
follow-up data for a subgroup. We calculated popula-
tion weights based on age, gender and how many
times OAT medication was collected during a week
in a binominal regression model with follow-up values
as the dependent variable. More weight was given to
cases with valid data, which were associated with
highest probability of having missing data, and less
weight was given to cases with lowest probability of
missing. The mean for the population weights was 1.0
(SD 0.12) in our model. Statistical significance was set
at p < 0.05 level. All analyses were made with STATA
SE 16.0.
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Results
Baseline characteristics of study sample
The patients were predominantly male (71%) with a
mean (SD) age of 44 years (10). The age range of the
study sample was 23–74 years. Most received
buprenorphine-based medication (60%) followed by
methadone (38%). Duration in OAT treatment ranged
from 0 to 25 years, with a mean (SD) of 7.9 (5.4) years.
Results therefore reflects HRQoL of patients that have
received OAT over a long period of time. Of the partici-
pants, 45% had completed secondary school and 40%
completed high school. Almost 80% received either dis-
ability pension or social benefits as main source of in-
come. Of the 152 OAT patients with children under 18
years, 21% reported they had no visiting rights (Table 1).
The distributions of sociodemographic variables were
similar for the baseline- and the follow-up samples.
However, the proportion of males increased from 71 to
76% in the follow-up sample and mean (SD) age in-
creased from 44 (10) to 45 (10) years compared to the
sample at baseline.
HRQoL of OAT patients at baseline
The distributions of unadjusted EQ-5D-5L scores are
presented as norm sets according to gender, age groups,
and OAT medications (Fig. 1). Overall, mean scores for
the five dimensions were 1.7 (95% CI: 1.6–1.8) for mo-
bility, 1.3 (95% CI: 1.2–1.3) for self-care, 1.8 (95% CI:
1.7–1.9) for usual activity, 2.3 (95% CI: 2.2–2.4) for pain/
discomfort and 2.7 (95% CI: 2.6–2.8) for anxiety/depres-
sion (additional file 2). “No problems” were reported by
62% for mobility, 85% for self-care, 58% for usual activ-
ities, 36% for pain/discomfort, and only 23% for anxiety/
depression. This means that the majority of patients had
no problems with mobility and conducting usual activ-
ities and self-care. On the other hand, extreme prob-
lems” with pain/discomfort were noted by 5 % and 7 %
reported “extreme problems” with anxiety/depression.
Under 1 % reported “extreme problems” with mobility,
self-care and usual activities. Females and patients re-
ceiving methadone treatment reported more problems
across all EQ-5D-5L domains compared to males and
patients on buprenorphine-based medications, respect-
ively. Patients in the age group 41–60 reported more




Gender, n = 609
Male 71%
Female 29%





Mean age (SD) 44 (10)





Duration of OAT treatment in years, mean
(SD), n = 583
7.9 (5.4)
Background demographics
Highest level of completed education, n = 588
Did not complete primary and secondary
school
5%
Completed primary and secondary school 45%
High school 40%
Undergraduate education ≤3 years 8%
Postgraduate education ≥3 years 2%
Main source of income, several answers possible, n = 611
Paid work (full time or part time) 7%
Sick pay or unemployment benefits 10%
Social or disability benefits 79%
Savings or scholarships 1%
Other 3%






At friends or family 12%
Other 2%
Living conditions n = 586
Living alone 63%
Living with others 37%
Children n = 587
Do not have children 44%




For those having children < 18 years old, n = 152
Having children < 18 with visiting rights 79%
Having children < 18, but no visiting rights 21%
OAT Opioid agonist therapy, SD Standard deviation,
an = number of respondents, some questions allow multiple answers
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problems on every domain except pain/discomfort com-
pared to patients under 40 years of age, while patients
over 60 years of age reported most problems for mobility
and pain/discomfort (additional file 2).
The mean (SD) EQ-5D-5L index value for OAT patients
was 0.699 (0.250) at baseline. Forty-three percent had an
index value above 0.8, meaning they had “no problems” in
the five health domains. Thirty-four percent of the sample
even had an index value above 0.848 (Norwegian reference
population [40]), meaning their HRQoL was better than
that of the Norwegian general population. Around 5 %
had an index value below 0.2, meaning they had “extreme
problems” in HRQoL. The distribution in baseline EQ-
5D-5L index values are shown in the Pen’s Parade (Fig. 2).
The parade shows the HRQoL distribution, and is defined
as a succession of every OAT patient included, with their
height proportional to their EQ-5D-5L index value, from
lowest to highest.
The mean (SD) EQ-VAS score of OAT patients was
57 (22) for the total sample at baseline, meaning their
Fig. 1 Proportion of individuals reporting problems by EQ-5D-5L domain; overall, by age, gender and OAT medication. OAT = opioid agonist
therapy. Altogether 609 respondents, 8 patients missed values on one dimension. 11 patients, which did not receive either methadone or
buprenorphine-based medications are left out of the illustration but not analysis. Proportions (%) and dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression). 1A: Overall, 1B: Gender 1C: OAT medication 1D: Age groups
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self-perceived health was considerably lower compared
to the Norwegian reference population of 80 (19) [40].
Females reported an EQ-VAS of 56 (23), while 54 (22)
for patients aged 41–60, and 51 (23) for patients older
than age 60. Patients on methadone reported 53 (22),
which was lower EQ-VAS compared to buprenorphine
with 58 (22) and buprenorphine-naloxone 65 (21).
Changes in HRQoL of OAT patients at follow up
Altogether 245 (40%) of the 609 patients at baseline
were included for the follow-up analyses. As shown in
the Pen’s Parade (Fig. 2), individual changes in EQ-5D-
5L index values for patients with follow-up data (n =
245) are indicated with vertical lines. For instance, a pa-
tient with an index value of 0.563 at baseline and a long
vertical line going up to 0.840 at follow-up means this
patient reported a significant improvement in HRQoL. A
patient with a vertical line going down from baseline
shows worsen HRQoL between baseline and follow-up.
Patients with no follow-up data (n = 364) or no change
at follow-up (n = 26) has no vertical line. Figure 2 also
shows that the majority of patients have a lower index
value than the Norwegian reference population, meaning
worse HRQoL, illustrated by values below the dotted
line. However, changes go in both directions and appear
substantial for some. This means that patients receiving
long-term OAT are at risk of relatively rapid changes in
index values in both better and worse directions. Over-
all, around 54% reported improvement in HRQoL,
around 35% reported worse HRQoL while 11% reported
no changes at follow up compared to baseline values.
The mean (SD) observed change was 0.038 (0.20) with
minimum and maximum values of − 0.646 and 0.639, re-
spectively. Females reported a mean (SD) change of
0.056 (0.17) compared to males 0.032 (0.21). Variation
in individual EQ-5D-5L index value changes from base-
line to follow-up is illustrated in additional file 3.
EQ-5D-5L index values improved significantly overall
(p = 0.004) and for both genders (m: 0.039, f: 0.016), age
group 26–40 (p = 0.002) and buprenorphine-based pa-
tients (p = 0.027) as shown in Table 2. The mean (SD)
EQ-5D-5L index value was 0.729 (0.237) at follow-up;
49% had an index value above 0.8 while 37% of the sam-
ple had an index value above the Norwegian reference
population. Around 4 % had an index value below 0.2.
Significant improvements in EQ-5D-5L scores were
found for mobility (p = 0.008) and pain/discomfort (p =
0.025) (Fig. 3 and Table 3).
Significant improvement in self-perceived health (EQ-
VAS) were found for males (p = 0.038).
Discussion
This study is one of the first to examine changes in
HRQoL in a sample of long-term OAT patients over a
one-year follow-up period. Most studies on HRQoL
demonstrate improvements in HRQoL upon treatment
entry, but data on long-term patients’ HRQoL is scarce.
Considerable impairments in HRQoL and self-perceived
health (EQ-VAS) were found in many of the OAT pa-
tients. However, large variations in EQ-5D-5L index
values were found between individuals, both at baseline
and at follow-up. Significant improvement in overall
HRQoL was observed at one-year follow-up with around
half of the OAT patients reported some improvement in
HRQoL while around one-third experienced worse
HRQoL at one-year follow up, with great individual vari-
ations. Males reported significant improvement in their
self-perceived health.
Compared to the general Norwegian population,
which reported no problems regarding mobility (85%),
self-care (98%), usual activities (82%), pain/discomfort
(54%) and anxiety/depression (79%) [40], OAT patients
reported in average consistently higher percentages of
problems across all EQ-5D-5L domains, especially pain/
discomfort and anxiety/depression where only 36 and
23% respectively, reported no problems. The mean (SD)
EQ-5D-5L index value for the Norwegian reference
population 0.848 (0.200) [40] was considerably higher
compared to the OAT patients at baseline. Mean (SD)
total EQ-VAS for the OAT patients at baseline was con-
siderably lower than the Norwegian reference population
who reported overall mean (SD) of 80 (19); females 80
(20) and older age 77 (19) [40].
Our findings are consistent with prior research, such
as Strada et. al (2019) study of a large OAT cohort in
Germany; found that OAT patients had a lower HRQoL
than the general population [41]. Several studies have
demonstrated that female OAT patients report worse
overall HRQoL compared to males [8, 27]. However it is
unclear why that is the case and gender-focused research
is urgently needed. Perhaps females are more vulnerable
for stigma, traumatizing events or maybe have a poorer
function upon entering OAT in the first place. Age is
also strongly correlated to poor physical HRQoL [41]. In
our sample the mean age was 44, which is consistent
with an aging OAT population in Norway [32, 42]. In-
creased age of OAT patients coupled with poorly re-
ported HRQoL, may place an increased demand for
health care services in the future. This raises a debate on
how level of OAT and various integrated treatment pol-
icies and strategies could better benefit OAT patients.
Even if OAT patients treated with methadone reported
worse HRQoL than those with buprenorphine, the re-
sults should be interpreted carefully. In current Norwe-
gian OAT guidelines buprenorphine is usually
recommended as first line substitution medication and
considered safer compared to methadone due to its par-
tial antagonistic effect [43]. It is also likely that patients
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may prefer buprenorphine because it is less sedative
than methadone, and that both younger and perhaps
more stable patients are dispensed buprenorphine, and
as such, results could be highly confounded.
Previous research has revealed that HRQoL improves
considerably at OAT treatment initiation and the first
few months [44]: however, not much research to date
has investigated the long-term effect of OAT on pa-
tients’ HRQoL [7, 22, 29]. For instance, one study among
patients on methadone maintenance treatment found
that QoL increased markedly in the beginning of the
observation, but decreased after 6 months [45] while
other studies only saw improvements in the beginning of
observation [27, 46]. There is therefore the general be-
lief, based on limited data, that once patients are en-
rolled in OAT, their HRQoL will remain low and does
not change substantially anymore. Our study challenges
that belief and is among the first to show that changes
in HRQoL, including positive changes, are possible.
Additionally, our findings also show that many patients
had extreme variations in index values from baseline to
follow-up, in both positive and negative directions. This
Fig. 2 Pen’s Parade: distribution from lowest to greatest health. Pen’s Parade: The distribution in baseline EQ-5D-5L index values, where 43% had
> 0.8 and 5% had < 0.2 at baseline. The dotted line represent the average reported index value of the Norwegian reference population
Table 2 OAT patients’ HRQoL and self-perceived health at baseline and follow up as measured by the EQ-5D-5L
EQ-5D-5L VAS, baseline EQ-5D-5L VAS, baselinea EQ-5D-5L VAS, follow-up EQ-5D-5L Index EQ-5D-5L Index EQ-5D-5L Index
n 609 n 245 n 245 n 609, baseline n 245, baselinea n 245, follow-up
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Overall 57 22 57 22 59 22 0.699 0.250 0.691 0.237 0.729 0.237
Gender
Female 56 23 57 25 57 23 0.653 0.260 0.613 0.273 0.669 0.261
Male 57 22 57 21 60 22 0.718 0.243 0.716 0.220 0.748 0.226
Age group
< 25 58 18 55 19 61 25 0.787 0.164 0.766 0.211 0.678 0.390
26–40 61 22 59 22 60 22 0.724 0.242 0.689 0.234 0.745 0.205
41–60 54 22 55 22 58 22 0.684 0.253 0.686 0.238 0.716 0.253
≥61 51 23 56 16 58 16 0.613 0.292 0.714 0.257 0.754 0.210
OAT medication
Methadone 53 22 54 21 58 23 0.636 0.260 0.657 0.228 0.686 0.236
Buprenorphine 58 22 58 22 60 22 0.726 0.235 0.716 0.238 0.758 0.232
Buprenorphine/
naloxone
65 21 59 30 54 26 0.775 0.242 0.558 0.352 0.737 0.335
OAT Opioid agonist therapy, SD Standard deviation
Index obtained from Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2018. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England.
Health Economics
aBaseline values for the 245 patients who were eligible for follow-up analysis
The possible range of scores for EQ-5D-5L (0–1, 0 = dead (scores < 0 is possible), 1 = full health) and EQ-VAS (0–100, 0 = worst health imaginable, 100 = best
health imaginable
Statistically significant changes are marked in bold (p < 0.05)
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suggests that OAT populations are susceptible to severe
impairment and also rapid improvements in their
HRQoL. Such swift alterations are perhaps less common
among other patient groups and future research should
examine what causes these changes in HRQoL in long-
term OAT patients.
HRQoL in the long-term OAT population was lower
in average compared to what is found in other patient
groups, such as diabetes type 1 and 2 [47], HIV/AIDS
patients [48] and patients with psychiatric comorbidities
such as mild to moderate anxiety and depressive disor-
ders, and residual state of bipolar disease [49]. Using the
inverse of disability weights (health state valuations) re-
ported in the Global Burden of Disease study (2017),
makes comparisons between HRQoL index values and
disability weights possible [50]. Research have shown
there is a high comorbidity of psychiatric disorders
among people with substance use disorders and individ-
uals on OAT [11, 12, 16], while a six-year follow-up
study demonstrated that the high psychiatric comorbid-
ity persisted in long-term OAT patients [51]. This may
have severe HRQoL impacts and patients with mental
disorders may therefore be overrepresented in the lower
extreme of the reported index values. Given the wide
distribution of severity of disease within the long-term
OAT population, treatment needs to be individualized
and better adapted to patient functioning and needs.
This opts for rethinking and reassessing OAT programs
to better facilitate for integrated treatment, which have
found to be consistently superior to treatment of sub-
stance use and mental disorders with separate treatment
plans [52].
Furthermore, as HRQoL profiles of OAT patients are
diverse and dynamic this has implications for personal-
ized patient care and the need for regular assessment of
HRQoL as an outcome. We need to better understand
what drives the extreme and rapid changes in HRQoL in
both positive and negative directions among OAT pa-
tients. We need to know how to best prevent large drops
in index score and how to increase and maintain the in-
creases in index score over time. Additionally, females
have worse HRQoL scores compared to men, which in-
dicates that OAT programs should particularly focus on
how to improve HRQoL of females and find explana-
tions for why females have lower HRQoL. Similarly, we
found that patients older than 40 years have worse
Fig. 3 EQ-5D-5L domains at baseline versus follow-up. OAT = opioid agonist therapy. Proportions (%) and dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression). Baseline and follow-up for the 245 patients who were eligible for follow-up analysis
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HRQoL. This shows that we need to re-examine health
care needs of older patients are met and how we can ad-
dress their needs better. This is particularly important as
long-term OAT patients are now aging and we need to
plan for aging populations receiving OAT.
A strength of this study is the large sample size of
long-term OAT patients at baseline who are receiving
the same level of integrated OAT treatment across their
respective OAT outpatient clinics in the two cities.
However, there are also limitations to our study. Follow-
up was conducted on a sub-group of the initial sample.
To reduce the selection bias due to the loss-to-follow-up
we performed an inverse probability weighted method.
In general, it is problematic to compare HRQoL between
studies as setting, population, and level of OAT inte-
grated treatment varies and different instruments are be-
ing used. This is also the case for comparisons between
results based on EQ-5D-3L and EQ-5D-5L, and when
different national value sets are being used. Comparative
performance across patient groups is driven by differ-
ences in the descriptive systems and associated value
sets [37] Another weakness is the absence of a
Table 3 Distribution of EQ-5D-5L dimensions at baseline and at follow-up
Mean time between baseline and follow-up is 375 days (95% CI: 358,6–391.9)
Baseline: 609 patients Follow-up: 245 patients
Dimension Baseline Baselinea Follow-up p value
Mobility mean (95% CI) 1.7 (1.6–1.8) 1.7 (1.5–1.8) 1.5 (1.4–1.6)
No problems n (%) 378 (62.1) 149 (60.8) 170 (69.4) 0.0081
Slight problems n (%) 119 (19.5) 53 (21.6) 40 (16.3)
Moderate problems n (%) 49 (8.1) 23 (9.4) 21 (8.6)
Severe problems n (%) 59 (9.7) 18 (7.4) 14 (5.7)
Unable to walk about n (%) 3 (0.5) 2 (1.0) 0 (0)
Self-care mean mean (95% CI) 1.3 (1.2–1.3) 1.3 (1.2–1.4) 1.2 (1.2–1.3)
No problems n (%) 517 (84.9) 202 (82.5) 204 (83.3) 0.4
Slight problems n (%) 56 (9.2) 27 (11.0) 29 (11.8)
Moderate problems n (%) 18 (2.9) 9 (3.7) 8 (3.3)
Severe problems n (%) 15 (2.5) 7 (2.9) 4 (1.6)
Unable to wash or dress n (%) 2 (0.2) 0 (0) 0 (0)
Usual activities mean (95% CI) 1.8 (1.7–1.9) 1.9 (1.8–2.1) 1.8 (1.6–1.9)
No problems n (%) 350 (57.5) 120 (49.0) 142 (58.0) 0.1
Slight problems n (%) 129 (21.1) 69 (28.2) 45 (18.4)
Moderate problems n (%) 64 (10.5) 23 (9.4) 32 (13.1)
Severe problems n (%) 58 (9.5) 27 (11.0) 24 (9.8)
Unable to do usual activities n (%) 5 (0.8) 5 (2.0) 2 (0.8)
Pain/discomfort mean (95% CI) 2.3 (2.2–2.4) 2.2 (2.1–2.4) 2.1 (1.9–2.2)
No pain/discomfort n (%) 218 (35.8) 90 (36.7) 109 (44.5) 0.0245
Slight pain/discomfort n (%) 142 (23.3) 58 (23.7) 53 (21.6)
Moderate pain/discomfort n (%) 127 (20.9) 53 (21.6) 47 (19.2)
Severe pain/discomfort n (%) 92 (15.1) 35 (14.3) 29 (11.8)
Extreme pain/discomfort n (%) 29 (4.8) 9 (3.7) 7 (2.9)
Anxiety/depression mean (95% CI) 2.7 (2.6–2.8) 2.7 (2.6–2.9) 2.7 (2.5–2.8)
Not anxious/depressed n (%) 137 (22.5) 48 (19.6) 63 (25.7) 0.3
Slightly anxious/depressed n (%) 157 (25.8) 66 (26.9) 46 (18.8)
Moderately anxious/depressed n (%) 136 (22.3) 56 (22.9) 64 (26.1)
Severely anxious/depressed n (%) 132 (21.7) 51 (20.8) 56 (22.9)
Extremely anxious/depressed n (%) 45 (7.4) 24 (9.8) 16 (6.5)
CI Confidence interval
P-value: based on paired t-test of means for the 245 patients with two time points
aBaseline values for the 245 patients who were included for follow-up analysis
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Norwegian value set. Both our study and the study of
the Norwegian reference population had to use value
sets that resembles the Norwegian population, and for
this reason the UK value set was chosen. Studies have
confirmed that the latter version of EQ-5D significantly
increase both reliability and sensitivity and can poten-
tially reduce the possible ceiling effects encountered in
the EQ-5D-3L earlier version [53, 54].
Conclusion
We found considerably lower HRQoL among long-term
OAT patients in average compared to the general Nor-
wegian reference population. However, this is a hetero-
geneous population. Around one-third had very good
HRQoL, higher than average Norwegian values. Im-
provements in HRQoL were found over the one-year
follow-up across most EQ-5D-5L dimensions with some
uncertainties on why this was seen. More research is ur-
gently needed to identify and understand why females
and older patients have worse HRQoL and shows there
is a need for more gender-and age-specific treatment in
OAT programs. The wide variations in HRQoL support
more emphasis on individualized treatment and person-
alized patient care, and the need for regular assessment
of HRQoL in OAT programs. Our study is among the
first to show that changes in HRQoL, including positive
changes, are possible even several years after initiation of
treatment. Future research should examine what causes
these changes in HRQoL in long-term OAT patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13011-020-00309-y.
Additional file 1. OAT = opioid agonist therapy. Flow chart of study
sample.
Additional file 2. EQ-5D-5L, descriptive health profile at baseline (fre-
quencies and proportions reported by dimensions and level). OAT = opi-
oid agonist therapy, CI = confidence interval. * = total number of
respondents. 8 patients who missed data on one dimension were in-
cluded in the analysis. ** = long acting morphine sulphate and other opi-
oid prescriptions.
Additional file 3. Changes in EQ-5D-5L index value per patient from
baseline to follow-up. 609 patients included at baseline, 245 patients at
follow-up one year later.
Abbreviations
HRQoL: Health related quality of life; INTRO-HCV: Integrated treatment of
hepatitis C virus infection; OAT: Opioid agonist therapy; QoL: Quality of life
Acknowledgements
Christer Kleppe, data protecting officer, Helse Bergen for his valuable
contribution and guidance in data management.
Authors’ contributions
This observational study was led by CFA and KAJ in terms of study design,
analyzes, drafting and writing the article. KAJ, JHV and LTF was particularly
involved with acquisition of data, analyzes and interpretation. Figures were
made by AGL and KAJ. KAJ, LTF, SS, JHV, AGL, SR, KI, JEA, and EML
contributed to the conception, writing, and revising the draft(s) critically. All
authors have read and approved the version to be published.
Funding
This study is part of the main INTRO-HCV study, which was funded by The
Norwegian Research Council (no. 269855) and the Western Norway Regional
Health Authority (“Åpen prosjektstøtte) with Department of Addiction Medi-
cine, Haukeland University Hospital as responsible institution. The funders
had no role in the study design, data collection and analyzes, decision to
publish, nor preparation of any content in the manuscript. Two of the au-
thors, CFA and JHV, are funded from the above research grant, whereas the
other authors are funded by their respective affiliations.
Availability of data and materials
The INTRO-HCV study is ongoing and as such the dataset is not publically
available. However, parts of the dataset used for EQ-5D-5L used for this pub-
lication may be available in an anonymous and shortened version upon con-
tacting the corresponding author: Christer F. Aas: christer.frode.aas@helse-
bergen.no
Ethics approval and consent to participate
The study was approved by the Regional committee for medical and health
research ethics (no. 2017/51/REK vest). It was conducted in accordance with
the Helsinki Declaration and STROBE guidelines All included participants
signed a written consent to partake in the study.
Consent for publication
Not applicable. No personal details on any of the participants are reported in
the manuscript, tables or figures.
Competing interests
None of the authors have competing interests.
Author details
1Bergen Addiction Research group, Department of Addiction Medicine,
Haukeland University Hospital, Østre Murallmenningen 7, N-5012 Bergen,
Norway. 2Department of Global Public Health and Primary Care, University of
Bergen, Bergen, Norway. 3Norwegian Centre for Addiction Research,
University of Oslo, Oslo, Norway. 4Department of Mental Disorders,
Norwegian Institute of Public Health, Oslo, Norway. 5Population Health
Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 6Research
Unit for General Practice, NORCE Norwegian Research Centre, Bergen,
Norway. 7Department of Social Sciences, NORCE Norwegian Research Centre,
Bergen, Norway. 8Department of Economics, University of Bergen, Bergen,
Norway. 9Department of Clinical Psychology, Medicine, University of Bergen,
Bergen, Norway. 10Division of Psychiatry, Haukeland University Hospital,
Bergen, Norway.
Received: 22 June 2020 Accepted: 25 August 2020
References
1. World Health Organization. Management of substance abuse: Dependence
syndrome, ICD-10 Clinical description; 2020. https://www.who.int/
substance_abuse/terminology/definition1/en/.
2. Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare
costs and utilization associated with high-risk prescription opioid use: a
retrospective cohort study. BMC Med. 2018;16(1):69.
3. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL,
Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, et al. Global patterns
of opioid use and dependence: harms to populations, interventions, and
future action. Lancet (London, England). 2019;394(10208):1560–79.
4. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden
of opioid-related mortality in the United States. JAMA Netw Open. 2018;
1(2):e180217.
5. European Monitoring Centre for Drugs and Drug Addiction: European Drug
Report. Trends and Developments. In.; 2019.
6. Strada L, Vanderplasschen W, Buchholz A, Schulte B, Muller AE, Verthein U,
Reimer J. Measuring quality of life in opioid-dependent people: a systematic
review of assessment instruments. Qual Life Res. 2017;26(12):3187–200.
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2020) 15:68 Page 10 of 12
7. Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, Shore
R, Hopkins S. Determinants of health-related quality of life of opiate users at
entry to low-threshold methadone programs. Eur Addict Res. 2006;12(2):74–
82.
8. Griffin ML, Bennett HE, Fitzmaurice GM, Hill KP, Provost SE, Weiss RD.
Health-related quality of life among prescription opioid-dependent patients:
results from a multi-site study. Am J Addict. 2015;24(4):308–14.
9. European Monitoring Centre for Drugs and Drug Addiction: Komorbiditet
— samförekomst av narkotikamissbruk och psykisk störning. Ett
underskattat tillstånd. In.; 2004.
10. Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA,
Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for
hepatitis C among people receiving opioid agonist therapy in Sweden and
Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev
Policy. 2020;15(1):44.
11. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W,
Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use
disorders and independent mood and anxiety disorders: results from the
National Epidemiologic Survey on alcohol and related conditions. Arch Gen
Psychiatry. 2004;61(8):807–16.
12. Hall W. What have population surveys revealed about substance use
disorders and their co-morbidity with other mental disorders? Drug Alcohol
Rev. 1996;15(2):157–70.
13. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F,
Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit
hyperactivity disorder in substance use disorder patients: a meta-analysis
and meta-regression analysis. Drug Alcohol Depend. 2012;122(1–2):11–9.
14. Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between
mental distress and poly-drug use: a ten year prospective study of patients
from substance abuse treatment. Addict Behav. 2015;48:71–8.
15. Mørkved N, Winje D, Dovran A, Arefjord K, Johnsen E, Kroken RA, Anda-
Ågotnes LG, Thimm JC, Sinkeviciute I, Rettenbacher M, et al. Childhood
trauma in schizophrenia spectrum disorders as compared to substance
abuse disorders. Psychiatry Res. 2018;261:481–7.
16. Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, Thabane L, Samaan
Z. The impact of comorbid psychiatric disorders on methadone
maintenance treatment in opioid use disorder: a prospective cohort study.
Neuropsychiatr Dis Treat. 2017;13:1399–408.
17. Connery HS. Medication-assisted treatment of opioid use disorder: review of
the evidence and future directions. Harvard Rev Psychiatry. 2015;23(2):63–75.
18. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren
J. Mortality among regular or dependent users of heroin and other opioids:
a systematic review and meta-analysis of cohort studies. Addiction. 2011;
106(1):32–51.
19. Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-
related treatment, interventions, and outcomes among incarcerated
persons: a systematic review. PLoS Med. 2019;16(12):e1003002.
20. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M.
Mortality among people who inject drugs: a systematic review and meta-
analysis. Bull World Health Organ. 2013;91(2):102–23.
21. Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow
FC, Ilgen M, et al. Effects of medication-assisted treatment on mortality
among opioids users: a systematic review and meta-analysis. Mol Psychiatry.
2019;24(12):1868–83.
22. Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, Stribling
JC, Schackman BR. Quality of life as an outcome of opioid use disorder
treatment: a systematic review. J Subst Abus Treat. 2017;76:88–93.
23. Bullinger M. Assessing health related quality of life in medicine. An overview
over concepts, methods and applications in international research. Restor
Neurol Neurosci. 2002;20(3–4):93–101.
24. Muller AE, Skurtveit S, Clausen T. Confirming the factor structure of a
generic quality of life instrument among pre-treatment substance use
disorder patients. Health Qual Life Outcomes. 2019;17(1):84.
25. Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J,
Ang A, Hser YI, Ling W, et al. Short term health-related quality of life
improvement during opioid agonist treatment. Drug Alcohol Depend. 2015;
157:121–8.
26. Lofwall MR, Brooner RK, Bigelow GE, Kindbom K, Strain EC. Characteristics of
older opioid maintenance patients. J Subst Abus Treat. 2005;28(3):265–72.
27. Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, Schafer I.
Quality of life profiles and changes in the course of maintenance treatment
among 1,015 patients with severe opioid dependence. Subst Use Misuse.
2011;46(6):705–15.
28. Millson PE, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, Shore
R, Hopkins S, Raftis S, Pearson M. Self-perceived health among Canadian
opiate users: a comparison to the general population and to other chronic
disease populations. Can J Public Health. 2004;95(2):99–103.
29. Karow A, Reimer J, Schafer I, Krausz M, Haasen C, Verthein U. Quality of life
under maintenance treatment with heroin versus methadone in patients
with opioid dependence. Drug Alcohol Depend. 2010;112(3):209–15.
30. Hayes CJ, Li X, Li C, Shah A, Kathe N, Bhandari NR, Payakachat N. Health-
related quality of life among chronic opioid users, nonchronic opioid users,
and nonopioid users with chronic noncancer pain. Health Serv Res. 2018;
53(5):3329–49.
31. Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S,
Lygren OJ, Dalgard O, Vickerman P, et al. Integrated treatment of hepatitis C
virus infection among people who inject drugs: study protocol for a
randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):943.
32. Waal H BK, Clausen T, Lillevold PH, and Skeie I.: SERAF Report: Status 2017.
MAR 20 years. Status, evaluations and perspectives. In.: The Norwegian
Centre for Addiction Research (SERAF); 2018.
33. World Health Organization (WHO). Classifications: ICD-10 online versions.
World Health Organization (WHO); 2019. [https://www.who.int/
classifications/icd/icdonlineversions/en/]. Accessed 13 Mar 2020.
34. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol
group. Ann Med. 2001;33(5):337–43.
35. Peak J, Goranitis I, Day E, Copello A, Freemantle N, Frew E. Predicting
health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A)
in the context of opiate dependence using routine clinical outcome
measures: CORE-OM, LDQ and TOP. Health Qual Life Outcomes. 2018;16(1):
106.
36. van der Zanden BP, Dijkgraaf MG, Blanken P, de Borgie CA, van Ree JM, van
den Brink W. Validity of the EQ-5D as a generic health outcome instrument
in a heroin-dependent population. Drug Alcohol Depend. 2006;82(2):111–8.
37. EuroQoL Research Foundation. EQ-5D-5l User Guide. 2019. [https://euroqol.
org/publications/user-guides/]. Accessed 27 Jan 2020.
38. Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of
studies comparing the measurement properties of the three-level and five-
level versions of the EQ-5D. PharmacoEconomics. 2018;36(6):645–61.
39. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related
quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.
40. Stavem K, Augestad LA, Kristiansen IS, Rand K. General population norms for
the EQ-5D-3 L in Norway: comparison of postal and web surveys. Health
Qual Life Outcomes. 2018;16(1):204.
41. Strada L, Schmidt CS, Rosenkranz M, Verthein U, Scherbaum N, Reimer J,
Schulte B. Factors associated with health-related quality of life in a large
national sample of patients receiving opioid substitution treatment in
Germany: A cross-sectional study. Subst Abuse Treat Prev Policy. 2019;14(1):
2.
42. Waal HBK, Clausen T, Håseth A, Lillevold PH, Skeie I. SERAF Report: Status
2014, an aging MAR-population? Oslo: The Norwegian Centre for Addiction
Research (SERAF); 2015.
43. Ministry of Health and Care Services. National guidline for medicaly assisted
rehabilitation (MAR) for opioid dependence. Oslo: The Norwegian Ministry
of Health and Care Services; 2010.
44. Braback M, Bradvik L, Troberg K, Isendahl P, Nilsson S, Hakansson A. Health
related quality of life in individuals transferred from a needle exchange
program and starting opioid agonist treatment. J Addict. 2018;2018:
3025683.
45. Habrat B, Chmielewska K, Baran-Furga H, Keszycka B, Taracha E. Subjective
quality of life in opiate-dependent patients before admission after six
months and one-year participation in methadone program. Przeglad
lekarski. 2002;59(4–5):351–4.
46. Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on
buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse.
2007;33(5):631–42.
47. Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the
associations of complications with EQ-5D scores. Health Qual Life
Outcomes. 2010;8:18.
48. Stavem K, Froland SS, Hellum KB. Comparison of preference-based utilities
of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res. 2005;
14(4):971–80.
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2020) 15:68 Page 11 of 12
49. Global Burden of Disease Collaborative Network. Global Burden of Disease
Study 2017 (GBD 2017) Disability Weights. Seattle, United States: Institute for
Health Metrics and Evaluation (IHME), 2018; 2018.
50. World Health Organization. Health statistics and information systems:
Disability weights, discounting and age weighting of DALYs. 2020. [https://
www.who.int/healthinfo/global_burden_disease/daly_disability_weight/en/].
Accessed 14 Mar 2020.
51. Soyka M, Strehle J, Rehm J, Buhringer G, Wittchen HU. Six-year outcome of
opioid maintenance treatment in heroin-dependent patients: results from a
naturalistic study in a nationally representative sample. Eur Addict Res. 2017;
23(2):97–105.
52. Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric
disorders. Soc Work Public Health. 2013;28(3–4):388–406.
53. Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-
to-head comparison of descriptive systems and value sets from seven
countries. PharmacoEconomics. 2018;36(6):675–97.
54. Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-
5D three-level system with a five-level version. Value Health. 2008;11(2):275–
84.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2020) 15:68 Page 12 of 12
Graphic design: Com
m
unication Division, UiB  /  Print: Skipnes Kom
m
unikasjon AS
uib.no
ISBN: 9788230855423 (print)
9788230847091 (PDF)
